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SUMMARY 
The 90 kDa heat shock proteins constitute a family of highly conserved molecular 
chaperones that are essential in all eukaryotic cells. Assisted by an increasing number of 
cochaperones, Hsp90 forms highly dynamic complexes with numerous client proteins, many 
of which are signaling molecules controlling cell homeostasis, proliferation, differentiation, 
cell death, etc. Therefore, Hsp90 sits at one of the center positions in the protein quality 
control system and requires delicate regulation by the combination of different mechanisms. 
It is already well established in the field that the multiple conformations of Hsp90 are driven 
by association/dissociation with nucleotide and ATP hydrolysis together with binding and 
release of cochaperones as well as client proteins. On the other hand, post-translational 
modifications are becoming increasingly recognized as another layer of regulation that adds 
up to the complexity of the whole machinery. Hsp90 is a phospho-protein: approximately 40 
sites have been detected in proteomics reports; nonetheless, individual phospho-sites seem 
to have different impact on the chaperone function of Hsp90. 
In the first part of this work, I aimed to analyze the global phosphorylation status of 
human cytosolic Hsp90 proteins in cancer versus non-cancer cells in a quantitative way and 
to examine whether the phosphorylation status relates to tumor selectivity characteristics of 
Hsp90 inhibitors. Due to technical issues, not all previously reported phosphorylation sites 
were detected. Thus, my data did not provide a clear conclusion about the global 
phosphorylation status of the Hsp90 proteins in cell lysates. My data also did not provide 
evidence for a correlation between detected phosphorylation sites and malignancy. Instead, I 
found indications for novel phosphorylation sites that were not covered in proteomics 
studies so far. The exploration of Multiple Reaction Monitoring Mass spectrometry (MRM-
MS) rather than normal liquid chromatography coupled with tandem mass spectrometry (LC-
MS/MS) also confirmed that such a specific approach could be utilized for further 
applications in quantification of target proteins and modifications in complex samples 
without the risk of losing target material in isolation steps or altering the relative abundance 
of modifications due to enrichment steps prior to MS. 
In the second part of this work, I focused on characterzing a novel serine 
phosphorylation that was first detected in the previous part and recently has been confirmed 
by other proteomics studies. Using S. cerevisiae as the model system in which both 
endogenous Hsp90 can be conditionally deleted, I was able to resolve the difference in 
chaperone function of human Hsp90 wild-type and phospho-mutants when being the sole 
source of Hsp90 proteins in yeast cells. From general yeast viability and cell morphology as 
well as specific chaperone activation capacity for well-defined client proteins, my data 
suggested that the human Hsp90 wild-type was indeed phosphorylated in vivo and 
demonstrated strongly a correlation between S365 phosphorylation and chaperone activity 
of Hsp90. S365 phosphorylation mimicking status was proven to be favorable for 
chaperoning glucocorticoid receptor (GR), heat shock factor (HSF-1) and the MAPKK Ste11 to 
response stronger and/or faster to each corresponding stimulus while showing no effect on 
transactivation activity of the transcription factor HAP1 (Heme activator protein), another 
known Hsp90 client. My results supported a hypothesis in which a single modification on the 
molecular chaperone would be sufficient to provide a certain level of client specificity and 
modulate cellular responses upon environmental stimuli.  
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To resolve further the mechanism of how S365 phosphorylation exerts its impact on 
Hsp90 function, I utilized in vitro minimal GR-activation system consisting of purified Hsp70, 
Hsp40, HOP, p23 and different Hsp90 wild-type or phospho-variant proteins. The profitable 
effect of S365E phospho-mimetic variant as compared with non-phosphorylatable variants 
was confirmed while that of wild-type protein was abolished due to the lack of post-
translational modifications from E. coli expression and purification. Given the in vivo results 
of not only GR but also of a few other client proteins, I also examined the interaction of the 
Hsp90 wild-type protein and S365 phosphomutants with cochaperones by size-exclusive 
chromatography coupled with fluorescence detector using labeled proteins and isothermal 
titration calorimetry. The results showed that S365 phosphorylation impairs the binding of 
Hsp90 protein to both cochaperones Aha1 and Cdc37. 
Altogether, the data provided evidence for phosphorylation at serine 365 on human 
Hsp90 that contributes to regulation of Hsp90 function via direct impacts on client and 
indirect effects via cochaperones involved in the chaperone cycle. As expected, the regulation 
of this molecular chaperone is the result of a delicate combination between several 
mechanisms rather than a single one, which would be more flexible to adapt to the variety of 
macro- and micro-environmental fluctuations that higher eukaryotes always must cope with.  
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ZUSAMMENFASSUNG  
Die 90kDa Hitzeschockproteine bilden eine Familie hoch konservierter 
molekularer Chaperone, die in allen eukaryotischen Zellen essentiell sind. Unterstützt von 
einer steigenden Anzahl von Cochaperonen bildet Hsp90 hochdynamische Komplexe mit 
zahlreichen Proteinen, Kliente genannt. Bei vielen handelt es sich dabei um Signalmoleküle, 
die die Zellhomöostase, -proliferation, -differenzierung, wie auch den Zelltod etc. steuern. 
Daher nimmt Hsp90 eine zentrale Rolle im Proteinqualitätskontrollsystem ein und erfordert 
eine sorgfältige Regulation durch eine Kombination verschiedener Mechanismen. Es wird 
angenommen, dass die mannigfaltigen Konformationen von Hsp90 durch die Assoziation/ 
Dissoziation von Nukleotiden, ATP Hydrolyse wie auch durch die Bindung und Freisetzung 
von Cochaperonen und Klientproteinen bestimmt werden. Daneben wird immer deutliche, 
dass posttranslationale Modifikationen eine weitere Ebene der Regulation bilden, die 
zusätzlich zur Komplexität dieser Maschinerie beitragen. Hsp90 ist ein Phospho-Protein: Ca. 
40 Phosphorylierungstellen wurden bereits in Proteom-Studien identifiziert. 
Nichtsdestotrotz scheinen einzelne Phosphorylierungsstellen die Chaperonfunktion von 
Hsp90 unterschiedlich zu beeinflussen. 
Das Ziel des ersten Teils dieser Arbeit war es, den globalen 
Phosphorylierungszustand der humanen, cytosolischen Hsp90-Proteine in Krebszellen im 
Vergleich zu nicht malignen Zellen quantitativ zu analysieren und zu prüfen, ob der 
Phorphorylierungsstatus mit Tumorselektivitätseigenschaften von Hsp90-Inhibitoren in 
Zusammenhang steht. Aufgrund von technischen Komplikationen konnten nicht alle zuvor 
bekannten Phosphorylierungsstellen nachgewiesen werden. Daher konnte mit diesen Daten 
keine eindeutige Aussage über den globalen Phosphorylierungsstatus von Hsp90-Proteinen 
in Zelllysaten gemacht werden. Meine Daten lieferten ebenfalls keinen Beleg für eine 
Korrelation zwischen den nachgewiesenen Phosphorylierungsstellen und Malignität. 
Stattdessen fand ich Hinweise auf neue Phosphorylierungsstellen, die bis dahin noch nicht 
von Proteom-Studien worden waren. Die Untersuchung mittels „Multiple Reaction 
Monitoring“ - Massenspektrometrie anstatt normaler Flüssig-chromatographie verbunden 
mit Tandem-Massenspektrometrie bestätigte auch, dass eine solch spezifische 
Vorgehensweise für weitere  Anwendungen in Quantifizierung von Targetproteinen und 
Modifikationen in komplexen Proben benutzt werden könnte. Dabei gäbe es nicht das Risiko 
das Targetmaterial in Isolationsschritten zu verlieren oder die relative Häufigkeit von 
Modifikationen aufgrund von Anreicherungsschritten, die vor MS notwendig sind, zu 
verändern. 
In dem zweiten Abschnitt dieser Arbeit konzentrierte ich mich auf die 
Charakterisierung einer neuen Serinphosphorylierung, die erstmals im vorherigen Teil 
beschrieben und kürzlich auch durch andere Proteom-studien bestätigt wurde. Mit S. 
cerevisiae als Modellsystem, in dem beide endogene Hsp90 codierende Gene durch ein Hsp90 
Gen des Menschen ersetzt wurde, war ich in der Lage, Unterschiede in der Chaperonfunktion 
vom humanen Hsp90β-Wildtyp und den Phospho-Mutanten festzustellen. Vom allgemeinen 
Hefewachstumsverhalten und der Zellmorphologie wie auch der spezifischen 
Chaperonaktivierungskapazität für gut beschriebene Klientproteine, wiesen meine Daten 
darauf hin, dass der Hsp90β-Wildtyp in vivo tatsächlich phosphoryliert war. Zudem zeigte 
sich eine starke Korrelation zwischen der S365-Phosphorylierung und der Chaperonaktivität 
von Hsp90β. Es wurde gezeigt, dass sich der S365-Phosphorylierungs-imitierende Zustand 
günstig auf das Chaperonieren des Glucocorticoid-Rezeptors (GR), Hitzeschock-Faktors (HSF-
1) und MAPKK Ste11 auswirkt, sodass diese stärker und/ oder schneller auf jeden 
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entsprechenden Stimulus reagieren, während sich kein Effekt auf die 
Transaktivationsaktivität des Transkriptionsfaktors HAP1 (Heme Aktivator Protein) zeigte, 
bei dem es sich um einen weiteren bekannten Hsp90-Klienten handelt. Meine Ergebnisse 
unterstützen die Hypothese, dass eine einzige Modifikation der molekularen Chaperone 
ausreichen würde, um einen bestimmten Grad an Klientenspezifität zu bestimmen und 
zelluläre Antworten auf Umweltreize modulieren zu können. 
Um weiterhin die Mechanismen aufzuklären, wie die S365-Phosphorylierung sich 
auf die Hsp90-Funktion auswirkt, verwendete ich ein in vitro Minimal-GR-Aktivationssystem 
bestehend aus aufgereinigtem Hsp70, Hsp40, HOP, p23 und Hsp90-Wildtyp oder 
verschiedene Hsp90-Phospho-Varianten. Es wurde bestätigt, dass die S365E-Phospho-
mimetische Variante einen günstigen Effekt im Vergleich zu den nicht phosphorylierbaren 
Varianten hat, während dies für das Wildtyp-Protein aufgrund der fehlenden 
posttranslationalen Modifikationen infolge der E.coli Expression und Aufreinigung nicht der 
Fall war. Angesichts dieser in vitro Resultate für GR, aber auch für einige andere 
Klientproteine, untersuchte ich auch die Interaktion von Hsp90-Wildtyp und den S365-
Phosphomutanten mit Cochaperonen mittels Größenausschluss-chromatographie und 
isothermer Titrationskalorimetrie. Die Ergebnisse zeigten, dass die S365-Phosphorylierung 
die Bindung von Hsp90β-Proteinen an die Cochaperone Aha1 und Cdc37 beeinträchtigt. 
Alles in allem bieten diese Daten einen Beleg dafür, dass die Phosphorylierung 
des Serins 365 im Hsp90β des Menschen zur Regulation der Hsp90-Funktion beiträgt, 
einerseits über direkte Auswirkungen auf Protein Klienten und anderseits indirekt durch 
Effekte auf Cochaperone, die in diesem Chaperonzyklus beteiligt sind. Wie erwartet, ist die 
Regulation dieses molekularen Chaperons eher das Resultat einer feinabgestimmten 
Kombination aus verschiedenen Mechanismen, als das Ergebnis eines einzelnen 
Mechanismus. Ersteres System wäre flexibler in der Adaption an große und kleinste 
Umweltschwankungen, welche höhere Eukaryoten immer bewältigen müssen. 
Introduction 
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1 INTRODUCTION 
1.1  PROTEIN FOLDING AND MOLECULAR CHAPERONES 
A single cell contains thousands of different proteins that fulfill a large variety of 
essential functions in metabolism, regulation and development. Proteins, after being 
synthesized as linear chains of amino acids, have to adopt defined three dimensional 
structures to fulfill their corresponding function. The process of structure acquisition 
(termed folding) is not the same for every protein: While many of them attain the appropriate 
structure and conformation very rapidly after synthesis, some remain in one or a few 
intermediate state(s) for an extended period and/or only fully transform into the native state 
when triggered by specific substrates or signals. Even though the process of folding is 
principally spontaneous without any cost of energy and determined only by the amino acid 
sequence of the protein and thermodynamics, protein folding inside a cell is more 
complicated. There are numerous intracellular factors that drive against the appropriate 
folding of a protein from its nascent polypeptide chain. Those factors include the vectorial 
release mode of nascent polypeptide chain, the rate of translation that is orders of magnitude 
slower than that of folding, the existence of many ribosomes translating on one mRNA and 
molecular crowding in the cytosol. Even when proteins have attained their native state, they 
are constantly in danger of misfolding due to colliding with other macromolecules in the 
cytosol, a threat which is enhanced by environmental factors such as thermal, heavy metals, 
or oxidative stress. Those situations render proteins to be trapped in malfunctioning and 
potentially toxic conformations which eventually cause severe diseases such as Alzheimer’s, 
Parkinson’s, Huntington’s, type II diabetes, cystic fibrosis, many types of cancer, etc. 
Therefore, most proteins need help from molecules called “molecular chaperones” to achieve 
and maintain their functional conformation (Frydman 2001). 
Molecular chaperones are so called because they guide proteins through these 
folding pathways without interfering or associating in the final folded product. The term 
molecular chaperone was first used in literature by Ron Laskey (1978) to describe 
nucleoplasmin, a nuclear protein that binds to histones and mediates nucleosome assembly 
and then extended by John Ellis (1987) to describe proteins that mediated the post-
translational assembly of protein complexes. The proteins that are now known as molecular 
chaperones actually have been discovered in several independent scientific works. 
Many molecular chaperones are strongly produced under heat stress conditions. 
They are therefore named Heat shock proteins (Hsp) plus their apparent molecular weight 
(40, 70, 90, etc …) on SDS polyacrylamide gels. Later, their close homologues (which are 
constitutively expressed) were called Heat shock cognate proteins (Hsc), also with the 
number indicated approximately molecular weight. Those heat shock proteins are greatly up-
regulated in response to the higher tendency of aggregation of cellular proteins in thermal 
stress. They prevent nonproductive intermolecular interactions between either nascent 
polypeptides or stressed-damaged proteins and restore their native structures, as well as 
promote degradation when these attempts fail. Thus, molecular chaperones do not only play 
a critical role in protein folding but also participate significantly in anti-aggregation including 
protein disaggregating, refolding and degradation in order to maintain protein homeostasis 
and response to stresses (Frydman 2001; Höhfeld et al. 2001; Young et al. 2004).  
Among the major chaperone systems, the highly abundant and in all eukaryotic 
cells, essential 90kDa heat shock protein (Hsp90) is unique due to its several intriguing 
characteristics (Young 2001; Pearl & Prodromou 2006; Wandinger et al. 2008; Dezwaan & 
Freeman 2008). In recent years, many onco-proteins were discovered to be Hsp90´s clients, 
making this protein a prime target for anti-tumor therapy. Understanding the molecular 
mechanism of Hsp90 is therefore not only scientifically interesting and challenging but also of 
high medical relevance.  
Introduction 
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1.2  HEAT SHOCK PROTEIN 90 
1.2.1 HSP90 GENERAL CHARACTERISTICS 
Hsp90 is a highly conserved member of the heat shock protein family with 60% 
sequence identity between yeast and human homologues and 40% between E. coli HtpG and 
human Hsp90β. Making up 1-2% of total cellular protein and even more when induced by 
stress, Hsp90 proteins are essential for viability of eukaryote cell, while dispensable in 
prokaryotes (Mayer & Bukau 1999; Pearl & Prodromou 2006). Surprisingly, the level of 
Hsp90 can be significantly reduced without affecting cell viability, at least in normal 
conditions (Nathan et al. 1997; Picard 2002).  
In most cells, Hsp90 proteins have several homologues not only in the cytosol but 
also in organelles such as mitochondria, endoplasmic reticulum and chloroplast. In the 
cytosol, there are mostly two isoforms of Hsp90 such as Hsp90α and Hsp90β in human 
(Homo sapiens), or Hsc82 and Hsp82 in budding yeast (S. cerevisiae). Isoforms are most 
known to differ in the regulation of their expression: either constitutively (like Hsp90β, 
Hsc82…) or inducible by stress (like Hsp90, Hsp82 …) 
1.2.2 HSP90 STRUCTURE  
The Hsp90 proteins throughout evolution share high structural homology with 
similar domain organizations. The protein forms dimer with each protomer consisting of 3 
main domains, linked flexibly to each other: N-terminal, middle, and C-terminal domain. In 
higher eukaryotes, an extended and highly charged linker region with variable lengths 
connects the N- domain to the rest of the protein (Figure 1-1). 
The N-terminal domain of Hsp90 contains the nucleotide binding pocket of the 
molecule, in a structure known as the “Bergerat” fold which Hsp90 shares with the members 
of the gyrase–Hsp90–histidine kinase–MutL (GHKL) family. It is composed of a two-layer α/β 
sandwich in which eight -sheet strands building the bottom of the ligand pocket, whereas 
surrounding and on-top -helices make up a cleft (Pearl & Prodromou 2006). Many well-
known Hsp90–specific inhibitors such as geldanamycin (GA) and radicicol also bind to this 
pocket, and hence severely affect Hsp90 activity. Another unique feature of the ATP binding 
region in Hsp90 as well as in proteins of GHKL family is a flexible structural element, the ATP 
‘lid’, a conserved loop consisting of two α-helices that claps over the nucleotide-binding 
pocket when ATP is bound and forms a closed conformation. This lid seems to be one 
important conformational switch for the ATP hydrolysis function of Hsp90 and is also part of 
binding sites for co-chaperones like p23/Sba1 and Cdc37 (Roe et al. 2004; Ali et al. 2006). 
The middle domain (M domain) consists of 2 α-β-α sandwiches connected to one 
another by an α3 helical coil, with the larger one near to the N-terminal domain and the 
charged linker. Compared to the structures of other GHKL family members, the Hsp90 M 
domain shows higher divergence of corresponding regions, and in particular the second 
smaller α-β-α motif represents an independent fold not found in other GHKL proteins. Amino 
acids 375 to 388 in the yeast homologue make up the conserved catalytic loop within the 
Hsp90 M domain, harbouring the arginine 380 residue that is essential for ATP hydrolysis as 
it contacts the -phosphate of ATP (Meyer et al. 2003). Moreover, ATP trapping (being locked 
in the nucleotide binding pocket to be hydrolyzed before it is released) occurs only in Hsp90 
fragments containing the middle domain, suggesting that the middle domain of Hsp90 is 
important for the trapping of the ATP molecule (Wegele et al. 2003).  
The Hsp90 M domain also has a large surface that was implicated in several 
publications to be involved in the binding of client proteins (Sato et al. 2000; Meyer et al. 
2003; Müller et al. 2004; Street et al. 2011). An exposed hydrophobic patch surrounding 
Trp300 and an amphipathic loop (residues 329–339) when being mutated showed severe 
effect in the maturation of v-src kinase (Meyer et al. 2003). In a very recent study using NMR 
Introduction 
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to investigate complex of Tau and human Hsp90, it is confirmed that Hsp90, in contrast with 
Hsp70 and Hsp60, uses this large surface (in combination with surfaces stretching over N-
terminal domain) as a permanently open and accessible docking region that accumulate 
otherwise low-affinity contacts into a strong interaction (Karagöz et al. 2014). 
 
FIGURE 1-1: DOMAIN ORGANIZATION OF THE YEAST HSP90.  
Left: Schematic domain organization of the yeast hsp90: N domain (N) (residue 1 -220, 
green), middle domain (M) (255-540, red) and c domain (C) (540-709, blue). Right: Full-
length yeast hsp90 dimer (pdb: 2cg9) in complex with AMPPNP and p23/sba1.   
As mentioned, Hsp90 is a constitutive dimer and the C-terminal domain is 
essential for the dimerization of a functional Hsp90 molecule (Minami et al. 1994). It consists 
of a curved α-helix, a three-stranded β-sheet, a three-helix coil and an extended disordered 
arm (Ali et al. 2006; Pearl & Prodromou 2006). A helix-strand segment (residues 587-610 in 
yeast Hsp82) packs tightly with the respective counterpart from the other protomer, creating 
a helix bundle that forms the dimer interface. The association between the Hsp90 protomers 
is on the order of Kd ~60nM and thus comparatively strong (Richter et al. 2001). Since only 
dimer form of Hsp90 is fully active (Chadli et al. 2000), the C-terminal domain is also 
indispensable. The C domain is not involved directly in the ATP hydrolysis reaction of Hsp90 
but it essentially contributes to this function by mediating the dimeric state: Cysteine bridged 
NM mutants of Hsp90 comprising only the N and M domain had ATPase activity similar to the 
wild - type protein whereas the monomeric NM variants had barely detectable ATP 
hydrolysis (Wegele et al. 2003).  
At the very end of this domain, there is a MEEVD motif, binding site for proteins 
with tetratricopeptide repeat (TPR). In fact, many of Hsp90´s cochaperones such as Cpr6, 
Cpr7, Hop, Tom70, Ppt1, Dpit47, CHIP … have TPR domain, which makes a solid confirmation 
for the second important role of C-terminal domain as domain for cochaperone interactions 
(Prodromou et al. 1999). This is also the missing part of HtpG in comparison to eukaryotic 
Hsp90 proteins, nevertheless, the overall fold of all Hsp90 proteins seem to be highly similar. 
It is noteworthy that even though Hsp90 is constitutively dimer, C-terminal domains of two 
protomers in the dimer do not always stably dimerized. In fact, in single molecule FRET, it 
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was shown that C-termini open and close with fast kinetics. Moreover, C-terminal 
dimerization is anti-correlated with N-terminal dimerziation and is also modulated by the 
nucleotide binding state of Hsp90 (Ratzke et al. 2010). 
1.2.3 HSP90 CHAPERONE ACTIVITY AND CLIENT PROTEINS 
1.2.3.1 HSP90 CHAPERONE ACTIVITY 
Hsp90 clearly has functions as a classical chaperone: its ability to suppress the 
aggregation process of model proteins under elevated temperatures without the need of ATP 
or other proteins were confirmed by in vitro experiments (Miyata & Yahara 1992; Jakob et al. 
1995). However, this seems to be only one aspect among Hsp90 functions. As mentioned 
previously, Hsp90 is found in high concentrations even in unstressed cells and is 
indispensable in most organisms also under physiological conditions (see section 1.2.1 (page 
11)). This indicates that Hsp90 is required in fundamental biological processes both in 
normal and stress conditions. However, among the heat shock protein, Hsp90 is unique 
because it is not required for the de novo folding of polypeptides. Instead, Hsp90 exerts its 
activity on later stage of folding, namely maturation, maintenance and activation of client 
proteins (Nathan et al. 1997; Wegele et al. 2004; Lindquist et al. 2010). In certain conditions, 
Hsp90 also have active roles in degradation of “hopeless” misfolded proteins (Murata et al. 
2001; Xu et al. 2002; Morishima et al. 2008; Stankiewicz et al. 2010). 
Although Hsp90 is frequently described as a ‘‘molecular chaperone machinery,’’ 
evidence showed that the Hsp90 machinery does not exist as one large complex containing 
Hsp90 and all co-chaperones but instead, Hsp90 and co-chaperone proteins interact with 
client proteins in a sequential order making several distinct complexes during the whole 
process (Smith 1993; Smith et al. 1993; Johnson et al. 1994; Smith et al. 1995; Johnson & Toft 
1995; Dittmar et al. 1996; Barent et al. 1998; Kosano 1998; Y Morishima et al. 2000; 
Yoshihiro Morishima et al. 2000; Kanelakis et al. 2002).  
Much of the current knowledge about the Hsp90 chaperone cycle was gained 
from research on steroid hormone receptors (SHRs), one of the earliest identified Hsp90 
client families by Pratt and coworkers. According to reconstitution experiments, the assembly 
of SHRs is a chronological progression through three major complexes with different 
cochaperone compositions. The cycle starts with the nascent polypeptide or the pre-existing 
SHR without its ligand being recognized and bound by Hsp70/Hsp40 system to form the so 
called “early complex”. The substrate-Hsp70 complex interacts with Hsp90 and they further 
form the “intermediate complex” whereby Hsp70 and Hsp90 is bridged by the organizing 
protein HOP (Smith et al. 1993; Dittmar & Pratt 1997; Chen & Smith 1998; Wegele et al. 
2004). The substrate is then transferred completely to Hsp90, making the “late complex” in 
which Hsp70 and HOP are replaced by p23 and immunophillins (Cyp40, FKBP52, etc) which 
stabilize the complex by arresting Hsp90 in its close and substrate-binding conformation 
(Smith et al. 1993; Smith 1993; Johnson et al. 1994; Forafonov et al. 2008; Freeman et al. 
2000). Further conformational changes in the late complex facilitate the maturation of SHR 
(mostly its hormone binding domain) so that it binds ligand with high affinity (Figure 1-2).  
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FIGURE 1-2: CHAPERONE CYCLE OF HSP90 FOR STEROID HORMONE RECEPTORS.  
Hsp70/Hsp40 forms an early complex  with the client protein. HOP can interact with both 
Hsp70 and Hsp90, bridging the two chaperones to facilitate client transfer to Hsp90 system 
in the intermediate complex .  Next, Hsp70 and HOP dissociate from Hsp90 -client complex 
and are replaced by p23 and immunophillins (FKBP proteins) forming the late complex , in 
which the client protein is activated by ligand binding or upstream signal.  
For some of the receptors, such as progesterone (PR), they have nuclear 
localization signals that are functional in the absence of hormone, and these receptors move 
into the nucleus where they exist in the same multiprotein heterocomplex with Hsp90. Other 
receptors, such as the glucocorticoid receptor, are localized predominantly in the cytoplasm 
in the absence of hormone and move into the nucleus in a hormone-dependent fashion. For 
those of the latter type, the dissociation of ligand-bound SHRs from Hsp90 complex was 
initially assumed to be a cytoplasmic event which happened before the ligand-bound SHRs 
enter the nucleus and act as transcription regulator. However, studies from the last three 
decades have convincingly demonstrated that efficient transport of ligand-bound SHRs into 
the nucleus (half-life approximately 5min) requires Hsp90 complex including hsp90 and 
cochaperones such as TPR immunophillins FKBP51 and FKBP52 (Czar et al. 1997; Galigniana 
1998; Galigniana et al. 2001; Galigniana et al. 2002; Davies et al. 2002; Galigniana et al. 2004; 
Harrell et al. 2004; Piwien Pilipuk et al. 2007; Echeverría et al. 2009; Galigniana et al. 2010). 
The alternative Hsp90-independent retrograde translocation of these receptors is much 
slower (40-60min half-life), allowing for degradasome formation and subsequent targeting of 
the receptor to proteasome (Galigniana et al. 2004).  
This model provides us with a first picture of how Hsp90 cooperates with 
different co-chaperones sequentially to assist the folding of its client proteins. However, the 
detailed mechanism for individual client or client family remains to be further elucidated. For 
example, many co-chaperones have been identified to regulate Hsp90 functions but only a 
few of them has been described in the current model of the chaperone cycle. Other 
cochaperones, such as Cdc37 and Aha1, have been demonstrated to be indispensible for 
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certain client or client class or beneficial under critical conditions. Their integration into the 
chaperone cycle would also be of great interest to the field. 
While early studies focused on protein folding, Hsp90's integration into the 
overall quality control system was not really appreciated until the benzoquinone ansamycin, 
geldanamycin (GA), was shown to be a specific inhibitor of the chaperone (Whitesell et al. 
1994). Numerous subsequent studies revealed that upon GA treatment, client protein kinases 
and transcription factors were rapidly destroyed via the ubiquitin/proteasome pathway 
(Uehara et al. 1986; Schulte et al. 1996; Hartmann et al. 1997; Whitesell et al. 1998; 
Nimmanapalli et al. 2001; Katschinski et al. 2002; Basso et al. 2002; Grbovic et al. 2006; Lu et 
al. 2010) and in the meantime, the Hsp70 system was induced (McLean et al. 2004; 
Davenport et al. 2007; McCollum et al. 2009). These events lead to remarkable results in 
oncogenic transformation as several of Hsp90 cellular substrates are conformational labile 
signal transducers that play key roles in all hallmarks of cancer development such as cell 
proliferation and survival (Raf-1, HER2, etc.), cell cycle progression and apoptosis evasion 
(p53, Akt, Cdk4, Cdk6, telomerase, etc.), tumor angiogenesis (HIF-1, VEGF, etc.), invasion 
and metastasis (MMP2, urokinase, etc.). On top of that, it’s worth noting that many oncogenic 
variants of these same client proteins display unusual stable association with Hsp90 
chaperone complexes, which results in impairing the normal proteolytic turnover of these 
molecules and in the end, providing an overall promoting of oncogenic transformation. This 
was observed with v-Src, an unstable protein kinase, which has a greater requirement for 
Hsp90 than its cellular counterpart c-Src (Xu & Lindquist 1993). Similarly, mutant forms of 
p53 and B-Raf protein kinase have stronger interactions with molecular chaperones than 
their wild type counterparts do (Sepehrnia et al. 1996; Whitesell et al. 1998; Esser et al. 2005; 
Müller et al. 2005; Grbovic et al. 2006). These observations may partly explain the higher 
sensitivity of tumor in contrast to normal, untransformed cells to Hsp90 inhibitors that are 
currently in clinical development.  These findings can also refer to another pivotal but 
previously unrecognized role of Hsp90 in evolution in which this unique chaperone acts as a 
capacitor by helping to fold polymorphic variants of the same protein (Rutherford & 
Lindquist 1998; Queitsch et al. 2002). Upon intense selection pressure within the particular 
host environment, these otherwise hidden variants may gain certain advantages over their 
wild type counterparts and take over normal cellular homeostasis control. In the case of 
cancer development, under extreme selection pressure such as hypoxia, high interstitial 
pressure, constant apoptosis signaling and nutrient deprivation, it is likely that those variants 
are the key determining proteins that shaping the ability of tumor cells to adapt and evolve. 
Hsp90, therefore, sits at a very critical position of the cellular quality control system: the 
nexus of final folding and degradation pathways, in addition to regulating expression of other 
quality control components. 
On the one hand, these critical roles of Hsp90 allow the potential of small 
molecule Hsp90 inhibitors to disrupt multiple oncogenic clients simultaneously which makes 
up a unique and therapeutically attractive feature of these compounds. On the other hand, it 
becomes very difficult to predict which patients are likely to benefit from such drugs if 
response is dictated by the constellation of molecular genetic defects present in their 
particular tumor.  
1.2.3.2 HSP90 CLIENT PROTEINS 
Hsp90 is a “selective” chaperone, whose principles for client selection are still 
poorly understood. The list of its clients consists of more than 200 proteins and is still 
enlarging.  
Transcription factors Kinases Others 
- Steroid hormone - Raf family (Raf-1, B-Raf) - Telomerase 
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receptors (GR, ER, PR, 
AR, etc.) 
- Heat shock factor-1 
(HSF-1) 
- P53 
- Hypoxia-induced factor 
1 (HIF-1) 
- Heme-activated protein 
(Hap1) 
- Stat2, Stat3, Stat5 
- Oct4 and Nanog 
- Etc. 
 
- Src family (v-src, Lck, 
Fyn, etc.) 
- Akt 
- Cyclin-dependent 
kinases (Cdk2, Cdk4, 
Cdk6, Cdk9, Cdk11, etc.) 
- ErbB2 
- Bcr-Abl 
- eEF-2 kinase 
- MAPK6 
- JAK1 
- VEGFR-1, VEGFR-2 
- Aurora-B 
- Etc. 
- Apaf-1 
- Calmodulin 
- Mdm2 
- DNA polymerase  
- Hepatis B virus 
reverse transcriptase 
- Tau 
- Proteosome 
- Myosin 
- Urokinase 
- Matrix 
metalloproteinase-2 
(MMP2) 
- Etc. 
TABLE 1-1: HSP90 CLIENT PROTEINS.  
The list consists of more than 200 proteins and can be categorized into 3 classes: 
transcription factors, kinases and others. A full list of updated Hsp90 clients can be found  
in:  http://www.picard.ch/downloads/Hsp90interactors.pdf  
Via its numerous clients, Hsp90 seems to influence many aspects of cell biology 
such as cell signaling, protein trafficking, innate immune response, cell motility, viral 
infection or even evolution. Currently, it is estimated that Hsp90 from S. cerevisiae physically 
or genetically interacts with more than 1000 different proteins, which accounts for ~20% of 
the yeast proteins, making it the most highly connected protein in the yeast genome (the 
BioGRID Interaction database and Lindquist et al. 2010). However, it is not clear to which 
extent all proteins found to physically interact with Hsp90 are really dependent on its action 
for adopting their functional states, or their requirement of Hsp90 are cell-type and/or 
environmental specific. 
In general, Hsp90 client proteins are diverse in sequence as well as in structure. 
Among these, transcription factors and kinases represent two major groups, indicating that 
Hsp90 has large impact on cellular regulatory processes (Table 1-1) (Wegele et al. 2004).   
Client recognition 
How Hsp90 recognizes specifically its client proteins despite high diversity in 
structures has remained one of the biggest questions in the field. In contrast to many other 
chaperone systems like Hsp70 that recognize exposed hydrophobic parts on partially 
unfolded proteins, Hsp90 seems to preferentially act on highly structured nearly native-like 
substrate proteins (Jakob et al. 1995). This finding was confirmed by several other studies 
lately. A recent study for example could show that Hsp90 specifically bound only to the 
structured region of a staphylococcal nuclease fragment that was otherwise largely unfolded 
(Street et al. 2011).  Also, in case of the steroid hormone receptors that are essentially depend 
on Hsp90 to acquire hormone binding activity in vivo, Hsp90 does likely not promote the 
folding of a newly translated polypeptide of the receptor. Instead, Hsp90 is involved in the 
late step of client maturation: reactivating the receptor for ligand binding after its being 
partially unfolded by Hsp70 (Kirschke et al. 2014). In general, the role of Hsp90 seems to be 
likely stabilization of a specific labile conformation of the client but not to promote its de 
novo folding. The conformational state of a protein might be a more important determinant 
for rendering it a candidate suited for Hsp90 binding than a particular well defined binding 
motif.  
This proposed hypothesis is further supported by a high throughput interaction 
system from study of (Taipale et al. 2012). In this work, the authors have illustrated evidence 
that determinants for Hsp90 binding in client proteins are both widely distributed and highly 
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localized depending on the client family itself. The client selectivity of Hsp90 for kinases, a 
major class of its client classes, is further mediated by the cochaperone Cdc37.  
From the Hsp90 side, according to the most recent results from an NMR study on 
Hsp90-Tau complex, client binding sites also seem to occupy a large sureface of 
approximately 106Å length that runs over two domains (N-terminal and M-domain) with 
many low affinity contacts including both hydrophobic and hydrophilic binding sites.  These 
low-affinity contacts, however, can build up to a high-affinity binding energy. This allows 
recognition of scattered hydrophobic residues in late folding intermediates that remain after 
early burial of the Hsp70 and other “early” chaperone sites (Karagöz et al. 2014). This large 
client binding interface of Hsp90 is also quite unique among the chaperones: it is rather an 
exposed surface than a cleft, pocket or chamber, more extended than that of any protomer of 
known chaperones (Hsp70s, Hsp60s or Hsp100s).  Remarkably, although no longer 
continuously connected, most of the substrate-binding hotspots in Hsp90 N and M domains 
remain accessible upon dimerization of N-terminal domains. These binding sites on Hsp90 
also do not interfere with interaction regions of many cochaperones, including Aha1 and p23. 
Interaction sites for Cdc37 are partially overlapping, however, since the specific client in this 
study is not a kinase (Tau) and Cdc37 is likely to bind to on the other protomer of the Hsp90 
dimer than the client protein (Vaughan et al. 2006), ternary complex should still be possible.  
1.2.4 HSP90 REGULATION MECHANISMS 
Given the numerous client proteins that are dependent on Hsp90 function, it is 
not surprised that Hsp90 has to be tightly and sophisticatedly regulated. Indeed, Hsp90 is a 
conformationally flexible protein that mostly associates with a subset of approximately 20 
proteins (termed “cochaperones”) to perform its function. Besides, binding and hydrolysis of 
ATP is essential and also known to contribute to driving the Hsp90 machinery through 
distinct conformations. These conformations in turn interact, assist the client protein to 
achieve or maintain a certain conformation and release it: Each of these steps is also coupled 
with dynamic association and dissociation of cochaperones. Moreover, evidence is emerging 
that post-translational modifications of Hsp90 itself are involved significantly as well in 
regulating this complex chaperone machinery.  In the following sections, each of these 
regulating factors of Hsp90 will be discussed in more details.  
1.2.4.1 ATPASE ACTIVITY OF HSP90 
Hsp90 proteins possess ATPase activity that is absolutely essential for its 
function (Obermann et al. 1998; Panaretou et al. 1998a). In general, the ATP hydrolysis by 
Hsp90 is slow, with a turnover number of ~0.5-1 min-1 for yeast Hsp90 (Panaretou et al. 
1998b; Weikl et al. 2000; Richter et al. 2001) and only 0.09 min-1 for human Hsp90 
(McLaughlin et al. 2002; Stankiewicz et al. 2010). The affinity of Hsp90 for nucleotide is 
rather weak with Kd (dissociation constant) on the order of ~100µM (Prodromou et al. 1997; 
Panaretou et al. 1998b; Weikl et al. 2000; Wegele et al. 2003) .  The ATPase-coupled 
conformational changes in Hsp90 have been studied intensively with much success provided 
from structural studies. 
In its ATPase cycle, Hsp90 adopts a number of structurally distinct 
conformations, which are induced by nucleotide (Graf et al. 2009). In the apo state, Hsp90 
adopts a V shape conformation, termed “open conformation”. ATP binding trigger a series of 
conformation changes including the closure of the lid segment in N domain, transient 
dimerization of the two N domains in the dimer and the docking of the catalytic loop from M 
domain into the nucleotide-binding pocket of the N domain (Pearl & Prodromou 2006; Ali et 
al. 2006). Finally Hsp90 reaches a more compact conformation, termed “closed 
conformation” in which the N domains are dimerized, locked by swapping of -strands 
between two protomers and M domains twisted along the molecule axis forming a “clamp” 
structure. Then Hsp90 reaches a fully closed state in which ATP hydrolysis occurs. After ATP 
is hydrolyzed, the N- domains disassociate, release ADP, Pi and Hsp90 returns to the open 
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conformation again. A region at the very beginning of the N-terminal (first 24 amino acids) 
was supposed to be an instrinsic regulator of Hsp90 ATPase activity because removal of this 
part on the one hand confers flexibility to the lid region but on the other hand,  results in loss 
of productive N-terminal dimerization and hence, also loss of ATPase activity (Richter et al. 
2002; Richter et al. 2006). 
 
FIGURE 1-3: MODEL OF THE HSP90 ATPASE CYCLE.  
The cylcle starts with Hsp90 in open conformation (top, left). After fast ATP binding, 
conformational changes in N-terminal domain resulted in repositioning of lid segment (I 1).  
Then N-terminal domains from two protomers dimerize (I 2) and rearrangement of N-M 
domains leads to the fully closed state in which atp hydrolysis occurs. Cochaperone s such as 
Sti1 or Aha1 regulate Hsp90 ATPase cycle by inducing structural changes that either blocks 
or facilitates formation of intermediate conformations. Reproduced from (Hessling et al.  
2009) 
The first view of “closed conformation” of a full-length Hsp90 came from the 
crystal structure of yeast Hsp82 bound with the co-chaperone p23/Sba and the non-
hydrolysable ATP analogue AMPPNP (Ali et al. 2006) (Figure 1-1). Recent biophysical studies 
using single molecule FRET assays allowed further dissecting of the ATP-induced 
conformational changes (Mickler et al. 2009; Hessling et al. 2009). In principle, there are two 
important intermediates between the open and closed conformation. The first intermediate 
(I1) has ATP bound and lid region closed over the nucleotide binding pocket but N domains of 
two protomers are still apart. Then the N-terminal dimerization leads to the formation of the 
second intermediate state (I2), in which the M domain repositions and interacts with the N 
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domain.  The transitions between open conformation to I1 and from I1 to I2 are rate-limiting 
steps of the ATPase cycle rather than the hydrolysis reaction itself (Hessling et al. 2009) 
(Figure 1-3). 
The dynamics of Hsp90 conformations were, however, shown to be only weakly 
coupled with the ATPase cycle in single molecule FRET (Mickler et al. 2009). This finding is 
also in agreement with a previous observation using ensembles from electron microscopy 
data (Southworth & Agard 2008), indicating that Hsp90, independence of nucleotide, has 
many conformational states and the binding of nucleotide would only shift the equilibrium 
more in favor of one or another state rather than locking all Hsp90 molecules in a single 
conformation.  
1.2.4.2 COCHAPERONES 
Hsp90 alone exhibits limited chaperone activity towards a wide range of 
subtrates. Hsp90 acts in a multiple-chaperone complex, including other chaperones, adaptors, 
modulators, etc. termed in general “cochaperones”, on client proteins. More than 20 of such 
cochaperones have been identified in eukaryotic cells and were shown to regulate Hsp90 in 
different ways such as via ATPase cycle as well as recruitment or release of specific client 
proteins to and out of the complex (Young & Hartl 2000; Richter et al. 2004; Pearl & 
Prodromou 2006; McLaughlin et al. 2006; Wandinger et al. 2008; Vaughan et al. 2009; 
Retzlaff et al. 2009; Retzlaff et al. 2010; Gaiser et al. 2010a; Li et al. 2011; Li et al. 2013). Some 
representative cochaperones will be discussed further in more details. 
HOP (Hsp70/Hsp90 Organizing Protein) 
HOP belongs to a class of proteins called TPR-containing proteins (TPR: 
tetratricopeptide repeat), which share the presence of a TPR domain in their structures. This 
TPR domain recognizes the C-terminal MEEVD motif in Hsp90 through a highly conserved 
clamp domain. Structurally, TPR domain consists of generally three degenerated 34-amino 
acid repeats forming two anti-parallels α helices separated by a turn. The helix-turn-helix 
motifs stack upon each other to form a superhelical groove, which interacts with TPR 
acceptor modules (Scheufler et al. 2000).  
Together with HOP, many other TPR proteins are also cohaperones of Hsp90 
such as members of PPIase family: Cyp40 (yeast homologous Cpr6/Cpr7), FKBP51, FKBP52, 
and phosphatase PP5 (yeast homologue Ppt1), etc (Barent et al. 1998; Wandinger et al. 
2006).  
Early experiments on steroid hormone receptors have identified Hsp90, Hsp70 
and HOP in a large 9S complex (Smith 1993; Wegele et al. 2004). Hsp70 is known to be a 
chaperone by itself, involved in folding nascent polypeptide and refolding misfolded proteins. 
HOP doesn’t have chaperoning activity but can bind to both Hsp90 and Hsp70, forming an 
intermediate complex in which the substrate is transferred from Hsp70 to Hsp90 for the final 
stage of folding (Wegele et al. 2004; Wegele et al. 2006). When deleted, its yeast homologue 
(Sti1) was shown to be important for GR maturation and also for an unrelated Hsp90 client 
protein, v-src kinase, confirming its role as Hsp90 cochaperone for clients in general (Chang 
et al. 1997).  
HOP contains three TPR domains: TPR1, TPR2a and TPR2b which allows it to 
interact simultaneously with Hsp70 and Hsp90 (both have EEVD motif at the C-terminus). It 
also inhibits the ATPase activity of Hsp90 non-competitively (Richter et al. 2003). Several 
studies have identified TPR1 and TPR2a being responsible for binding to Hsp70 and Hsp90, 
respectively (Scheufler et al. 2000; Brinker et al. 2002). However, further evidence using 
truncation constructs of HOP in ATPase assays, pulldown, crosslinking experiments and 
hydrogen deuterium exchange mass spectroscopy (HD-MS) have revealed that interaction 
between Hsp90 and HOP involves also TPR2b and also provided more insights into the 
molecular mechanism of how HOP inhibits Hsp90’s ATPase activity (Flom et al. 2007; 
Johnson et al. 2007; Lee et al. 2012).   Taken from the Hsp90 side, there is an overall 
reduction of conformational flexibility of Hsp90 when bound to HOP. In more details, HOP 
utilizes both TPR2a and TPR2b to stabilize Hsp90 in an open conformation preventing N-
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terminal dimerization and docking of the NBD with the MD (Richter et al. 2003; Lee et al. 
2012).  These findings explain why HOP can facilitate client transfer from Hsp70 to Hsp90 
system and provide more proofs that HOP may be required by most Hsp90 clients to interact 
with Hsp90.   
p23 
p23 is the smallest protein in the Hsp90 machinery (molecular weight 18-25 
kDa) which was first characterized in the Hsp90-steroid hormone receptor complex (Johnson 
et al. 1994). Together with HOP, Hsp70, Hsp40 and Hsp90, p23 make up a minimal in vitro 
system that is capable of chaperoning Hsp90 client proteins such as steroid hormone 
receptors or hepatitis B virus polymerase (Hu et al. 1997). Similar to HOP, p23 was also 
reported as a part in Hsp90 complexes with several other clients such as estrogen receptor, 
human Fes protein-tyrosine kinase, human heat shock transcription factor Hsf1, human aryl 
hydrocarbon receptor (Nair et al. 1996), telomerase (Holt et al. 1999) and hepadnavirus 
reverse transcriptase (Hu et al. 1997), etc. Whether p23 directly binds to those client proteins 
or via Hsp90 is not clear, since unlike most of other Hsp90 cochaperones, p23 itself has a 
chaperone activity to passively prevent aggregation of denatured proteins (Bose et al. 1996; 
Freeman et al. 1996).  
This protein is also a well conserved component of the Hsp90 machinery, 
composed of 2 domains: N-terminal mainly formed by β-sheets and an unstructured C-
terminal tail. p23’s own chaperone activity (but not its binding to Hsp90) is dependent on 
this unstructured part (Weikl et al. 1999).  Interestingly, this region was also reported to be 
important for activation of progesterone receptor (Weaver et al. 2000) and regulation of 
telomerase (Woo et al. 2009) via the Hsp90 system. 
Binding of p23 to Hsp90 is direct and enhanced significantly by ATP as well as 
decreased by ADP (Johnson & Toft 1995; Sullivan et al. 1997). A crystal structure of yeast 
p23/Sba1 and full length yeast Hsp90 (Hsp82) has given even more interesting insights into 
the mechanism of p23 interacts with Hsp90: p23/Sba1 has several contacts with the backside 
of the ATP-lid in the N-terminal domain of Hsp90 which is only presented in the correct 
three-dimensional configuration when Hsp90 is in the ATP-bound state; moreover and 
unexpectedly, p23 stabilizes the catalytic loop in an active conformation (Ali et al. 2006). In 
contrast to p23/Sba1 positioning in the crystal structure that favors a ATP-hydrolysis-
promoting conformation of yeast Hsp90, biochemical evidence in several publications 
demonstrate that similar to HOP, p23 inhibits Hsp90’s ATPase activity (McLaughlin et al. 
2002; Panaretou et al. 2002; Richter et al. 2004; McLaughlin et al. 2006). Recently, work from 
our group by hydrogen-deuterium exchange mass spectroscopy and single turnover ATPase 
assay have demonstrated that p23/Sba1 reduces the conformational flexibility of the ATP lid 
and thus, preventing product release which resulting in inhibiting ATPase activity (ref: from 
Frontiers paper: Graf).  
p23 can form ternary complexes with Hsp90 and Cpr6 or PP5 (Harst et al. 2005; 
Woo et al. 2009; Li et al. 2011), but competes with HOP/Sti1 (Li et al. 2011) and Aha1 (Harst 
et al. 2005; Li et al. 2013) for binding, indicating clearly that p23 enters at a late stage of 
Hsp90 chaperone cycle. It is reasonable to postulate that after the client is transferred from 
Hsp70 to Hsp90 via HOP, p23 joins the complex, traps Hsp90 in a closed state with extensive 
inter-dimer contact and sustains this conformation for the completion of client activation 
before the release of the ATP hydrolysis product. 
Aha1 
One interesting cochaperone of Hsp90 is Aha1 (“Activator of Hsp90 ATPase 1). 
Aha1 is first identified by homology searches with Hch1, (“high-copy Hsp90 supressor 1), 
which rescues the phenotype of a Hsp90 ts-mutation (E381K) (Nathan et al. 1999; Panaretou 
et al. 2002). Both, Hch1 and Aha1, were found to directly interact with Hsp90, in vivo and in 
vitro (Panaretou et al. 2002). Hch1 and Aha1 have a stimulatory effect on the Hsp90 ATPase 
activity, however, to different extents. The isolated Aha1 N- terminal fragment, which 
corresponds to the Hch1 full-length protein, also stimulates Hsp90’s ATPase but only to 
approximately 25% that of full length protein, whereas its C-terminal fragment had no effect. 
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Hch1 was shown to stimulate Hsp90 ATPase activity to a similar extent as Aha1-N, but only at 
higher concentrations of the cochaperone required (Panaretou et al. 2002). Given their 
overlapping functions with respect to Hsp90 ATPase activation, it is surprising that yeast 
cells contain both Hch1 and Aha1 at the same time while in higher organisms only Aha1 
homologues can be found. A knockout of either Hch1 or Aha1 in yeast cells did not result in 
any obvious growth defect, suggesting that their function might be intimately connected only 
with rather specific Hsp90 clients. However, when Hsp90 levels were depleted in cells or 
under other stress conditions, a double knockout of Hch1 and Aha1 led to a reduced 
thermotolerance (Panaretou et al. 2002; Lotz et al. 2003). Results from v-src maturation 
which is Hsp90-dependent in Saccharomyces cerevisiae also indicates that Hch1 can to some 
extent compensate for Aha1 functions and that both cochaperones obviously impact on 
Hsp90 client protein activation (Panaretou et al. 2002; Lotz et al. 2003). The concentration of 
Aha1 in cells seems to be critical. Overexpression of Aha1 can have deleterious effects as 
shown for CFTR (Mollapour et al. 2014) . The folding and maturation of CFTR is so inefficient 
that it requires prolonged association with molecular chaperones (Loo et al. 1998; Youker et 
al. 2004), while by accelerating ATPase cycle of Hsp90, Aha1 reduces dwell time of client in 
the chaperone complex. Thus, for the Hch1/Aha1 cochaperones, unique property of 
accelerating Hsp90 ATPase activity seems to be connected with the activation of certain 
Hsp90 client proteins, supporting the hypothesis that cochaperones might importantly 
contribute to the client specificity of the Hsp90 machinery. 
Details on interactions between the N- terminal domain of Aha1  bound the 
Hsp90 M-domain were discovered from crystallography study (PDB: 1USV), revealing 
possible mechanism of Aha1 effects on the Hsp90 cycle (Meyer et al. 2004). The N domain of 
Aha1, with its elongated cylindrical structure orienting along the long axis of Hsp90´s M 
domain, interacts extensively with all three subdomains of this segment (Figure 1-4). Most 
interactions are polar, between those basic residues exposed on M domain´s surface and 
acidic residues from Aha1. There is one notably non-polar contact (since it involves the 
catalytic residue Arg380 of Hsp90), in which a hydrophobic patch on Aha1 packs against a 
similar patch on Hsp90. By comparing the structures of Hsp90´s M domain in free and Aha1-
bound crystals, it is hypothesized that Aha1 interactions causes some movements in the 
catalytic loop of Hsp90´s M domain, which release the catalytic Arg380 from its retracted and 
inactive interaction with nearby residues, enabling its insertion into the nucleotide-binding 
pocket in the N-terminal domain. FRET measurements also support this hypothesis: The 
presence of Aha1 was shown to enable Hsp90 bypassing the I1 state (ATP-bound and lid 
closed) to directly reach the I2 state (N-terminal dimerized and M-domain repositioned 
towards ATP-binding pocket) in the ATPase cycle (Hessling et al. 2009) (Figure 1-3).  
 The C-domain of Aha1 was shown to further contribute to the ATPase 
stimulation by providing additional binding contacts with the N domain of the opposing 
Hsp90 protomer or a hydrophobic groove formed by transient, ATP-dependent dimerization 
of both Hsp90 N domains which stabilizes its closed dimerized conformation capable of ATP 
hydrolysis (Retzlaff et al. 2010; Koulov et al. 2010).  Interestingly, Aha1 binds in an 
asymmetric fashion to Hsp90, one molecule of the cochaperone per Hsp90 dimer is sufficient 
for full ATPase stimulation, leaving the possibility of a simultaneous client protein binding to 
an Hsp90 - Aha1 complex (Retzlaff et al. 2010).  
In size-exclusion chromatography, Aha1 competes with HOP/Sti1, Cdc37 and p23 
for binding to Hsp90 (Harst et al. 2005). Recently, using analytical ultracentrifugation, it was 
further resolved that Aha1 together with Cpr6 and nucleotide dissociates HOP/Sti1 from 
Hsp90-client complex to accelerate the progression of the chaperone cycle to fully-closed 
state of Hsp90 in which Aha1 is then replaced by p23 (Li et al. 2013).  
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FIGURE 1-4: CRYSTAL STRUCTURE OF YEAST 
AHA1 IN COMPLEX WITH YEAST HSP90  
(Aha1: N-terminal domain, Residue 1-156, 
colored yellow)  (Hsp90: M-domain, residue 
272-530, colored red) (Pdb 1usv) .  
Aha1/Hsp90 interaction is 
considered to be important for the chaperoning 
of many Hsp90 clients, including ErbB2, v-src, 
Cdk4, c-raf, etc (Holmes et al. 2008; Lotz et al. 
2003; Panaretou et al. 2002). However, the 
significant decreased Aha1 interaction with 
certain Hsp90 variants provoked observable 
effects only with a selected number of clients 
(Mollapour, Tsutsumi, et al. 2011; Mollapour et 
al. 2014) indicating that Aha1 is critical only for 
selective clients in the Hsp90 client set and like 
the cochaperones p23 and Cdc37 (Felts & Toft 
2003; MacLean & Picard 2003; Kimura et al. 
1997), may have additional activities in cells 
that are independent of its role in modulating 
Hsp90 activity (Sun et al. 2012).  
Cdc37  
Cdc37 is another co-chaperone which 
inhibits the ATPase activity of Hsp90 (Siligardi 
et al. 2002; Gaiser et al. 2010b). This interference is mediated by the insertion of the Cdc37 
R167 side chain into the nucleotide binding pocket of Hsp90, which directly inhibits the 
binding of ATP (Roe et al. 2004). Furthermore, the packing of C-terminal helixes of Cdc37 
onto Hsp90’s lid segment prevents its closing over the nucleotide-binding pocket and blocks 
the access of catalytic residue(s) from Hsp90’s M-domain to the pocket. Finally, Cdc37 
positions itself between the two N domains of Hsp90 dimer, impeding their dimerization and 
thus, arrests Hsp90 ATPase cycle in a conformation responsive for client loading (Roe et al. 
2004; Siligardi et al. 2002)  (Figure 1-5). These structural findings are in agreement with 
studies in yeast which exhibited interaction between Cdc37 and Sti1/HOP - the cochaperone 
that also acts in client transfering to Hsp90 - either in cell extract or in purified system. The 
biological significance of this interaction also has been shown genetically. Combinations of 
cdc37 and sti1 mutations are synthetically lethal (Abbas-Terki et al. 2002), and strains lacking 
Sti1 are defective in maturation of the Ste11 kinase, a defect that can be suppressed by 
overexpression of Cdc37 (Lee et al. 2004). 
Cdc37 was originally identified by genetics study in S. cerevisiae as a gene 
essential for cell cycle progression (hence the cdc designation for cell division cycle), which is 
in agreement with biochemical evidence of its association and critical role for important 
cyclin-dependent kinases such as Cdc28 (Reed 1980; Gerber et al. 1995). It has been proven 
to be essential for viability in many eukaryotic model organisms even though poorly 
consevered (MacLean & Picard 2003). It is also found in the complex of Hsp90 and the 
tyrosine kinase v-src and later, in the complex of Hsp90 and many other kinase clients 
(Stepanova et al. 1996; Grammatikakis et al. 1999; Shao et al. 2001; Abbas-Terki et al. 2000; 
H. Wang et al. 2002; Mort-Bontemps-Soret et al. 2002; Vaughan et al. 2006; Taipale et al. 
2012). Therefore, it has been long thought that Cdc37’s primary function is an Hsp90 specific 
cochaperone for protein kinases. Kinases in general have diverse structures, however, all 
contain a conserved catalytic domain, especially the glycine-rich (Gly-X-Gly-X- X-Gly) motif, 
which Cdc37 recognizes and binds with its N-terminal domain (Shao et al. 2003; Prince & 
Matts 2005; Terasawa et al. 2006; Vaughan et al. 2006; Polier et al. 2013).  Similar to p23, 
Cdc37 has its own intrinsic chaperone activity which was shown by stabilizing purified 
unfolded β-galactosidase in an activation competent state (without refolding it) and also the 
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inherently unstable casein kinase II in vitro (Kimura et al. 1997). More interestingly, in vivo, 
Cdc37 can even partially compensate for decreased Hsp90 function, for e.g in maintaining v-
Src (an Hsp90 kinase client) activity. An Hsp90-binding deficient Cdc37 variant when over-
expressed can replace the essential full-length protein as well (Kimura et al. 1997; P. Lee et al. 
2002). Cdc37 is also not entirely dedicated to kinases as substrates, although they dominate 
the currently known list of Cdc37 clients. It was shown to interact with and together with 
Hsp90, is required for androgen receptor (Rao et al. 2001) and hepadnavirus reverse 
transcriptase activation (X. Wang et al. 2002). 
 
FIGURE 1-5: CRYSTAL 
STRUCTURE OF HUMAN 
CDC37 IN COMPLEX WITH 
YEAST HSP90  
(Cdc37: C-Terminal,  
residues 125-378, 
colored green) (Hsp90: 
N-Terminal domain, 
residues 1-214, colored 
pink – the lid region is 
highlighted in blue) (Pdb 
1us7).  
 
 
 
Taken together, the data suggests that Cdc37 may act on client proteins 
independently of Hsp90 and that the function of Cdc37 on kinase and not-kinase client 
proteins of Hsp90 is rather more than just introducing the clients to Hsp90 or stabilizing 
their complex with Hsp90. 
As mentioned, the list of Hsp90 cochaperones consists of many more components 
including Hsp70, FKBP51/FKBP52, CHIP, PP5, Ppt1, Cyp40, Sgt1, Tah1, Pih1, Cns1, VCP, etc. 
Most of the Hsp90 co-chaperones were first identified by virtue of their co-purification with 
Hsp90 complexes isolated from cell extracts; or were identified by virtue of physical or 
genetic interactions with Hsp90 proteins. These cochaperones regulate the ATPase activity of 
Hsp70 or Hsp90 and/or have specific in vivo functions, such as localization or trafficking. 
They also may affect Hsp90 function in a client-specific manner. The overall composition of 
the Hsp90 molecular chaperone machine appears to vary in diverse eukaryotic organisms, 
and genes encoding co-chaperones that stimulate (Aha1) or inhibit (Hop/Sti1 and Cdc37) the 
essential ATPase activity of Hsp90 are not absolutely conserved (Johnson & Brown 2009).   
Recently, proteomic data also showed that all known cytoplasmic Hsp90 
cochaperones were by far sub-stoichiometric to the total cytosolic pool of Hsp90 proteins 
(Finka & Goloubinoff 2013). A substoichiometric molar ratio 1:7 was found for the p23 
(which inhibits Hsp90 ATPase), 1:16 for the Hsp70/Hsp90-organizing protein (STIP1, HOP), 
1:34 for Aha1 (activator of the Hsp90 ATPase (AHSA1), 1:41 for the ubiquitin ligase CHIP, and 
1:46 for the oncogenic cochaperone adaptor CDC37. Such substoichiometric ratios indicate 
that none of the cochaperones form intrinsic subunits of core Hsp90 dimers and rather 
associate dynamically to regulate the numerous cellular activities of Hsp90 (Finka & 
Goloubinoff 2013). Thus, the function of most co-chaperones may be restricted to subsets of 
client proteins either species-specific or in response to certain cellular conditions. 
Furthermore, these findings also indicate that in cells, there are further regulation 
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mechanisms that modulate distinct cochaperone recruitment to Hsp90 complexes at different 
stage of the chaperone cycle.  
1.2.4.3 POST-TRANSLATIONAL MODIFICATIONS 
Another level of regulation that has gained increasing attention is post-
translational modifications of Hsp90. 
Hsp90s are known to be heavily post-translational modified, including 
phosphorylation at several sites (serines, threonines and tyrosines), S-nitrosylation, 
acetylation, lysine methylation, ubiquitination and most recently SUMOylation with effects 
observed on client and/or cochaperones interaction, client maturation and subsequent, 
degradation (Figure 1-6) (S P Lees-Miller & Anderson 1989; Bali et al. 2005; Kovacs et al. 
2005; Martínez-Ruiz et al. 2005; Dote et al. 2006; Duval et al. 2007; Scroggins et al. 2007; 
Yang et al. 2008; Kurokawa et al. 2008; Kekatpure et al. 2009; Mollapour, Shinji Tsutsumi, et 
al. 2010; Mollapour, Tsutsumi, et al. 2011; Franco et al. 2013; Mollapour et al. 2014). 
Although some of the modified amino acid positions have already been identified (mostly by 
incorporation of the corresponding radio-labeled groups and/or mass spectrometry), it is 
still a challenging task to obtain a global qualitative or quantitative picture of the 
modifications. 
S-nitrosylation is a reversible modification in which a nitrogen monoxide group 
is attached to the thiol side chain of cysteine. For this modification, a feedback loop between 
human Hsp90 and its substrate endothelial nitric oxide synthase (eNOS) was discovered 
(García-Cardeña et al. 1998; Martínez-Ruiz et al. 2005).  eNOS activity depends on the 
chaperone activity of Hsp90; whereas the nitrosylating agent NO modifies human Hsp90 at 
Cys597 (in the C-terminal domain) and this modification inhibits the Hsp90 ATPase activity, 
which in turn diminishes the up-regulation of eNOS activity by Hsp90. This might facilitate a 
tight regulation of cellular NO production in a negative feedback loop (Martínez-Ruiz et al. 
2005). Further studies also showed that surprisingly both C-terminal as well as N-terminal 
association properties of C597-nitrosylated variant of Hsp90 were altered and thus, 
equilibrium between different conformations of Hsp90 is also shifted (Retzlaff et al. 2009).  
 
 
FIGURE 1-6: POST-TRANSLATIONAL MODIFICATION SITES ON HSP90 .  
Phosphorylation S (light blue) or T (Dark blue) or Y (purple); Methylation K (Black); Acetylation K 
(green); Ubiquitination K (red); S-Nitrosylation C (pink) and Sumoylation K (orange)) 
Acetylation is the post-translational modification that adds acetyl groups to 
proteins, typically on lysine residues. Histones are one of the first and major acetylation 
target and thus, historically acetylating enzymes were termed histone acetylases (HAT) and 
deacetylating enzymes histone deacetylases (HDAC). However, these enzymes act on more 
protein targets than histone, including Hsp90. For acetylation of Hsp90, a similar scenario to 
S-nitrosylation emerges. Histone deacetylase (HDACs) inhibitors, which result in the 
hyperacetylation of Hsp90, lead to a reduced interaction with and maturation of several of its 
substrate proteins, such as p53, Raf1, Bcl-Abl, and the glucocorticoid receptor (Yu et al. 2002; 
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Nimmanapalli et al. 2003; Murphy et al. 2005; Kovacs et al. 2005)(Kovacs et al. 2005; Murphy 
et al. 2005; Yu et al. 2002; Nimmanapalli et al. 2003). As a consequence, an increase in 
proteasomal degradation of some Hsp90 substrates was detected. Besides the ability to 
interact with its substrate proteins, the ATP binding properties of Hsp90 was also shown to 
be compromised upon acetylation of Hsp90 (Murphy et al. 2005; Rao et al. 2008). The 
enzymes deacetylating Hsp90 were identified to be mostly HDAC6, but also HDAC10 or 
HDAC1 (Kovacs et al. 2005; Zhou et al. 2008; Park et al. 2008).  It is however not clear yet 
whether distinct HDACs alter Hsp90 acetylation state on individual site or they may work 
redundantly.  In vivo, Hsp90 is acetylated at several sites; one was identified as Lys294 (in 
human Hsp90α) (Scroggins et al. 2007). Using acetylation-mimicking variant or a mutant that 
connot be acetylated of Hsp90, the authors have shown that acetylation at this lysine on 
Hsp90 leads to diverse effects on the chaperone interaction with different cochaperones 
while mostly weakens its interaction with client proteins (Scroggins et al. 2007). Acetylation 
of Hsp90 is also required for viability in Saccharomyces cerevisiae indicating its significant 
role to at least one important Hsp90 client in yeast (Scroggins et al. 2007). 
SUMOylation in Hsp90 was already reported several times in proteomics studies 
in the last ten years (Panse et al. 2004; Zhou et al. 2004; Pountney et al. 2008). However, 
identification of individual SUMOylated lysine residues and their impact on Hsp90 function 
remained unexplored until a very recent publication by Neckers and colleagues, in which a 
SUMOylation of an N domain lysine conserved in both yeast and human Hsp90 were 
demonstrated to initiate recruitment of Aha1 to the chaperone complex in cells. Interestingly, 
the N-terminal SUMOylation of Hsp90 is asymmetric and it also unexpectedly facilitates 
binding of Hsp90 inhibitors and sensitizes yeast and mammalian cells to these drugs 
(Mollapour et al. 2014). 
Phosphorylation is one of the most common post-translational modifications of 
proteins in general and has been extensively studied over decades. Phosphorylation of Hsp90 
is not an exception: Hsp90 was detected as a phosphoprotein associated in 
immunoprecipitated v-src polypeptides from in vitro or in vivo synthesis in late 1970s (Sefton 
et al. 1978).  Hsp90 phosphorylation level is quite high under physiological conditions: it is 
one of the major phosphorylated proteins in cells both under normal and heat shock 
conditions (Kelley & Schlesinger 1982; S P Lees-Miller & Anderson 1989). More interestingly, 
Hsp90 has several phosphorylated isoforms as could be observed in 2D gel (Welch et al. 
1983). For mammalian Hsp90 proteins, the majority of Hsp90 molecules contain on average 
5.8 mol of phosphate per mol of dimer (Iannotti et al. 1988). 
Phosphorylation of Hsp90 was reported to occur on serine, threonine and 
tyrosine residues distributed along the proteins in all three domains (Iannotti et al. 1988; S P 
Lees-Miller & Anderson 1989; Smith 1993; Mimnaugh et al. 1995; Zhao et al. 2001; Adinolfi et 
al. 2003; Ecroyd et al. 2003; Ogiso et al. 2004; Duval et al. 2007; Kurokawa et al. 2008; Miyata 
2009; Mollapour, S. Tsutsumi, et al. 2010; Mollapour, Tsutsumi, et al. 2011; Soroka et al. 
2012; Muller et al. 2012; Solier et al. 2012; Barabutis et al. 2013).  Kinases suggested to 
phosphorylate Hsp90 include casein kinase 2 (CK2), DNA-dependent protein kinase (DNA-
PK), protein kinase A (PKA), GSK3-, Akt and in yeast cells, Swe1/Wee1 and the Akt homolog 
Sch9 (S P Lees-Miller & Anderson 1989; Morano & Thiele 1999; Barati et al. 2006; Muller et 
al. 2012; Mollapour, Shinji Tsutsumi, et al. 2010; Mollapour, Tsutsumi, et al. 2011; Solier et al. 
2012). Interestingly, one of the cofactors associating with Hsp90 via a TPR domain is 
PP5/Ppt1, a bona fide phosphatase which dephosphorylates Hsp90 in a specific manner only 
when bound to Hsp90 (Wandinger et al. 2006). Dephosphorylation of Hsp90 is important for 
its in vivo function, as in a PPT1 deletion strain, the maturation of several substrate proteins 
was found to be impaired (Wandinger et al. 2006).  
On the other hand, influences of phosphorylation on Hsp90 activity are diverse 
and site-dependent. Some phosphorylation sites seem to be involved in client-specific 
manner, whereas others regulate more or less all studied client proteins with similar or 
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contradictory effects (S P Lees-Miller & Anderson 1989; Susan P Lees-Miller & Anderson 
1989; Duval et al. 2007; Mollapour, S. Tsutsumi, et al. 2010; Mollapour, S. Tsutsumi, Truman, 
et al. 2011; Solier et al. 2012; Muller et al. 2012) .  More details on regulation of Hsp90 by 
some well-characterized phosphorylation sites of Hsp90 will be discussed further in the 
following.  
Thr5 and Thr7 (human Hsp90) (Susan P Lees-Miller & Anderson 1989; Solier et 
al. 2012; Quanz et al. 2012)  
Study in late 1980s by Lees-Miller et al has shown that double-stranded DNA-
activated protein kinase isolated from HELA cells is able to phosphorylate Hsp90 at Thr5 
and Thr7 (these residues are not conserved in the Hsp90 isoform) (Susan P Lees-Miller & 
Anderson 1989). More than 20 years later, both reports from Quanz et al and Solier et al have 
further gained insights into physiological significance of this phosphorylation event: Hsp90 
phosphorylation by DNA-PK is linked to response to DNA-damage and critically involved in 
both DNA damage repair foci as well as apoptosis events (Quanz et al. 2012; Solier et al. 
2012).  
Thr36 (human Hsp90) or Thr31 (human Hsp90) or Thr22 (yeast Hsp82) 
(Mollapour, Tsutsumi, et al. 2011; Mollapour, S. Tsutsumi, Kim, et al. 2011) 
Thr22 in yeast Hsp82 is a conserved threonine residue in the N domain of Hsp90 
which corresponds to Thr36 in human Hsp90 or Thr31 in human Hsp90. Work by 
Mollapour et al in 2011 has provided evidence that in yeast, Thr22 is the only site in the N-
terminal domain of Hsp90 that gets phosphorylated by CK2 (which is not the case in human 
Hsp90 where CK2 phosphorylates numerous threonine residues in the N-terminal domain). 
This is an unexpected finding as Thr22 in yeast Hsp90 or Thr36 in human Hsp90 is not 
followed by series of acidic residues as commonly known for CK2’s recognition motif. 
Thr22 is among a group of residues that have been shown to form an interacting 
cluster in ATP-bound Hsp90. The hydrophobic interactions established by this cluster are 
essential for N-terminal dimerization and are necessary for active site formation and for 
ATPase activity (Cunningham et al. 2008). CK2-mediated phosphorylation of Thr22 requires 
ATP binding but not N-dimerization. In vitro and in vivo assays ultilizing nonphosphorylatable 
and phosphomimetic variants of Hsp90 at this residue reveals that CK2-dependent 
phosphorylation status at this position influences Hsp90 chaperone activity in a very 
complicated manner. Mutation of this residue to the nonphosphorylatable variant (T22A) did 
not significantly affect Hsp90 ATPase activity, while phosphomimetic mutation (T22E) 
reduced ATPase activity by more than half, although both mutants were able to support yeast 
growth when present as the sole Hsp90 in vivo. Consistent with its reduced ATPase activity, N 
domain dimerization of yHsp90-T22E in the presence of AMPPNP was less efficient than that 
of either wild-type yeast Hsp90 or yeast Hsp90-T22A. Neither T22 mutants were able to fully 
chaperone several kinase clients in yeast, including v-src, Ste11, and Mpk1/Slt2. In general, 
yeast Hsp90-T22E displayed the more severe chaperone defect. In mammalian cells, the 
situation is similar. Because neither nonphosphorylatable nor phosphomimetic Hsp90 
mutants are competent to chaperone v-src, conformational changes provided by dynamic 
phosphorylation and dephosphorylation of T22/T36 are likely to be necessary for optimal 
Hsp90 chaperoning of this client while it is not clear which is optimal for the other clients. On 
the other hand, in yeast, Hsp90 T22E mutation supported greater than 4-fold more 
glucocorticoid receptor (GR) activity compared to wild-type Hsp90, while mutation to T22A 
resulted in less than half the GR chaperoning activity of wild-type Hsp90 despite their 
uniform binding to GR in immunoprecipitation (IP) assay. Like GR, stability and/or 
maturation of the highly dependent Hsp90 client CFTR was enhanced in both yeast and 
mammalian cells expressing T22E/T36E Hsp90 variant. Thus for some particular clients, 
including GR and CFTR, phosphorylation of Hsp90 at T22/T36 seem to be of great benefit.  
Similar to chaperoning effect on kinase clients, interactions of Hsp90 with the 
cochaperones Aha1 and Cdc37 are severely weakened in both forms of Hsp90 phospho 
mutants. This effect on cochaperone interaction is likely part of the underlying mechanism 
for the chaperoning defects since Aha1 overexpression in vivo not only restored association 
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of Cdc37 and Aha1 itself with Hsp90 but also repaired fully or partly Hsp90 chaperone 
activity for kinase clients. Interestingly, Aha1 overexpression even reduced the chaperone 
activity of yeast Hsp90-T22E to the level of wild-type yHsp90, while increasing GR activity in 
the context of yeast Hsp90-T22A to twice that of  wild-type yHsp90. Overall, CK2-dependent 
phosphorylation of T22/T36 in Hsp90’s N domain significantly affects chaperone function in 
yeast and mammalian cells, allowing Hsp90 to discriminate among its extensive client set, in 
part by modulating interaction of the cochaperones Cdc37 and Aha1.  
Another important characteristic of phosphorylation at Thr22/Thr36 is that 
phosphomimetic variant when expressed as sole source of Hsp90 in yeast exhibits increased 
sensitivity to wide range of Hsp90 inhibitors at high concentrations. This result identifies T22 
as an important determinant of Hsp90 inhibitor sensitivity in yeast.  
Tyr38 (human Hsp90) or Tyr24 (yeast Hsp82) (Mollapour, Shinji Tsutsumi, et al. 
2010) 
Swe1/Wee1 tyrosine kinase is an Hsp90 client that regulates the G2/M cell cylcle 
transition by phosphorylating Cdc28 (Booher et al. 1993; McGowan & Russell 1993; Harvey & 
Kellogg 2003). Swe1 also directly phosphorylates a conserved tyrosine residue (Tyr24 in 
yeast Hsp82 and Tyr38 in human Hsp90) in the N-terminal domain of Hsp90 proteins both 
in vitro and in vivo using yeast model. In yeast cells, Swe1-mediated phosphorylation of 
Hsp90 occurs in S phase of the cell cycle and causes Hsp90’s translocation from nucleus to 
cytoplasm. There was no tyrosine phosphatase identified to be involved despite extensive 
search using phosphatase inhibitors by the authors, suggesting that this tyrosine 
phosphorylation may be switched off by degradation. 
Similar to Thr22, Tyr24 belongs to the interface between two N-terminal 
domains in yeast Hsp82 dimer (Cunningham et al. 2008). Swe1/Wee1 targets Tyr24/Tyr38 
when Hsp90 in an “open” conformation (N-terminal undimerized) because this residue is not 
accessible when Hsp90 is in the “closed” conformation. Mutation of this residue to a non-
phosphorylatable amino acid (Y24F/Y38F) reduces Hsp90 binding to Aha1 and p23 
cochaperones and negatively affects the ability of Hsp90 to chaperone selected set of client 
proteins including v-src, ErbB2, Raf-1, Cdk4, Ste11, etc, suggesting positive effect of Hsp90 
phophorylation at this tyrosine residue on client activation. Notably, the phosphomimetic 
variant which represents constitutive phosphorylation at this residue cannot complement 
double deletions of Hsp90 in yeast and purified protein exhibits almost no ATPase activity 
despite the fact that it binds to to nucleotides with a similar affinity as wild type protein. It is 
intriguing to see how one phosphorylation site which in principle turns the protein into a 
better chaperone for clients instead causes harmful influences in general growth and finally 
leads to lethality. It is very likely that this phosphorylation is only crucial for maximized 
activation of certain client(s) in this very narrow time window (S-phase) and must be 
removed rapidly before it exerts harmful effects.   
The authors also showed that inhibition of kinase activity on wild type protein or 
using non-phosphorylatable variant of both yeast and human Hsp90 result in increased 
binding to geldanamycin from yeast lysate. This finding is also in agreement with 17AAG-
induced apoptosis assay in PC3 and HELA cells in which numbers of apoptotic cells is 
elevated when treated in addition with Wee1 kinase inhibitor. Given the fact that affinity to 
geldanamycin of purified wild type and non-phosphorylatable Hsp90 are comparable, these 
observations strongly indicate that phosphorylation status at this Tyr24/Tyr38 only 
mediates binding to geldanamycin indirectly via another layer of regulation inside cellular 
environment - which may be binding partners to Hsp90 in this particular phosphorylated 
form or even another modification primed by this phosphorylation on Hsp90 itself.  
Thr-90 (human Hsp90)  (Wang et al. 2009; Wang et al. 2012) 
Thr-90 phosphorylation was systematically investigated by work of Wang et al., 
in which they presented evidence that protein kinase A (PKA) specifically phosphorylates 
Hsp90 at this site. This phosphorylation is significantly elevated in proliferating cells as 
compared with that in starved conditions in HELA cells that transiently overexpressed PKA. 
More importantly, this phosphorylation event was shown to regulate Hsp90 secretion and 
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subsequently, promote tumor invasiveness in MCF-7 cells. It’s noteworthy that PKA, also 
known as cAMP-dependent protein kinase, has been implicated in a wide range of cellular 
processes and specially regulates cell proliferation in response to growth factors and/or 
nutrients. These results highlighted Thr-90 phosphorylation as a promising candidate for 
tumor progression diagnostic marker. 
Ser231 and Ser263(human Hsp90) or Ser225 and Ser255 (human Hsp90)  
(Dougherty et al. 1987; S P Lees-Miller & Anderson 1989; Ogiso et al. 2004; 
Degiorgis et al. 2005; Molina et al. 2007; Han et al. 2008; Dephoure et al. 2008; Kurokawa et 
al. 2008; Old et al. 2009; Xia et al. 2009; Woo et al. 2009; Iliuk et al. 2010; Bennetzen et al. 
2010; Olsen et al. 2010; Herskowitz et al. 2011; Zhao et al. 2011; Hsu et al. 2011; Phanstiel et 
al. 2012; Weber et al. 2012; Kettenbach et al. 2013; Shiromizu et al. 2013; Zhou et al. 2013)  
These are probably the two most common phosphorylation sites of Hsp90 which 
were detected in numerous proteomics (Degiorgis et al. 2005; Molina et al. 2007; Han et al. 
2008; Dephoure et al. 2008; Old et al. 2009; Xia et al. 2009; Olsen et al. 2010; Iliuk et al. 2010; 
Hsu et al. 2011; Zhao et al. 2011; Herskowitz et al. 2011; Phanstiel et al. 2012; Weber et al. 
2012; Kettenbach et al. 2013; Zhou et al. 2013; Shiromizu et al. 2013) and biochemical 
studies (Susan P Lees-Miller & Anderson 1989; Ogiso et al. 2004; Kurokawa et al. 2008; Woo 
et al. 2009). First identified in HELA cell extracts in 1989 for both Hsp90 isoforms (S P Lees-
Miller & Anderson 1989), these serine phosphorylations  could be confirmed by an in-vitro 
phosphorylation assay using CK2 from HELA cells, calf thymus or rabbit reticulocytes. 
Although Hsp90 is highly phosphorylated, Lees-Miller et al only determined 1.7mol 
phosphate per mole purified Hsp90 from HELA cells (which may be due to limited techniques 
at the time) which were corresponding to these two serine sites, indicating their high 
abundance or even constitutive phosphorylation status in cellular Hsp90 population.  
Ser231 and Ser263 (human hsp90) are two conserved residues in the Hsp90 
charged linker region, which has not been resolved by crystallography and is thought to be 
flexible and largely unstructured. More importantly, this region is implicated to be critical in 
modulating Hsp90 (Tsutsumi et al. 2009; Hainzl et al. 2009). These two conserved serines on 
both human Hsp90 isoforms are followed by positive-charged residues which matches well to 
the recognition motif of CK2 and indeed, they are phosphorylated by this ubiquitous and 
constitutive kinase at least in vitro (S P Lees-Miller & Anderson 1989). However, CK2 also 
phosphorylates many other sites on Hsp90 proteins (Mollapour, Tsutsumi, et al. 2011; 
Mollapour, S. Tsutsumi, Kim, et al. 2011) and Ser263 on Hsp90 is also reported to be 
phosphorylated by another kinase (B-Raf) in rat mesangial cells (Old et al. 2009). So it is not 
clear yet whether CK2 is the relevant and only kinase in vivo that phosphorylates these sites 
in certain cell types or in redundance with B-Raf . 
Up to now, several other studies detected this phosphorylated form of Hsp90s 
associated with Hsp90 client proteins such as aryl hydrocarbon receptor (AhR)(Ogiso et al. 
2004), apoptotic peptidase activating factor 1 (Apaf-1)(Kurokawa et al. 2008), telomerase 
(Woo et al. 2009), etc. Effects of these phosphorylations are quite diversed and seem to be 
client-dependent.  
Work by Ogiso et al. has demonstrated that in purified AhR complexes from cell 
extracts, Hsp90 was phosphorylated in both these serines while in Hsp90, only Ser231. 
Mutation of Ser 226 and 255 to alanine, which cannot be phosphorylated, increased Hsp90 
binding to AhR, whereas mutation to glutamic acid, which mimics phosphorylated Ser did not 
affect binding as compared with wild type protein in IP assay. AhR was also more active when 
coexpressed with the Ser 226/255Ala Hsp90 mutant. These data are consistent with a 
model in which phosphorylated Hsp90 interacts more weakly with client proteins, whereas 
unphosphorylated Hsp90 interacts more strongly. However, although important, it is likely 
that phosphorylation of Ser 226/255 is not the sole determinant of AhR association with 
Hsp90 because both residues were phosphorylated also in free (AhR-unbound) Hsp90 (Ogiso 
et al. 2004).  
Surprisingly, although these serine phosphorylation seems to be abundant and 
very likely even constitutive in many cell types including cancer cell types such as HELA (S P 
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Lees-Miller & Anderson 1989), hepatocellular carcinoma (Han et al. 2008), melanoma (Old et 
al. 2009),  invasive breast cancer MDA-MB-231 (Iliuk et al. 2010), etc, they were absent in 
Ba/F3 leukemia cells (Kurokawa et al. 2008). Hypophosphorylated Hsp90 bound strongly to 
Apaf-1, preventing cytochrome c-induced Apaf-1 oligomerization and caspase-9 recruitment 
while phosphorylated Hsp90 interacted weakly with the apoptosome in untransformed 
cells. Expression of mutant Hsp90 (S226A/S255A), which mimics the hypophosphorylated 
form in leukemic cells, conferred resistance to cytochrome c-induced apoptosome activation 
in normal cells,  confirmed that phosphorylation of these residues on Hsp90 is linked to 
inhibition of apoptosome function. Moreover, inhibition of Hsp90b phosphorylation triggers 
some degree of chemoresistance in the leukemic cells, potentially because of apoptosome 
inhibition whereas expression of Hsp90b (S226A/S255A) per se is not sufficient to transform 
normal Ba/F3 cells or primary mouse hematopoietic cells suggesting that additional 
oncogenic signaling is necessary to drive tumorigenesis. 
In this work (Kurokawa et al. 2008), the authors also reported that suppression 
of these abundant or constitutive phosphorylations of Hsp90 is mediated by leukemogenic 
tyrosine kinases Bcr-Abl, FLT3/D835Y and Tel-PDGFR although the detailed molecular 
mechanism is not yet uncovered. It could very likely be that these leukemogenic tyrosine 
kinases upregulate an Hsp90-directed phosphatase(s) or downregulate a kinase(s) targeting 
these sites. It is also interesting to note that little binding of the Hsp90 isoform to Apaf-1 
was observed, indicating an isoform functional division.  
The model in which unphosphorylated Hsp90 have stronger interactions with 
client proteins than phosphorylated protein and thus, chaperone those clients better is once 
again challenged in the case of telomerase, as reported in a study of (Woo et al. 2009). The 
authors have shown that full-length p23 enhances Hsp90 phosphorylation by facilitating 
interactions of the chaperone with CK2 and results in increased telomerase activity. In 
contrast, a capase-truncated p23 form supports binding of the phosphatase PP5 to Hsp90 or 
prevents PP5’s dissociation from Hsp90 which boost dephosphorylation of the chaperone. 
The dephosphorylated Hsp90, in turn, negatively affects telomerase activity. The site-specific 
influences were confirmed by introducing phosphorylation-defective (S231A/ S263A) and 
phosphomimetic (S231E/S263E) constructs of human Hsp90 into HELA cells. The double 
mutant S231A/S263A displayed decreased Hsp90 serine phosphorylation, indicating that 
these residues are authentic targets for phosphorylation and more importantly, did not 
support telomerase activity; whereas the S231E/S263E phospho-mimetic mutant enhanced 
telomerase activity to an extent similar to that of the wild-type protein. 
Tyr301 (human Hsp90) (Duval et al. 2007; Kettenbach et al. 2013) 
A study of Duval et al in 2007 characterized another tyrosine phosphorylation 
site of human Hsp90, Tyr301, which has been detected recently in another proteomics 
report in 2013 (Kettenbach et al. 2013).  Duval and coworkers have demonstrated that 
Vascular endothelial growth factor receptor 2 (VEGFR-2)–bound Hsp90 is phosphorylated 
in response to VEGF stimulation in a c-src–dependent manner on this tyrosine residue and 
that this event is necessary for VEGF-induced eNOS association to Hsp90 resulting in 
stimulated NO production. Tyrosine phosphorylation of Hsp90 is an early event in VEGF-
mediated signal transduction in endothelial cells: It is increased after VEGF stimulation of 
endothelial cells and is present only when internalization of the VEGF -2 is allowed. 
The Tyr-301 residue of Hsp90 is located at the beginning of the middle domain 
of Hsp90 which is implicated in client binding (Hawle et al. 2006a; Karagöz et al. 2014), and 
this region has previously been shown to mediate the interaction of Hsp90 with eNOS and 
Akt (Fontana 2002; Sato et al. 2000). In addition, this tyrosine residue is extremely conserved 
from yeast to human, supporting for the possibility that phosphorylation at this site may 
govern a wide variety of functions in multiple organisms.  
Thr725 and Ser726 (human Hsp90) or Ser718 (human Hsp90) (Muller et al. 
2012; Dephoure et al. 2008; Phanstiel et al. 2012)  
Other interesting phosphorylation sites on human Hsp90 and  are at the 
extreme C-termini of the proteins, in proximity of the MEEVD motif which is the binding site 
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for TPR cochaperones. They were already detected in proteomics papers earlier (Dephoure et 
al. 2008; Phanstiel et al. 2012) but only recently characterized by Muller et al. The series of 
acidic residues in MEEVD motif makes this region perfectly match to CK2’s recognition 
pattern. Nevertheless, in an in vitro assay using peptides, not only CK2, but CK1 and GSK3b 
kinases also could phosphorylate these sites.  Given their specific positions, as expected, these 
phosphorylations have strong effects on the interactions between Hsp90 and TPR 
cochaperones such as CHIP and HOP. Both data result from an enzyme-linked 
immunosorbent assay and fluorescence polarization consistently showed that non-
phosphorylated C-terminal peptides of Hsp90 interact more strongly with CHIP than the 
phosphorylated forms of these peptides. In contrast, HOP binds more strongly to the 
phosphorylated peptide of Hsp90. These findings were once again confirmed in IP 
experiments from HEK293 cells using wild-type or phospho-mutants (phosphomimetic and 
nonphosphorylatable variants) of both Hsp90 isoforms. More significantly, the authors 
demonstrated that primary human cancer cells contain high levels of phosphorylated Hsp90s 
and show increased levels of HOP protein (Muller et al. 2012). 
It is known that Hsp90 do not only chaperone client protein for maintenance, 
maturation or activation but also extend to regulate degradation of unfolded clients. In this 
protein triage decision to maintain protein homeostasis, the fate of client proteins is not 
decided solely by Hsp90 but rather by a concerted cooperation of Hsp70, Hsp90 and the 
specific adaptors HOP or CHIP. While HOP is important in coordination between Hsp70 and 
Hsp90 for protein folding, the E3-Ubiquitin Ligase CHIP targets Hsp90 client for 
ubiquitination and degradation (Chang et al. 1997; Chen & Smith 1998; Murata et al. 2001; Xu 
et al. 2002; Hernández et al. 2002; Song & Masison 2006; Stankiewicz et al. 2010; Lindquist et 
al. 2010). These data identify C-terminal phosphorylation of Hsp90 as a switch for regulating 
co-chaperone binding and indicate that cancer cells possess an elevated protein folding 
environment by the combination of co-chaperone expression and chaperone modifications.  
Additionally, looking at the phosphorylation aspect of Hsp90 in a broader view, 
given that Hsp90 proteins are heavily phosphorylated, it is comprehensible to hypothesize 
that different phosphorylation events could happen in a sequential order and in combination 
during Hsp90 cycle. However, only recently a few studies addressed the phosphorylation 
events of Hsp90 from this angle.  
A global approach by Buchner and colleagues provided evidence for regulation of 
Hsp90 by a series of phosphorylation sites (Soroka et al. 2012). Using a yeast strain deleted 
for Ppt1, which encodes a serine/threonine phosphatase, the yeast homolog of PP5, and 
SILAC (Stable isotope labeling with amino acid in cell culture), they identified 10 
phosphorylation sites in middle domain and dimerization domain of Hsp82/Hsc82. In 
general, using all-A or all-E mutants that mimics either non-phosphorylatable or 
phosphoylated status of all corresponding sites, the authors could show that phosphorylation 
decelerates the Hsp90 machinery, reduces chaperone function in vivo, sensitizes yeast cells to 
Hsp90 inhibition and affects DNA repair processes.  
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FIGURE 1-7: PROPOSED MECHANISM OF HSP90 PHOSPHO-REGULATION.  
Four phosphorylation sites influences the conformational dynamics of Hsp90 by employing different mechanisms. 
Phosphorylation at S379, located right next to ATPase catalytic-critical residues, interferes directly with structural 
rearrangements within the catalytic region. Modification at S485 which is positioned in the hinge region between 
middle domain and C-terminal domain modulates conformational flexibility within dimeric Hsp90. 
Phosphorylation of S602 and S604 in the C-terminal domain impairs intersubunit communication required for 
activation of ATP hydrolysis that can be induced by Aha1 (Soroka et al. 2012). 
Particularly, among these sites, four serine phosphorylation sites (S379, S485, 
S602 and S604) were proven to influence several aspect of the conformational cycle of 
Hsp90. Individually, they share the common property of decreasing the ATPase activity of the 
chaperone and the first two serines phosphorylation in the middle domain also impair 
general chaperone activity of Hsp90. These properties are not surprising for modification at 
S379 in the middle domain because this site is situated in the catalytic loop next to R380, a 
key residue required for ATP hydrolysis, and therefore, it is very likely that modification at 
the adjacent S379 disrupts the essential interactions within the catalytic region. The second 
active phospho-site, S485, is positioned at the lower part of middle domain, close to the 
junction with the C-terminal domain. Phosphorylation at S485 not only interferes with the 
ATP hydrolysis cycle but also the association with co-chaperones by reducing the 
conformational flexibility of Hsp90. Modifications at S602/S604 in the dimerization domain 
are dispensable for yeast viability and activation of specific set of client, nevertheless, still 
impairs both basal ATPase activity and activation by Aha1. The binding of the 
phosphomimetic mutants at these sites to Aha1 as characterized in analytical 
ultracentrifugation also indicates that phosphorylation at S602 and S604 interferes with 
cochaperone-induced structural rearrangements across subunits. The mechanistic analyses 
of the active phospho-sites showed that each site has a unique mode of action, including an 
influence on the formation of the catalytic site, the conformational flexibility of the protein 
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and intersubunit communication (Figure 1-7). They can be seen as switch points for the 
conformational communication within distant domains of Hsp90. 
Another profound investigation by Neckers and colleagues on the Hsp90 and 
Cdc37-mediated chaperone cycle for protein kinase clients set light on a series of important 
tyrosine phosphorylation events (Xu et al. 2012) (Figure 1-8). In fact, the posttranslational 
modification status of both Hsp90 and Cdc37 enables the cycle to proceed unidirectionally. 
 
 
FIGURE 1-8: PROPOSED MODEL FOR THE SEQUENTIAL TYROSINE PHOSPHORYLATION EVENTS 
THAT DRIVE THE HSP90 AND CDC37-MEDIATED CHAPERONE CYCLE FOR PROTEIN KINASE 
CLIENTS  
The cycle starts with (a) the Ck2-phosphorylated Cdc37 interacting with protein kinase (k) client and bringing it 
to Hsp90. The co-existence of Cdc37 and PP5 in the Hsp90-client complex as shown in (b) allows 
dephosphorylation of Cdc37 and prepares for other phosphorylation events on Cdc37 that reduces binding 
between Cdc37 and protein kinase (c). Y197 on Hsp90 further disrupts interaction between Hsp90 and Cdc37 
leading to dissociation of the cochaperone from the complex while another phosphorylation Y313 promotes 
binding of Aha1 to Hsp90 (d). Aha1 accelerates the chaperone cycle of Hsp90 resulting in release of the protein 
kinase client and Aha1 in turn also dissociates from the Y627-phosphorylated Hsp90 (e). Cdc37 and Hsp90 then 
both can be dephosphorylated to enter a new cycle (Xu et al. 2012). 
S13-phosphorylated Cdc37 binds to a protein kinase client of Hsp90 and both 
interact with Hsp90 forming a ternary complex. The additional association of this complex 
with PP5 phosphatase allows dephosphorylation of Cdc37 at S13 and priming for access of 
Yes kinase, which results in Y4 and/or Y298-phosphorylated Cdc37. This phosphorylation 
form of Cdc37 has weaker interaction with kinase clients (individual clients are affected to 
different degrees by phosphorylation at either one or both tyrosines). Interestingly, this 
modification does not disturb association with Hsp90. Nevertheless, Cdc37-bound Hsp90 is 
so restrained in its conformation that it cannot advance to other conformations that are 
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required for ATP hydrolysis, i.e. dissociation of Cdc37 is essential for the chaperone cycle to 
procceed. It would be even more beneficial if dissociation of Cdc37 could in the meantime 
facilitate association of other cochaperones that are critical for later steps in the chaperone 
cycle such as Aha1 or p23. Such coupled-effect should be mediated via modification on the 
main player, Hsp90 itself. Indeed, further phosphorylation of Hsp90 on Y197 (possibly by Yes 
kinase but not limited to it) promotes dissociation of Cdc37 from the chaperone complex, 
while Hsp90 phosphorylation on Y313 induces conformational changes favoring recruitment 
of Aha1, which stimulates Hsp90’s ATPase activity and drives maturation of the client kinase. 
Finally, Hsp90 phosphorylation on Y627 leads to dissociation of Aha1, PP5, and client kinase 
to complete the cycle. Assumingly, dephosphorylation of both Hsp90 and Cdc37 later would 
then enable them to enter a new cycle. 
Post-translational modifications of Hsp90 certainly have added another layer of 
regulation to the complexity of Hsp90 system. The enrichment of PTMs of Hsp90 in 
metazoans as compared to that in prokaryotes and single cell eukaryote indicates that 
through evolution, in these multi-cellular species, Hsp90 has gained more clients and/or had 
to adapt with more diverse conditions which require additional fine-tuning of the system. 
Therefore, understanding the influences of individual post-translational modifications as well 
as the simultaneous or sequential combination among them will undoubtedly be highly 
rewarding as they complement our knowledge of the multilayered system that eukaryotes in 
general and human cells in particular have developed to precisely control Hsp90 functions. 
1.2.5 TUMOR SELECTIVITY OF HSP90 INHIBITORS 
The most particular characteristics of Hsp90 as a molecular cheprone is its client set 
comprising more than 200 proteins (Pearl & Prodromou 2006), many of which are key 
components for the formation, growth and survival of cancer cells (Xu & Neckers 2007). This 
client set renders Hsp90 a promising target for cancer treatment since inhibiting Hsp90 
should affect several essential regulatory circuits in cancer cells at once. Initially, Hsp90 was 
not considered a suitable target since this molecular chaperone is essential in all eukaryotic 
cells tested. Nevertheless, it was shown by several studies that tumor, but not normal cells, 
accumulate Hsp90 inhibitors and are much more sensitive to those compounds (Whitesell et 
al. 1992; Nguyen et al. 2001; Solit et al. 2002; Chiosis & Neckers 2006; Breinig et al. 2009). 
These observations on the tumor selectivity of Hsp90 inhibitors had encouraged the entrance 
of two GA analogues (17-AAG and 17-DMAG) into clinical trial and several other screening or 
synthesis for new small molecule that inhibits Hsp90 specifically. However, the molecular 
mechanism of this tumor selectivity remains elusive. 
In vitro, using different approaches, several research groups have reported different 
aspects and even contradictory results on Hsp90-inhibitors affinity and sensitivity (Kamal et 
al. 2003; Llauger-Bufi et al. 2003; Gooljarsingh et al. 2006). Using co-IP and competitive 
binding assays, Kamal et al. have measured an approximately 100-fold higher binding affinity 
of 17-AAG to tumor cell derived Hsp90 as compared to Hsp90 from normal cells. They also 
detected that in tumor cells, unlike in normal cells, almost the entire Hsp90 population is in 
complex with cochaperones. In vitro reconstituted Hsp90 complexes also exhibit higher 
ATPase activity, suggesting that they are in an active form. From these findings, Kamal et al. 
has proposed that due to its more-than-normal busy roles in cancer cells, a bigger fraction of 
Hsp90 proteins is in complexes in an activated, high-affinity conformation (Kamal et al. 
2003). However, these results have been challenged by Llauger-Bufi et al. and Gooljarsingh et 
al. who reported the same high affinity for purified recombinant human Hsp90 (Llauger-Bufi 
et al. 2003; Gooljarsingh et al. 2006). 
Despite different binding affinities determined for Hsp90-inhibitor complexes in vitro, 
the tumor selectivity of the inhibitors in vivo for both cell culture and animal xenograft 
models is found to be consistent in many studies by assessing cell viability, oncoproteins’ 
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degradation, accumulation etc (Whitesell et al. 1992; Nguyen et al. 2001; Solit et al. 2002; 
Eiseman et al. 2005; Biamonte et al. 2006; He et al. 2006; Breinig et al. 2009) (Figure 1-9).  
 
FIGURE 1-9: HSP90 INHIBITION R EDUCES HEPATOCELLULAR CARCINOMA (HCC) CELL GROWTH 
HCC cell lines and the nontumorigenic hepatocyte cell line HACL-1 were treated with increasing concentrations of 
Hsp90 inhibitors, and cell viability was analyzed after 24 and 48 hours with MTT assays to assess cell viability. 
Assays were performed in sextuplicate, and data are expressed as the mean  standard deviation (n >=3) (Breinig 
et al. 2009). 
Therefore, identification and characterization of tumor-specific properties 
responsible for the tumor selectivity of Hsp90 inhibitors can contribute significantly to our 
understanding of the molecular mechanism of Hsp90 and the development of advanced 
anticancer drugs that specifically target to the most prevalent form of Hsp90 in cancer cells. 
1.3  DETECTION OF PHOSPHORYLATION MODIFICATIONS BY MASS 
SPECTROMETRY (MS) 
Direct analysis of modifications requires isolation of the correctly processed 
protein in a sufficiently large amount for biochemical study - a feat that has only been 
possible in very few cases. The introduction of MS methods has offered an opportunity to 
detect PTMs in general and phosphorylation in particular with high sensitivity and resolution. 
MS measures mass-to-charge ratio (m/z), yielding the molecular weight and the 
fragmentation pattern of peptides derived from proteins. It therefore can be applied as a 
general method for all modifications that change the molecular weight. 
1.3.1 STANDARD TANDEM MASS SPECTROMETRY (MS/MS) ANALYSIS  
A standard workflow for the identification of PTM include the following steps: 
isolation or purification of the protein of interest; enzymatically digestion, normally by 
trypsin; separation of the digestion products by liquid chromatography (LC); analysis of the 
eluting peptides by tandem mass spectrometry (MS/MS); and data evaluation by a database 
search engine. In these MS/MS experiments, peptide ions (precursor ions) are isolated in a 
first stage of the mass spectrometer and then activated by collision with inert gas leading to 
fragmentation, usually at the peptide bonds. The fragmentation pattern of PTM containing 
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peptides is similar to that of the unmodified peptide with the mass difference of precursor ion 
and differences at those fragments that contain the modified amino acid, if the modified 
amino acid remains inact during the fragmentation process. These differences are their mass 
increment and thus, ideally the peptide sequence, the mass and location of the modification 
can be determined.  
In practice, there are several inherent difficulties for the analysis of phospho-
proteins. Even though MS proteomics has been very successful in identifying proteins in 
complex samples, these investigations typically mapped only a few peptides per protein, 
which is sufficient for identification but not for the determination of PTMs across the full-
length sequence of a protein. First of all, obtaining full-sequence coverage for the unmodified 
protein already demands much more material than mere identification of it by MS 
sequencing. Moreover, protein modifications are typically not homogeneous and the possible 
combinations of different modification types on a certain protein are simply too large. The 
amount of protein in a single modification state can thus be a very small fraction in the total 
amount of the target protein. For these reasons, a central consideration in the 
characterization of global modifications of a specific protein is the need for as large an 
amount of the protein as possible. A general recommendation for PTM study is to start with 
amounts in the microgram range. A number of enrichment strategies in order to increase the 
relative abundance of the phosphopeptides or proteins of interest to that of unmodified 
counterparts has been developed, including immobilized metal affinity chromatography 
(IMAC), phospho-specific antibody enrichment, beta-elimination of phospho-serine and –
threonine and replacement of phosphate group by biotinylated moieties, etc.  
In most of the cases, the protein of interest is enzymatically digested into peptide 
level and the peptides are further fragmented by MS/MS. Even though the starting amount of 
peptides from a given protein is the same, it results very often in very different signal 
intensities for each of these peptides detected in MS. Thus, some of the peptides will be 
clearly visible and others not at all. This is particularly the case for complex samples and for 
modified peptides that often do not ionize as well as unmodified peptides. To avoid signal 
suppression which is commonly observed when highly complex peptide mixtures are injected 
into the mass spectrometer, peptides are typically separated before injection by reversed-
phase chromatography to gain subsequent fractionation. Even so, it does not necessarily 
result in complete sequence coverage because it is still limited by the binding to the reversed 
phase column or by the optimal m/z range that most mass spectrometers can detect. For 
example, very short peptides of only a few amino acids or very long peptides of >30 amino 
acids are often not detected. This limitation can be alleviated by a combination of enzymatic 
digestion using enzymes with different specificity. The first choice of enzyme is usually 
trypsin, which cleaves C-terminal to arginine and lysine, therefore resulting in peptides with 
basic amino acids at the C terminus, which are most easily sequenced by MS. A second 
enzyme can then be endoproteinase Asp-N or Glu-C, which are also very specific. A example 
of such combinational approach was reported in work of Mohammed et al in which the 
authors have employed 4 proteases to reach 88% sequence coverage and identified novel 
phosphorylation sites of component proteins from purified yeast RNA polymerase II and III 
(Mohammed et al. 2008).  
However, there is still no assurance that every part of the protein is covered and 
even if that were the case, a minor, modified form of a peptide may still escape detection. One 
possible reason is the lability of the modification itself: it can be lost even before the peptide 
itself fragments. The phosphogroup (+80 Da) can be stable (in the case of phospho-Tyrosine) 
or relatively labile (in the case of phospho-Threonine and especially phospho-Serine). It is 
still possible, however, to detect these modifications using “neutral loss scanning” for the loss 
of a phosphate moiety (98Da (H3PO4)) from the parent ion and “precursor-ion scanning” 
either for an ion at m/z 79 (PO3-) in negative ion mode for Ser/Thr phosphorylation or an ion 
at m/z 216.043 for Tyr phosphorylation in positive ion mode (Figure 1-10) (Mann & Jensen 
2003). 
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FIGURE 1-10: THE GENERATION OF NEUTRAL LOSS OR PRECURSOR IONS FROM 
PHOSPHORYLATED RESIDUES 
In (A): phospho-Serine with neutral loss (H3PO4 (-98)) or generation of an indicator ion (PO3- (-79)) (similar for 
phospho-Threonine).  
In (B): The phospho-Tyrosine immonium ion is generated by a combination of a- and y-type cleavage of a 
phospho-Tyrosine containing peptide, producing a diagnostic immonium ion having m/z 216. 
Another risk that could cause the failure of detection of post-translational 
modifications happens in the final step: the database search. The experimentally determined 
peptide masses are matched against the list of peptide masses expected from the protein 
sequence. The nonmatching masses can arise as a result of contaminating proteins, 
unexpected or incomplete cleavage, or common chemical modifications (e.g., methionine 
oxidation). The remaining masses are inspected for mass differences compared with the 
expected peptides that correspond to a modification. On the one hand, one would like to 
include all the parameters as flexible as possible so that every detected precursor m/z and 
MS/MS spectra peaks can be assigned; on the other hand, the combination of all possible 
parameters, as mentioned, would significantly increases the false positive rate and duration 
of database search, some even to a degree that is technically limited. The correct selection of 
parameters for database search to tolerate best for both extremes is therefore critical.  
1.3.2 MULTIPLE REACTION MONITORING MASS SPECTROMETRY (MRM-MS) 
As mentioned, the identification of global phosphorylation status of a protein 
remains technically challenging due to both the low occurrence of these phosphopeptides and 
their intrinsic physicochemical nature, resulting in generally poor ionization and detection 
using standard MS techniques. Any step of isolation and enrichment prior to MS analysis may 
accidentally lead to counter-selection for the target modification. A better approach, 
obviously, is a direct selection based on pre-existing knowledge about the modifications of 
interest; nevertheless, it should involve as few processing steps prior to MS as possible. A 
relatively new MS approach, which meets such requirements, is named Multiple Reaction 
Monitoring (MRM) MS (also known as Selected Reaction Monitoring (SRM)). 
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MRM exploits the unique capabilities of triple quadrupole (QQQ) MS for 
quantitative analysis. In MRM, the mass-resolving Q1 isolates the precursor, Q2 acts as a 
collision cell, and mass-resolving Q3 brings selected fragmented ions from the precursor to 
the detector (Figure 1-11). A precursor/product pair is often referred to as a transition. 
Several such transitions (precursor/fragment ion pairs) are monitored during the elution of 
the sample from the reversed-phase LC, yielding a set of chromatographic traces with the 
retention time and signal intensity for a specific transition as coordinates. The two levels of 
mass selection with narrow mass windows result in a high selectivity, as co-eluting 
background ions are filtered out very effectively. Unlike in other MS-based proteomic 
techniques, no full mass spectra are recorded in QQQ-based SRM analysis. The non-scanning 
nature of this mode of operation translates into an increased sensitivity by one or two orders 
of magnitude compared with conventional “full scan” techniques. In addition, it results in a 
linear response over a wide dynamic range up to five orders of magnitude. This enables the 
detection of low-abundance proteins in highly complex mixtures, which is crucial for 
systematic quantitative studies. 
  
FIGURE 1-11: MASS SPECTROMETRY IN MS/MS OPERATING MODE AS COMPARED WITH 
MULTIPLE REACTION MONITORING (MRM) MODE.  
 (HTTP://WWW.BROADINSTITUTE.ORG/SCIENTIFIC-
COMMUNITY/SCIENCE/PLATFORMS/PROTEOMICS/MRM-MULTIPLE-REACTION-MONITORING)  
MRM is an information-dependent method, specially designed to analyze a single 
target protein rather than a general phosphorylation screening tool. MRM measurements are 
quantitative analyses that are strictly targeted to a predetermined set of peptides and depend 
on specific transitions for each selected peptide. Therefore, prior knowledge about the 
protein of interest is required to define those transitions. First, for each targeted protein, 
those peptides that present good MS responses and uniquely identify the targeted protein, or 
a specific isoform thereof, have to be identified. This can be achieved by manual calculation, 
available software or characterization from digestion mixture of purified proteins and 
synthetic peptides. Recently, a proteomic database called ProteomicsDB has been made 
available at https://www.proteomicsdb.org/ which assembled 92% of the human proteome 
using data from thousands of LC MS/MS experiments. A Windows appplication called Skyline 
(MacCoss Lab) also uses MS/MS spectral libraries to predict and choose suitable precursor 
ions to establish MRM methods. Such databases and programs provide enormous amount of 
information and a very convenient interface for the design and interpretation of MRM 
experiments that can be used initially for this step. Second, for each of those peptides, those 
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fragment ions that provide optimal signal intensity and discriminate the targeted peptide 
from other species present in the sample have to be determined. These optimized transitions 
are the essence of an MRM assay as they provide enough specificity to allow confident 
identification and quantification of targeted protein in complex samples. The time and effort 
required to establish these conditions is the price to pay for the excellent quantitative 
performance of MRM-based experiments. However, once established, such assays can be used 
indefinitely in any study that involves the particular targeted protein, for e.g., a study across 
several cell lines. 
MRM applications in phosphorylation quantification analysis, on the one hand, 
are very promising since many biological effects are often due to changes in the level of 
modification rather than the total presence or absence of it. On the other hand, they are 
further limited by the fact that the precursor ion must contain the corresponding modified 
residue of interest regardless of whether such a peptide has good MS responses (i.e. to be  
well-ionized, has optimal mass range, unique for the protein or isoform of interested, etc).  
1.4  AIMS & APPROACH  
We were interested in tumor selectivity of Hsp90 inhibitors and hypothesized 
that this difference in affinity for Hsp90 inhibitors is due to different post-translational 
modifications in the two cytosolic human Hsp90 proteins Hsp90α and Hsp90β in malignant 
vs non-malignant cells. Therefore, we planned to characterize post-translational modification 
patterns in these cytosolic Hsp90s from a range of malignant and non-malignant hepatocyte 
carcinoma (HCC) cell lines. Starting with phosphorylation – the most prevalent post-
translational modifications in eukaryotic cells, we utilized Mass Spectrometry (MS) to 
perform a global and relatively quantitative analysis of phosphorylation status of Hsp90s 
from hepatocytes. Our goal was to detect major phosphorylation site(s) of cytosolic human 
Hsp90s that contribute to the strong preference effect on inhibitors binding. It is generally 
accepted in the field that human cytosolic Hsp90s exists in the cells with different 
conformations, presumably also different post-translational modification states.  For that 
reason, first of all, to avoid distortion of the natural steady-state levels of phosphorylation in 
cells, we used phosphatase inhibitors only at the time point of extract preparation and not for 
some hours during culturing of the cells before harvest, as generally done in 
phosphoproteomics projects to enrich in vivo the phosphorylation abundance. Secondly, the 
divergent inhibitor-binding effect is very unlikely to originate from phosphorylation of a 
minor part but rather from the major portion of the human Hsp90 population. This specific 
aim led to another important difference in our subsequent approach as compared with 
general proteomics analysis: in our experiments, no selective phosphopeptide enrichment 
steps were included. We were therefore dependent on exhaustive identification of peptides 
and furthermore, would have to reach full sequence coverage to conclude on the 
phosphorylation map of Hsp90.  
For this global and relatively quantitative analysis, I planned to isolate Hsp90 
from cell lysates, digest by different proteases and finally analyze by MS/MS for Hsp90 
identification and phosphorylation detection. I employed two strategies to isolate Hsp90 
from cancer cells, (1) affinity chromatography using a biotinylated variant of the Hsp90 
inhibitor geldanamycin and streptavidin coupled to magnetic beads (GA-beads), and (2) IP 
with a specific antibody. At the beginning, in-solution digestion was more preferred than in-
gel digestion to avoid introducing artificial modifications and limitation of final elution 
volume. However, in later analyses, I used in-gel digestion to enhance sequence coverage. 
In parallel, we planned to analyze selected known phosphorylation sites using 
MRM-MS (Unwin et al. 2005). MRM-MS approach allows to monitor peptides of interest (in 
our case, phospho-peptides) directly from cell lysate samples without any 
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isolation/enrichment step, ensuring that no bias is introduced prior to MS, and hence, 
suitable for quantitative analysis.  
As mentioned briefly in the previous section, there have been several proteomics 
analyses in which phosphopeptides from cytosolic human Hsp90s were detected. 
Nevertheless, only a few phosphorylation variants have been characterized further by 
biochemical assays and were reported to be related to or responsible for specific effects on 
Hsp90 such as T36, Y38, T90 (of the  isoform) and Y301(of the  isoform) (Duval et al. 2007; 
Wang et al. 2009; Mollapour, Shinji Tsutsumi, et al. 2010; Mollapour, Tsutsumi, et al. 2011; 
Wang et al. 2012). In all cases, individual kinases responsible for the specific phosphorylation 
site were identified. They were important kinases that are intimately involved in processes 
leading to tumor development, for e.g. CK2 or PKA. Discussions in more details about each 
individual phosphorylation site have been mentioned previously (see section 1.2.4.3). 
Moreover, even though the influence of these sites on Hsp90 conformational and ATPase 
cycle has been characterized, none of the phosphorylation sites was studied for their natural 
cellular abundance. Based on these reasons, we selected them as targets to monitor in 
complex samples their degree of phosphorylation and whether their status correlates with 
tumor development conditions and drug binding feature of Hsp90 in cancer versus non-
cancer cells (Table 2-4). Novel phosphorylation site(s) from our MS data should also be 
included.  
The results from both MS approaches were considered for further 
characterization of novel and/or interesting phosphorylation site(s). For this section, I 
planned to utilize a range of in vivo and in vitro assays that have been established in the 
group, including the use of yeast as a model system and purified wild-type and 
phosphomutants Hsp90 proteins together with cofactors such as clients and cochaperones 
for interaction and activation experiments. 
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2 RESULTS & DISCUSSION S 
2.1  ANALYSIS OF PHOSPHORYLATION OF HUMAN HSP90 IN CANCER CELL 
LINES 
2.1.1 ISOLATION OF HSP90 PROTEINS FROM CELL LYSATES 
This part was initially planned to be performed by our partner in M. Kern’s 
group, Pathology Institute of University Heidelberg. We started with the HCC cell line 
HepG2, which displayed the strongest response to Hsp90 inhibitors (Breinig et al. 2009). As 
the control for a non-tumorigenic human liver epithelial cell line, we had planned to use 
HACL-1. However, we encountered two problems.  
First, the IP did not work with all the antibodies tested by our partner. We didn’t 
get specific precipitation of Hsp90 as well as enough material for further analysis. So at the 
beginning, we only got Hsp90 proteins from pulldown experiments using biotinylated-GA. 
Second, the control non-tumorigenic human liver epithelial cell line HACL-1 
didn’t grow well in culture, and hence, we could not get enough cells as well as Hsp90 
proteins extracted from it in both isolation methods. We decided to use another HCC cell 
line, Snu182 instead of HACL-1. Snu182 displayed much less response to Hsp90 inhibitors 
as compared to HepG2 (unpublished data, personal communication of M. Breinig).  
 (A) 
 
(B) 
 
FIGURE 2-1: GA-BIOTIN PULL-DOWN OF HSP90 FROM CELL EXTRACTS.  
Shown are Western blots against Hsp90 of different fractions from a GA-biotin pulldown assay of (A) 
HepG2 or Snu182 (data from cooperation partner, M. Breinig) or (B) HELA lysates. In (B), either 
200µg (+) or 500 µg (++) of total  lysate were used. A volume of the input material corresponding to 
20 µg was loaded on the gel. In Bound and Unbound fractions, identi cal volumes were loaded for all  
samples.  
In addition, I myself performed GA-biotin pulldown from HELA cells, a cervical 
cancer cell line, for MS analysis using a modified GA-pulldown protocol from M. Breinig. HELA 
cells were included in our analysis to compare the results with those from HepG2 and Snu182 
Results & Discussions   
41 
 
so that liver-specific features could be distinguished from general cancer specific 
modifications.  
From these three different cell lines: HepG2, Snu182 and HELA, Hsp90 proteins 
could be pulled-down using GA-Biotin beads (Figure 2-1). Moreover, using the same amount 
of GA-beads while increasing the total protein amount, I could isolate more Hsp90 proteins 
from HELA lysates without saturating the beads. I assumed that the population of Hsp90 
bound on GA-beads should mainly contain the fraction of interest which has high affinity to 
the Hsp90 inhibitor GA. 
Later, using an antibody specific for Hsp90, I was also able to 
immunoprecipitate Hsp90 proteins from both HELA and HepG2 (Figure 2-2). Snu182 was not 
included due to discontinued supply from Pathology Institute. Unlike the case of GA-pulldown 
experiments, an elution step in the IP is mandatory to separate Hsp90 from IgG which stays 
bound on the beads so that I could use it in subsequent in-solution digestion. Of note, the 
elution step was not required in later analyses, in which I applied in-gel digestion prior to MS.  
 (A) 
 
 
(B)  
 
FIGURE 2-2: IMMUNOPRECIPITATION (IP) OF HSP90 FROM CELL EXTRACTS USING HSP90-
ANTIBODY (SPA-840).  
Shown in (A) is a Western blot against Hsp90 of Flowthrough (FT) and Elution fraction from IP of  
HepG2. Either total protein amount of 50 µg (+) or 100 µg (++) was used; the larger sample was 
concentrated so that both samples had identical starting volume.  
Shown in (B) is SDS-PAGE of Flowthrough (FT), Wash and Elution f ractions from IP of HELA. Either 
total  protein amount of 30 µg (+) or 60 µg (++) was used, the larger sample was concentrated so that 
both samples had identical starting volume.  
In these IP, Hsp90 proteins in HELA and HepG2 extracts were successfully 
immunoprecipitated, suggesting that this antibody can effectively pull-down both isoforms or 
that the isoforms in cell extracts form heterodimers and thus, can be pulled-down using the 
antibody specific for Hsp90. 
To ensure that most of Hsp90 proteins in cell extracts were immunoprecipitated 
and I did not only analyze a fraction of Hsp90 (which may not be representative for overall 
cellular Hsp90), I also made several attempts to immunoprecipitate Hsp90 using antibodies 
against the -isoform or Hsp90 in general (without specificity to either isoform). However, 
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the IP using these antibodies were in general much less efficient as can be shown in Figure 
2-3 (elution fractions). Western blotting to evaluate IP efficiency showed that very little 
amount of both Hsp90 isoforms were detected in the elution fractions. Most of Hsp90 
proteins seemed to stay unbound in the Flowthrough fractions or bound on protein A-beads. 
As stated previously, I could not use the Bead fraction for the subsequent in-solution 
digestion because the signal from IgG coupled on beads would dominate and interfere with 
the detection of Hsp90 proteins in the same fraction.  
 
FIGURE 2-3: IMMUNOPRECIPITATION (IP) OF PURIFIED HSP90 (MIXTURE OF EQU AL AMOUNT 
OF BOTH ISOFORMS) USING HSP90 -ANTIBODY (CAYMAN-K41220A)  
Western blots against Hsp90 of different fractions. (A): Overlay of Western blot against human Hsp90 
both isoforms (In red: anti -human hsp90 ; in green: anti- human Hsp90); (B) & (C): Western blot 
against human hsp90   and , respectively.  
In the end we decided to continue GA-pulldown and IP experiments with the -
specific antibody (SPA-840) for MS analysis. 
2.1.2 GLOBAL MS ANALYSIS OF ISOLATED HSP90 FROM CELL LYSATES 
2.1.2.1 DETECTION AND SEQUENCE COVERAGE OF HSP90 IN CELL LYSATES 
MS analysis by the MaXis mass spectrometer 
In these MaXis MS analyses, I received the HepG2/Snu182 GA-pulldown samples 
from our partner in the Pathology Institute and prepared similar pulldown experiments from 
HELA cells. The samples were digested using in-solution digestion protocol and subjected to 
the MaXis mass spectrometer.  Due to limited sample amount, only in-solution digestion of 
the bead-bound fractions of GA pulldown by Trypsin were applied, and in a few batches, also 
by Glu-C or Asp-N.  
In the pulldown experiments, we utilized biotinylated-GA and Streptavidin-beads 
to capture Hsp90 from lysates. The interaction of the biotin and streptavidin is the strongest 
noncovalent biological interaction known, which has a dissociation constant, Kd, in the order 
of 10-14M. For that reason, I did not attempt to break this biotin-streptavidin interaction to 
elute Hsp90 but directly used the Bead fraction (will be reffered to as “Bound” fraction in GA-
pulldown experiments). The Bound fractions in a Tris-base buffer were applied to SpeedVac 
in order to concentrate to the smallest volume possible. The dried Bound fractions were then 
resuspended in an ammonium bicarbonate buffer with 8M Urea to denature the proteins. 
Further denaturation steps include addition of DTT and iodoacetamide to fully reduce and 
modify cysteine residues. The denatured protein mixtures were diluted to lower than 4M 
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Urea which allowed digestion by LysC. An additional dilution to less than 2M Urea enabled 
further digestion of the proteins by Trypsin. The overall digestion mixtures were then 
injected into the LC-MS/MS system for analysis. 
In general, cytosolic Hsp90 isoforms (Hsp90 and Hsp90) were detected as the 
first and second hits in most GA pull-down MS runs. In control runs (pulldown cell lysates 
using beads without Biotinylated-GA), Hsp90 proteins were either not detected or could 
sometimes be detected with sequence coverage less than 5%. However, the sequence 
coverage of Hsp90 proteins in these analyses were also far below required values. From 
HepG2 cell extracts, Hsp90 and Hsp90 were detected with an average 26% and 42% 
sequence coverage, respectively. The situation is similar for samples from HELA and from 
Snu182 extracts (Table 2-1).  
Due to insufficient sequence coverage, a conclusion about the phosphorylation 
status of Hsp90 in these cell extracts was not possible. Of notes, the set of peptides detected 
in the 3 different cell lines was highly overlapping, implying that they were peptides with 
good MS reponses. The missing part of the sequence could contain less-well ionized peptides; 
peptides that did not bind to reversed-phase column or those that had m/z values outside the 
MS optimal range of detection. The Mascot database search gave indications that the in-
solution digestion was not complete: there were peptide ions with larger m/z values than the 
range of the database search. Even when I increased the digestion duration for both enzymes, 
the results were not much improved. The denatured proteins in the presence of bead 
matrices might form aggregates on the beads that reduced accessibility for proteases. 
Therefore, for later MS analyses, I applied GA pull-down or IP samples onto SDS-
polyacrylamide gels to separate beads from the denatured proteins. In-gel trypsin digestion 
was applied and MS analysis was carried out using an Orbitrap mass spectrometer, which has 
a greater sensitivity in MS/MS as compared to the MaXis mass spectrometer. 
Sequence coverage 
(%) 
Hsp90 Hsp90 
HepG2 26.00  6.51 42.00  2.00 
Snu182 24.00  2.83 40.50  2.12 
HELA 25.20  5.17 46.00  1.2 
TABLE 2-1: SEQUENCE COVERAGE OF HSP90 ISOFORMS IN ANALYSIS BY THE MAXIS MS 
The data are presented in average  standard deviation from 2-4 experiments. 
There was also an interesting feature in those MS analyses: Human Hsp90 
isoform was always the first hit and detected with sequence coverage two-fold higher than 
that of Hsp90 in most of these runs (Table 2-1).  
This observation suggested that Hsp90 was always enriched more in our 
samples than Hsp90. There could be three potential explanations for it:  
(1) Binding of Hsp90 to GA-beads is stronger than that of Hsp90; or 
(2) Under non-heat shock conditions, Hsp90 is higher expressed than Hsp90; 
or 
(3) Different post-translational modifications on each isoform in lysates diverge 
their binding to GA-beads.  
(4) Downstream processing steps after isolation from cell extracts such as in- 
solution digestion and MS analysis provide preference for detection of one isoform over the 
other. 
To test whether the first possibility is the case, a GA-pull down assay using 
purified Hsp90 and Hsp90 was performed. Under similar conditions including the 
incubation duration and the amount of GA-beads, the binding of both purified proteins to GA-
beads was similar but much weaker as compared with Hsp90 proteins from lysates (see 
Figure 2-15, page 67). The second possibility could be examined by relative quantification of 
Hsp90 isoforms in cell lysates using quantitative Western blotting and isoform-specific 
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antibodies. However, it is unlikely that this possibility is the case because in later IP and GA-
pulldown experiments followed by in-gel digestion and Orbitrap MS analysis this difference 
in sequence coverage between two isoforms decreased significantly (Table 2-2).  The findings 
from the next part also ruled out the third hypothesis that difference originated from post-
translational modifications and pinpointed to downstream processing steps in these initial 
GA-pulldown experiments as reasons for this Hsp90-preferred detection. 
MS analysis by the Orbitrap mass spectrometer 
In these Orbitrap MS analyses, I prepared the HepG2/HELA samples myself using 
either GA-pull down experiments or IP assays and loaded the elution and/or beads fractions 
on gel. The in-gel digestion and MS analysis were performed in cooperation with MS facility, 
ZMBH. 
 
Isolation method 
Sequence 
coverage (%) 
Hsp90 Hsp90 
IP 
HepG2 55.5  10.6 59    11.3 
HELA 53  14.1 63   11.3 
GA-pulldown 
HepG2 53  10.7 56  12.6 
HELA 49.4  16.4 60.2  13.9 
TABLE 2-2: SEQUENCE COVERAGE OF HSP90 ISOFORMS IN ANALYSES BY THE ORBITR AP MS 
USING EITHER IMMUNOPRECIPITATION (IP) OR GA-PULLDOWN AS HSP90 IS OLATION METHOD.  
The data are presented as average  standard deviations from 2-4 experiments. 
Similar to the MaXis MS analyses, in all runs, cytosolic Hsp90 proteins were 
detected as first hits. The sequence coverage of both Hsp90 isoform were increased 
significantly to the average of 50-65% and 55-70% for Hsp90 and Hsp90 respectively 
(Table 2-2). This enhanced efficiency was gained from the utilizing of in-gel digestion and the 
Orbitrap MS instead of in-solution digestion and QTOF MS, respectively. Nevertheless, there 
were higher fluctuations in the sequence coverage from similar IP or GA-pulldown 
experiments suggesting instability of instrument performance. Of note, in contrast to the 
MaXis MS results, the data from Orbitrap MS analyses showed no significant difference 
between two cytosolic Hsp90 isoforms. 
A comparison plot between the sequence coverage of human Hsp90 proteins 
from MS analyses from the Maxis and the Orbitrap mass spectrometer showed that they were 
mostly overlapped (Figure 2-4). As mentioned, the peptides in those regions might be those 
that have good MS responses regardless of the digestion method and the mass spectrometer. 
A few peptides such as the very N-terminal peptide (2-41 of Hsp90 or 2-36 of Hsp90) or 
the charge linker peptide (227-245 of Hsp90 or 222-234 of Hsp90) were preferentially 
detected in one or the other analyses, suggesting that their abundance, stability, digestion and 
ionization behaviors might be at critical levels. Moreover, among the detected peptides in 
both MS analyses, many of them contained miss-cleavage site(s), indicating that both of the 
in-solution and in-gel digestion could have been further improved for higher efficiency. 
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(A) 
 
 (B) 
 
FIGURE 2-4: SEQUENCE COVERAGE OF HSP90 PROTEINS IN MS ANALYSES 
Shown are the peptides detected at least in 2 MS analyses from the Maxis mass spectrometer (colored in red) or 
the Orbitrap mass spectrometer (colored in blue). The peptides are plotted for human Hsp90 in (A) and Hsp90 
(B). 
 
2.1.2.2 IDENTIFICATION OF PHOSPHORYLATION SITES 
Despite limited sequence coverage, we were able to detect some phosphorylation 
sites on both human Hsp90 isoforms (Table 2-3). Interestingly, in GA-pulldown experiments 
followed by in-solution digestion and MS analysis by the MaXis mass spectrometer, more 
novel phosphorylation sites were identified as compared with analysis by Orbitrap even in 
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similar GA-pulldown experiments. On the contrary, in all the Orbitrap MS analyses, despite 
having higher sequence coverage, identification of phosphorylation sites was more limited. 
We detected overall fewer sites and only those that had been reported in proteomics studies 
except for Y667, which was also only identified once in our experiments. This could be due to 
the process of in-gel digestion in the absence of specific enrichment of phospho-peptides 
from our limited starting material. The in-gel digestion protocol further limited us in the 
volume that could be loaded onto the gel: in fact, a smaller amount of sample can be included 
in a standard in-gel digestion reaction than an in-solution digestion reaction. Even though 
Hsp90 proteins could be readily stained by colloidal Coomassie staining, the different 
phosphorylated species might be present in the gel band with insufficient amounts.  
We also had no overlapping phosphorylation sites between two MS analyses, 
suggesting that different digestion protocols and LC-MS/MS systems had larger influence on 
the detection than we expected, especially since the starting amount of the material was 
limited. Interestingly, approximately half of the phosphorylation sites detected in MS 
analyses using the MaXis or the Orbitrap mass spectrometer, do not belong to overlapping 
regions (Figure 2-4). In those phosphorylation sites that belonged to overlapping regions, the 
abundance of a modified peptide resulted from in-gel vs in-solution digestion might deviate, 
giving the possibility that in analyses using one mass spectrometer, the abundance was below 
detection threshold. In a very special case of the peptide 584-604 of human Hsp90, the 
peptide itself is rather long with 21 amino acid and contains several serines, threonines, 
tyrosines (in total 7 phosphorylatable residues) that are even next or close to one another 
(Figure 2-4). Precursor ion of this peptide suggested that there were more than one 
phosphorylation site and hence, the assignment for exact modified residues could be 
compromised. 
 Hsp90 Hsp90 
 
 
 
 
 
 
GA-pull down 
In-solution 
digestion 
MaXis MS 
T19 
S31 
T36 
Y38 
S39 
T88 
T109 
S113 
T115 
T594 
S595 
T14 
S26 
T31 
Y33 
S34 
S45 
S48 
T104 
S108 
T110 
S365 
S586 
S587 
T593 
 
 
GA-pulldown or IP 
In-gel digestion 
Orbitrap MS 
T99 
S231 
S263 
T317 
Y627 
T645 
Y667 
T94 
S226 
S255 
T309 
S594 
T595 
Y596 
TABLE 2-3: PHOSPHORYLATION SITES DETECTED BY MS IN HEPG2, SNU182 AND HELA CELL 
EXTRACTS AFTER HSP90 ISOLATION.  
In bold are sites that are reported on Phosphosite website (http://www.phosphosite.org/homeAction.do) (mostly 
detected in proteomics studies) and in red is the site we chose for detailed characterization in the next part. The 
sites from peptides that do not belong to overlapping regions are colored in blue. 
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There were a few phosphorylation sites detected in our analysis, such as T36, 
Y38 (Hsp90) and corresponding T31, Y33 (Hsp90) or S365 (Hsp90 only), etc that have 
just recently been added to the phosphosite database. The N-terminal phosphorylation sites 
T36 and Y38 (Hsp90)/T31 and Y33 (Hsp90) were detected in yeast and characterized in 
details by another group (Mollapour, S. Tsutsumi, et al. 2010; Mollapour, Tsutsumi, et al. 
2011). The novel S365 phosphorylation site of Hsp90 was chosen to be the target for further 
characterization in my next part of the project. 
Using two methods of isolation also allowed us to tackle the cellular Hsp90 
population from different angles. Since in both methods I was able to isolate the majority of 
cellular Hsp90, I expected to compare also the interaction partners of Hsp90 from them. In 
contrast to MS results from GA-pulldown experiments, MS results from IP revealed a large 
number of interesting co-immunoprecipitated proteins such as Hsp70, Hsc70, STIP1, Cdc37, 
Aha1, CHIP, PP5, UNC-45, etc as cochaperones; cyclin-dependent kinase 1 (Cdk1), DNA repair 
protein Rad50, histone H1, importin -1, exportin proteins (XPO1, XPO2, XPO5,…), etc as 
clients and DNA-dependent protein kinase (DNA-PK), 14-3-3 proteins, S100 calcium-binding 
protein (S100P) … as interactors that could be either or both. This was expected since GA 
either dissociates cochaperones and clients from Hsp90 complex or prevents transfer of 
client proteins to Hsp90; whereas in IP, Hsp90-client-cochaperon complexes could be 
preserved. Nevertheless, as our focus was phosphorylation as a post-translational 
modification type that contributes to tumor selectivity of Hsp90 drugs, we did not follow up 
any further on these co-IP hits. 
Unfortunately, all the novel phosphorylation sites that we identified did not 
exhibit a clear correlation with the tumor specificity of Hsp90 inhibitors because either they 
were detected in both fraction of GA-bound and GA-unbound or were not detected 
reproducibly. Since our aim was to detect quantitative as well as qualitative differences in 
phosphorylation between cell lines, we did not include any specific phospho-peptide 
enrichment steps in vivo (before cell lysis) or in vitro. Our results could be limited due to the 
transient nature of the phosphorylation status of cellular Hsp90 proteins.  
Furthermore, regarding to the tumor selectivity characteristics of Hsp90 
inhibitors, on the contrary to what we hypothesized, the fraction of Hsp90 that contribute 
significantly to tumor specificity of Hsp90 inhibitors need not to be the majority. That would 
explain why without enrichment, our isolation methods were not robust enough for MS/MS 
identification later. Another possibility is another post-translational modification type, not 
phosphorylation, is responsible for tumor selectivity of Hsp90 inhibitors. This seems to be 
more likely under the light of recent study by Neckers and colleagues (Mollapour et al. 2014). 
In their work, Neckers and colleagues provided evidence that SUMOylation on the N-terminal 
of Hsp90 leads to more sensitivity to its inhibitors. Although SUMOylation of Hsp90 was 
reported previously (Panse et al. 2004), for the first time, the site of SUMOylation and its 
consequences for Hsp90 function were identified and characterized. It was unexpected, even 
to the authors that Hsp90 inhibitors had higher affinity for SUMOylated Hsp90 and as a 
consequence, increased SUMOylation could sensitize cells to Hsp90 inhibitors. 
2.1.3 MRM-MS ANALYSIS OF SELECTIVELY KNOWN PHOSPHORYLATION SITES 
In this special MS approach, we limited our analysis to 5 phosphorylation sites of 
human Hsp90 proteins: T36 and/or Y38, T90, Y309 (numbering is referred as in the  
isoform) and S365 (only of the  isoform) (Table 2-4) and wanted to monitor the 
phosphorylation status of these sites in crude cell lysate without any isolation method. The 
sites were selected due to their importance for cancer progression or their being the target of 
cancer-related kinases. The MRM profile was constructed from four parameters that were 
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obtained from one or multiple standard LC MS/MS experiments: (i) chromatographic elution 
order of phosphorylated peptides (retention time window), (ii) phosphorylated peptide 
(precursor ion) mass to charge ratio (m/z) and charge state (z), (iii) characteristic b- and y-
fragment ion m/z ratio, and (iv) collision energy required for fragmentation to obtain b- and 
y-fragment ions. This MRM-MS profile of each peptide would then be applied to monitor its 
status in cell lysate samples. This MRM-MS characterization step was done in collaboration 
with S.Link (MS facility, ZMBH, Heidelberg). 
There were actually a few more phosphorylation sites that we also would like to 
select for this MS approach, for e.g. the two serine phosphorylation sites in the charge linker 
(S236 and S255). However, they weren’t readily fitted to certain requirements of MRM-MS: 
the surrounding region contains series of lysine residues which make generating exact tryptic 
peptide with predicted mass not feasible or the peptide as digested by other proteases is 
either larger or smaller than the optimal range for the precursor mass. In addition to the 
phospho-peptides, we also selected other peptides from digestion of purified human Hsp90 
and  (those that have good MS responses) to ensure the selection and characterization of 
Hsp90 proteins in complex samples. We also included peptides for the purpose of 
distinguishing between isoforms. In total, we include a list of approximately 90-100 
transitions (precursor/fragment ion pairs) for MRM-MS analysis (Appendix Table S1). 
For each phoshorylation site, we synthesized a tryptic peptide containing the 
specific site, except for T36 and Y38 which cannot be separated into two peptides because 
they are only 2 amino acids away from one another. Moreover, there were no lysine or 
arginine residues nearby in this N-terminal region for tryptic cleavage so that we had to use 
Glu-C digestion, which generated a relatively large peptide. These differences later turned out 
to be quite problematic since the large peptide containing these single or double 
phosphorylation sites were not readily detected even in the synthesized form (which we 
could utilize in much more abundant quantity than in cell lysate samples). Therefore, we 
gained no MS results for these phosphorylation sites in cell lysate samples.  
Site (numbering 
as in Hsp90) 
Phosphorylated synthetic petide Reference 
T36 IAQLMSLIINTFYSNKE (Mollapour, S. 
Tsutsumi, Kim, et al. 
2011), (Mollapour, 
Tsutsumi, et al. 
2011) 
Y38 IAQLMSLIINTFYSNKE  
 
ditto  
T36/ Y38 IAQLMSLIINTFYSNKE  
 
Ditto 
T90 TLTIVDTGIGMTK  (Wang et al. 2009; 
Wang et al. 2012) 
Y309 NPDDITN/QEEYGEFYK  (Duval et al. 2007) 
S365 (Hsp90) VFIMDSCDELIPEYLNFIR  This work  
TABLE 2-4: SELECTED PHOSPHORYLATION SITES TO BE MONITORED IN MRM-MS APPROACH  
For the rest including T90, Y309 and S365 phosphorylation peptides, we could 
detect and monitor their transitions well when using synthetic peptides. However, only the 
non-phosphorylated forms of the peptides were found in cell lysates, except for the S365-
containing peptide.  
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The identification of S365-phosphorylated peptide was also not straightforward: 
Only MRM-MS was not enough because the transitions eluted in the expected retention time 
window but with low intensities and were interfered by other signals. Therefore, a further 
fragmentation step was included in Q3 (MS3) and MS3 scans were recorded. In parallel, the 
MS3 fragmentation patterns of transitions from S365-phosphorylated synthetic and other 
peptides (both non-phosphorylated and phosphorylated) were also generated to build up a 
MS3 “library”. We then could perform “library identification”, i.e. comparing the MS3 
fragmentation spectrum of interesting transitions with that of each component in our library 
to identify the transition that have the most similar MS3 fragmentation pattern (Appendix 
Figure S1, in cooperation with S. Link, MS facility, ZMBH). In our case, the MS3 fragmentation 
spectra of the transitions of interest were indeed matched well with that of corresponding 
transitions from S365-phosphorylated synthetic peptide under identified MS conditions, 
allowing us to confirm the presence of S365-phosphorylated peptide in HELA crude lysate 
samples. The low signal intensity of S365-phosphorylated parental peptide and transitions 
suggested their substoichiometric abundance as compared with the non-phosphorylated 
counterpart. However, we were unable to conclude more in details because due to 
interference of MS3, relative quantification between phosphorylated versus non-
phosphorylated forms of this peptide was not possible any more. The low abundance of 
cellular S365-phosphorylated Hsp90 proteins could be the result of dynamic 
phosphorylation/dephosphorylation cycle and/or client-specific activity of Hsp90. Besides, 
we could not completely rule out the possibility that in the only processing procedure of in-
solution or in-gel digestion, the total amount of S365-phosphorylated peptide was reduced or 
became harder to detect in MS due to for e.g. instability or being less well-ionized than the 
unmodified counterpart. This will be further discussed in the next section. 
All Hsp90 petides containing T90 or Y309 were detected in non-phosphorylated 
forms in HELA cell extract samples. Our data provided evidence that under normal 
conditions, those sites were not phosphorylated at all or their basal phosphorylation levels 
are lower than MS detection threshold. Due to the lack of detected phosphorylated forms of 
these peptides, we did not continue with relative quantification to compare between 
phosphorylation status. In general, the MRM-MS succeeded in detection of most 
phosphorylation sites that we selected. In normal HELA samples, the selected 
phosphorylation sites of Hsp90 proteins were dominantly in unmodified form, indicating that 
their phosphorylations are highly specific in response to their particular stimulus or 
environmental signals such as overexpression of PKA for T90 or VEGF for Y309. 
During optimization procedure for MRM-MS, we recognized other requirements 
of this approach such as the parent peptides must be accurately produced by protease 
digestion and should not be either too small or large (m/z value between 400 to 1000); the 
characterization of peptides and transitions might require purified or synthetic materials; the 
b-/y-fragment ions also should contain at least 4 amino acids and should not be 
complementary; the relative stoichiometric ratio between phosphorylated peptide and its 
non-phosphorylated counterpart should be in a certain range to ensure confidently detection 
for both forms; etc. For those reasons, our quantification for the selected phosphorylation 
sites of Hsp90 proteins was not complete.  
Nevertheless, with modified and coupled approaches such as the utilization of 
phosphatase treatment or spiked-in of stable isotope-labeled standards, the application of 
MRM-MS as a quantitative method for a number of selected proteins or other modification 
sites is highly feasible.  
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2.2  CHARACTERIZATION OF PHOSPHORYLATION AT SERINE 365 IN 
HUMAN HSP90  
2.2.1 IDENTIFICATION AND VERIFICATION OF S365 PHOSPHORYLATION IN 
HUMAN HSP90 
The phosphorylated peptide of serine 365 on Hsp90β has first been detected in 
HepG2 and Snu182 cell lysates using the MaXis mass spectrometer (see section 2.1.2, Table 
2-3). The tryptic peptide 360-378 from Hsp90 was fragmented well, yielding a number of b 
and y-ions series, which enabled exact assignments of 16 out of 19 amino acids of the peptide. 
Parent mass of the peptide and the a-6th ion allowed specifically identification of the 
phosphorylation site to serine 365. Moreover, there wasn’t any other potential site in the 
peptide sequence (Figure 2-5B). It should be mentioned that there was also MS detection of 
the same peptide but in non-phosphorylated form. It was also well-fragmented and the b, y-
ion series covered most of the sequence, too (data not shown). This observation implies that 
the population of Hsp90 proteins in the cells is heterogenous: some of which are 
phosphorylated at serine 365, others are not. The ratio between phosphorylated and non-
phosphorylated Hsp90 could well be an important factor to determine the affinity of the 
whole population to inhibitors. 
Interestingly, the cysteine residue next to serine 365 phosphorylation site was 
detected unmodified (Figure 2-5A) despite treatment with DTT and iodoactemide in both in-
solution and in-gel digestion methods, whereas the same cysteine residue on the 
corresponding non-phosphorylated peptide was detected as alkylated form, suggesting that 
the phosphorylation at serine might influence the alkylation reaction of this cysteine or result 
in different accessibility and conformation for alkylation. 
However, phosphorylation on serine 365 of human Hsp90 was not readily 
detected in all MS analyses by the Orbitrap mass spectrometer despite our attempt of using 
Preferred Mass list, indicating that this S365 phosphorylation was not abundant and may not 
be as well-selected by the ion trap in Orbitrap MS as by the quadrupole in MaXis MS. Several 
attempts later using synthetic phosphorylated vs non-phosphorylated peptides and MS 
detection on the Orbitrap MS revealed that the lack of modification on cysteine of the peptide 
made it unstable and thus, hindered further detection. Even with synthetic peptides, after 
treatment with DTT and iodoacetamide as we did for Hsp90 protein before digestion or not 
as control, the intensity of the phosphorylated and non-alkylated peptide detected in MS was 
at least 100-fold less than that of peptides which have all other combination between 
phosphorylation and alkylation status (Figure 2-6). Of note, with synthetic peptides, we could 
use in high amount and defined starting material, unlike with complex lysate samples in 
which we had little control over these factors. This finding suggested that the combination of 
phosphorylation and not-being alkylated status caused the bad MS response of the modified 
peptide. The MS characterization of S365-phosphorylated synthetic peptide was done in 
cooperation with L. Behrens, MS facility, ZMBH. 
Indeed, this could explain why by the time we identified the S365 
phosphorylation site of human Hsp90, there was no phosphoproteomics data for it. Only 
later in human ES and iPS as well as Jurkat cells (T-cell leukemia cell line), this S365 
phosphorylation was also reported (Phanstiel et al. 2012) (Phosphosite database). 
We had to use the MRM-MS technique followed by MS3 and library identification 
to verify this phosphorylation site (see section 2.1.3, page 47). Indeed, S365 phosphorylation 
was confirmed in HELA cells (Appendix Figure S1): the corresponding peptide was identified 
in the phosphorylated and non-alkyated form. 
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(A) 
 
(B) 
 
FIGURE 2-5: IDENTIFICATION OF S365 PHOSPHORYLATION IN HUMAN HSP90 . 
(A) Screenshot of MS/MS spectrum of peptide 360 -378 containing S365 phosphorylation in human 
Hsp90  (Biotools, Bruker) .  
(B) Peptide 360-378 of human Hsp90  with detected a, b , y ions marked with violet, red and blue 
arrows, respectively.  
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FIGURE 2-6: MRM-MS DETECTION OF SYNTHETIC PEPTIDES CONTAINING THE S365 PHOSPHORYLATION SITE IN PHOSPHORYLATED OR NON-
PHOSPHORYLATED FORM TREATED OR NOT TREATED WITH IODOACETAMID E  
The phosphorylated peptide is treated without (A) or with (B) iodoacetamide which modifies its cysteine to the carbamidomethyl form. 
Similar treatment was performed for non-phosphorylated peptide in (C) and (D). All 4 samples were injected to the LC-MS system at 100 fmol. 
The normalized detection levels (NL) of all transitions  in (A) are in 104 range, at least 100-1000x less than those of  transitions in (B), (C), (D), indicating that the phosphorylated and 
cysteine-modifed form of the peptide is not as readily detected as other forms.  
(A)  
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Position of serine 365 on human Hsp90 
Serine 365 on human Hsp90 locates in a helix belonging to the middle domain 
(mH2, (Karagöz et al. 2014))  of the chaperone, facing into the “inner space” that formed 
between the two protomers in the closed conformation of the dimer. Therefore, in principal, 
the site is not accessible to kinases and phosphatases when the Hsp90 is in its closed 
conformation, implicating that phosphorylation and dephosphorylation of this site must 
happen when Hsp90 protein is in open conformation and the phosphorylated or 
unphosphorylated form of Hsp90 can then be trapped by converting into the closed 
conformation. These events can also be coupled with Hsp90’s client protein binding and 
release. Such dynamic events of phosphorylation and dephosphorylation on the one hand, 
would be challenging for us to identify the involved kinase or phosphatase but on the other 
hand, would be highly competent for fine-tuning the chaperone. The middle domain of Hsp90 
is known as binding site for client proteins such as Cdk4, v-src, glucorcorticoid receptor, Tau, 
etc and some cochaperones like Aha1, Unc-45, etc (Meyer et al. 2003; Hawle et al. 2006b; 
Vaughan et al. 2006; Scroggins et al. 2007; Street et al. 2011; Karagöz et al. 2014; Lorenz et al. 
2014). Therefore, it is very likely that phosphorylation of serine 365 of the middle domain 
can directly influence both client and cochaperone interactions of Hsp90 proteins. In 
addition, it can also participate in modulating dynamic conformational changes of Hsp90 in 
the N- and C-terminal parts. 
 
FIGURE 2-7: POSITION OF S365 I N AN HSP90-CLIENT COMPLEX.  
Tau (yellow mesh) in complex with human Hsp90  (cyan cartoon). Leucine residues of Hsp90 that 
belong to binding surface are depicted in red spheres. Serine 365 is marked in red. Adapted from 
(Karagöz et al . 2014) .  
Isoform-specific conservation of S365 
This serine phosphorylation site of human Hsp90 is specific for this iosform 
since the corresponding residue in Hsp90 is an asparagine (N) – which cannot be 
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phosphorylated. Interestingly, in Saccharomyces cerevisiae, the homologous position is 
occupied by the phosphomimetic residue glutamate (E). Alignment of several other 
homologous sequences of cytosolic Hsp90 proteins (normally two isoforms) reveals 
intriguing pattern of evolution: the serine residue is conserved in all   isoform proteins 
whereas in all  isoform proteins, the corresponding residue is asparagine and also highly 
conserved (Figure 2-8). These isoforms are differed in their expression and induction 
mechanism as well as cell-type specificity and functions, nonetheless, these differences are 
still not fully characterized (Subbarao Sreedhar et al. 2004; Kuo et al. 2007; Millson et al. 
2007; Milicevic et al. 2008; Gao et al. 2013; Silva et al. 2013). In the cellular context, Hsp90 
emerges as a fast-response, cytoprotective isoform; while Hsp90 seems to be associated 
with long-term cellular adaptation and facilitates cellular evolution. The isoform-specific 
conservation at this residue in Hsp90 proteins suggests that this serine phosphorylation 
could involve in isoform-specific tasks of Hsp90 such as regulating certain clients or upon 
response to particular conditions. The isoform-division cellular tasks of Hsp90 proteins could 
be performed simply by the switch of phosphorylatable and non-phosphorylatable residues. 
It can be highly informative to elucidate these isoform-specific tasks in relation to the 
phosphorylation status of serine 365 in human Hsp90. However, in the scope of this project, 
I do not focus on the isoform-specific issues of Hsp90 proteins, but rather on its effects on the 
human Hsp90 isoform only.  
 
FIGURE 2-8: SEQUENCE ALIGNMENT OF HSP90 PROTEINS IN EUKARYOTES DEMONSTRATES A 
POSSIBLE EVOLUTION ROLE OF RESIDUES AT THIS POSITION (365 ON HUMAN HSP90 ). 
For each organism, two cytosolic isoforms were taken for alignment. As shown in consensus 
sequence, apart from yeast which has in both isoforms glutamate (E) at this corresponding position, 
all other organism exhibit a high conservation of serine (S) for the beta isoform and asparagine (N) 
for the alpha isoform. Sequence alignment was performed by online Clustal Omega tool of  EMBL -EBI 
(Link: http://www.ebi.ac.uk/Tools/msa/clustalo/) . 
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The presence of a glutamic acid at the corresponding position which resembles 
the phospho-mimetic state of the serine residue in both cytosolic Hsp90 isoforms of 
Saccharomyces cerevisiae, the simplest eukaryotic organism, is also intriguing. It has been 
suggested that the phosphorylation patterns in yeast and man are quite different despite that 
the majority of yeast phosphorylation sites are conserved residues also in the human 
proteins (Gnad et al. 2010; Soroka et al. 2013). In our case, on the contrary, the need for a 
negative charge at this position seems to be conserved and is fulfilled either by glutamic acid 
in yeast homolog or phosphorylation of serine in human Hsp90. Given the flexibility gained 
from phosphorylation of serine residue in human Hsp90 instead of glutamic acid residue in 
yeast and the complete replacement into asparagine in the  isoform, it can be envision that 
the role of this phosphorylation site is modulated in a finer manner or tuned down in human 
Hsp90 homolog as compared with its yeast counterpart. Due to the enlargement of human 
Hsp90 clientele, the increase in cellular processes in adaptation to environmental stimuli and 
the evolution of protein kinase family after the divergence of higher eukaryotes from yeast, 
many other phosphorylation sites of Hsp90 protein could have been utilized and took over 
part of the role. It is also conceivable that the combination between S365 phosphorylation 
and other modifications (either on the same Hsp90 molecule or on the interaction partners) 
in higher eukaryotes becomes more critical. 
Potential kinase 
Serine 365 of human Hsp90 is followed by acidic residues and hence, is well-
matched to phosphorylation recognition motif of CK2 kinase. However, in in-vitro 
phosphorylation assay using CK2 and subsequent MS analysis, S365 phosphorylation was not 
detected together with all other CK2-targeted phosphorylation sites on human Hsp90 
except two serines at the linker region (S226 and S255). This result suggested that additional 
specific in vivo conformation and/or associated factors might be required for serine 365 
phosphorylation of human Hsp90. Moreover, besides being a kinase that phosphorylates 
many other sites in human Hsp90 proteins, CK2 is also a client protein of Hsp90, making it 
technically impossible to test for in vivo phosphorylation of this particular serine residue of 
human Hsp90 by CK2 without a specific antibody that recognizes uniquely the 
phosphorylated S365. We attempted to produce such an antibody using purified 
phosphomimetic variants as well as the phosphorylated peptide, however, both approaches 
did not yield successful results. Therefore, so far, our method to demonstrate in vivo 
phosphorylation of S365 in human Hsp90 is limited to MRM-MS. 
2.2.2 IN VIVO S365 PHOSPHORYLATION IS BENEFICIAL FOR HSP90 CHAPERONE 
ACTIVITY 
General chaperone activity 
In order to gain more insights into the impact of serine 365 phosphorylation on 
the function of human Hsp90, we constructed non-phosphorylatable and phospho-mimetic 
variants of human Hsp90β and introduced them as sole source for Hsp90 in yeast. We used 
alanine replacement as non-phosphorylatable (S365A) and glutamic acid as phospho-mimetic 
variants (S365E) as generally utilized in the field of phosphorylation studies. We also 
included another non-phosphorylatable variant by asparagine replacement for serine 365, 
which also mimicking the corresponding residue on human Hsp90. While the human wild-
type Hsp90β protein and the phosphomimetic variant (S365E) were able to complement the 
lethal phenotype of the double deletion of the endogeneous yeast Hsp90 genes similarly, two 
non-phosphorylatable variants of Hsp90β complemented more poorly (Figure 2-9A), 
indicating that phosphorylation of Hsp90β is important for its full functionality at least in 
Saccharomyces cerevisiae.  
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The yeast cells containing only human Hsp90β protein (wild-type or mutants) 
also exhibited another striking phenotype: their overall size was three to five-fold bigger than 
that of the isogenic yeast strain that habors at least one copy of yeast hsp90 genes (Figure 
2-9B). This morphological effect demonstrated that there were abnormalities in yeast cell 
cycle control and it is very likely that involved proteins in this process are regulated by 
Hsp90. Indeed, in Saccharomyces cerevisiae, the kinase Cdc28 (corresponding human 
homolog Cdk1), the master player of yeast cell cycle, together with the Cla4 protein kinase, 
which is involved in septin formation and subsequently bud elongation, have been shown to 
interact with Hsp90 (Mollapour, S. Tsutsumi, et al. 2010; Hsieh et al. 2013) and thus, very 
likely are client proteins of Hsp90. Another well-known client protein of Hsp90, heat shock 
factor-1 (Hsf1), was also reported to be related to spindle pole body duplication (Zarzov et al. 
1997), a process that eventually could lead to abnormal cell size, too.  Apparently, human 
Hsp90 proteins are less potent in chaperoning yeast client proteins as compared to yeast 
Hsp90, partially due to their much weaker ATPase activity as well as their altered 
interactions with yeast cochaperones. Therefore, it is likely that these yeast protein kinases 
were less chaperoned by the human wild-type Hsp90 or variant proteins and thus, result in 
such morphological change. 
To test whether yeast strains harbouring only human Hsp90 proteins suffered 
severe defects in cell cycle progression, we performed cell cycle analysis of these strains 
using Flow cytometry. The results confirmed that all four yeast strains containing human 
Hsp90 wild-type and phosphomutants were haploid with more cells were in G2/M phase 
than wild-type yeast carrying endogeneous Hsp90 proteins, nevertheless, no higher DNA 
content were observed (Figure 2-10), ruling out the possibility that cell cycle in these yeast 
strains were fully arrested but rather only delayed or prolonged. The budding and growth of 
daughter cells happened eventually. 
Moreover, on top of the overall large size of yeast cells containing human Hsp90 
proteins, the largest size effect belonged to the non-phosphorylatable variant S365A while 
phospho-mimetic variant S365E had almost an identical cell size to that of wild-type Hsp90 
(Figure 2-9B). This phenotype provided us with hints that wild-type Hsp90 could be 
phosphorylated in Saccharomyces cerevisiae and phosphorylation at S365 participates in 
chaperone activity of the protein for cell-cycle-control client proteins. 
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FIGURE 2-9: GENERAL IN VIVO FUNCTION AND PHENOTYPE OF YEAST CONTAINING EITHER 
HUMAN HSP90  WILD-TYPE OR S365 PHOSPHO-MUTANT PROTEIN AS THE SOLE SOURCE OF 
HSP90 PROTEIN.  
(A) Complementation assay: Yeast cells containing either human Hsp90  wild-type (WT) or 
phosphomutant protein (SA: S365A; SE: S365E, SN: S365N), were tested whether they could 
complement the double deletion of both yeast Hsp90 cytosolic isoforms.  
(B) The average cell volumes of yeast cells in (A): W303 is the yeast strain containing yeast Hsp90;  
the others are isogenic yeast strains with hsp82 and hsc82 genes deleted and instead the human 
hsp90  encoding gene on a plasmid was introduced (labeled as in A). The data are expressed as mean 
 standard error of the mean (SEM) from n>=70 single cells. Experiments were performed in 
collaboration with R. Knieß.  
 
0 
200 
400 
600 
800 
1000 
1200 
1400 
W303 WT SE SA SN 
V
o
lu
m
e
 [
fL
] 
Results & Discussions 
61 
 
 
FIGURE 2-10: CELL CYCLE ANALYSIS OF YEAST STRAINS CONTAINING EITHER YEAST HSP90 OR 
THE ISOGENIC YEAST STRAINS CONTAINING ONLY HUMAN HSP90  AS THE SOLE SOURCE OF 
HSP90 PROTEIN.  
W303a/:  yeast strains containing yeast Hsp90 and the isogenic strains with human Hsp90  proteins 
(WT: wild-type; SA: S365A; SE: S365E, SN: S365N). Experiments were performed in collaboration 
with R.Knieß.  
Client-specific effects 
Even though plating efficacy of the non-phosphorylatable Hsp90 variants on FOA 
medium was much lower as compared to wild-type and S365E variant, once adapted to grow 
with Hsp90-S365A or S365N as sole source of Hsp90, these variants grew with slightly 
slower rates as compared to that of strains harbouring the wild-type (Figure 2-11). 
Nevertheless, they could still be utilized to query the possible role of serine 365 
phosphorylation for distinct aspects of chaperone function.  
R. Knieß in the lab developed GFP-based reporter assays in yeast to analyze the 
activity of selected Hsp90 clients, including the mammalian glucocorticoid receptor 
(glucocorticoid response) and three endogeneous yeast Hsp90 clients: the heat shock factor-
1 HSF-1 (heat shock response), the mitogen-activated protein kinase (MAPK) Ste11 
(pheromone response) and the Heme activator protein (Hap1). 
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FIGURE 2-11: GROWTH CURVE OF YEAST STRAINS CONTAINI NG EITHER HUMAN HSP90  WILD-
TYPE OR S365 PHOSPHO-VARIANT PROTEIN AS THE SOLE SOURCE OF HS P90 AT30°C.  
The growth curve for WT: wild-type is in black; SA: S365A in pink; SE: S365E in green and SN: S365N 
in brown.  
The mammalian steroid receptor GR is a well-characterized Hsp90-dependent 
transcription factor that has been applied as a sensitive readout for Hsp90 function in yeast 
in several studies (Bohen 1995; Nathan & Lindquist 1995; Chang et al. 1997; Mollapour, 
Shinji Tsutsumi, et al. 2010; Mollapour, Tsutsumi, et al. 2011; Mollapour et al. 2014). To 
examine the potential influence of S365 phosphorylation on the chaperoning of GR by human 
hsp90, yeast strains with wild-type, S365A, S365E and S365N mutants were transformed 
with a plasmid that constituitively expressed GR. The strain was further integrated into the 
genome a fragment carrying glucocorticoid-response elements followed by GFP reporter 
gene. The cells were treated with doxycyclin to initiate the response and GFP expression was 
monitored in the time course of 6 hours. GFP signals in different strains were normalized by 
another fluorescence signals under regulation of translation elongation factor-1 (TEF) 
promoter which represents overall translation in the cell at the same time point. Our data 
showed that GR response was weakened in yeast containing S365A and S365N – the two non-
phosphorylatable variants – as compared with that in yeast having human Hsp90 wild-type 
or S365E-phosphomimetic mutant (Figure 2-12A). Further analysis revealed that the 
activation rate constants for GR response of wild-type or S365E were approximately double 
that of the other two variants (Appendix Figure S2), which strongly demonstrated that 
phosphorylation of human Hsp90-S365 was important for chaperoning of the steroid 
receptor GR.  
Next, we employed the similar reporter system for two endogeneous yeast Hsp90 
client proteins: the kinase Ste11 in pheromone response and HSF-1 in heat shock response. 
Ste11 is one of the kinase participated in a MAPK signaling cascade that transmit and relay 
mating signal in Saccharomyces cerevisiae (Zhou et al. 1993; Kjærulff et al. 2005). Its stability 
and activity require Hsp90 and Cdc37 (Louvion et al. 1998; Abbas-Terki et al. 2000). To look 
at the chaperoning of Ste11 by human wild-type hsp90 and phospho-mutant proteins, we 
constructed a pheromone response element in front of GFP gene and integrated the whole 
cassette into yeast genome as for GR’s response element. The response was initiated by 
addition of alpha factor and GFP signals were measured during 7 hours. The signals were 
normalized as described before to overall protein translation. We obtained similar results: 
S365A and S365N both exhibited much reduced pheromone response than wild-type and 
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S365E (Figure 2-12B). The data qualified well as evidence for strong impact of S365-
phosphorylation on chaperoning Ste11 kinase.  
 
(A) Glucocorticoid response     (B) Pheromone response 
   
 (C) Heat shock response 
 
FIGURE 2-12: IN VIVO S365 PHOSPHORYLATION IS BENEFI CIAL FOR HSP90 CHAPERONE 
ACTIVITY .  
Constructs of corresponding response elements followed by GFP were introduced into yeast 
containing either human Hsp90  wild-type (WT); S365A (SA); S365E (SE) or S365N (SN) as the sole 
source of Hsp90 protein. Time-course GFP signals were recorded and normalized with the signal 
from TEF promoter which represent overall translation activity of each cell. In A, B and C, response 
signals were labeled in black for WT, pink for SA, green for SE and brown for SN.  
(A) Glucocorticoid response (B) Pheromone response. (C) Heat shock response at  37°C (left) or 42°C 
(right).  
In C, the response is expressed as mean  SEM from 4 independent clones. Experiments were done in 
collaboration with R. Knieß.  
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In the case of HSF-1, heat shock response element was placed in front of GFP 
gene and integrated into the yeast genome similar as in the other cases. Yeast cells were 
grown at 25°C and heat shocked at either 37°C or 42°C. GFP signals and overall translation 
signals were monitored during 2.5 hours. The results of the heat shock response were similar 
to the results of both glucocorticoid and pheromone response (Figure 2-12C). Therefore, 
same as for glucocorticoid receptor and the MAPK Ste11, S365-phosphorylation status 
appears to be an important determinant for effective chaperoning HSF-1 in yeast. 
Finally, we assessed the effect of S365-phosphorylation on chaperoning another 
Hsp90 client in yeast, HAP1. HAP1 is a heme-activated transcription factor that mediates the 
effects of oxygen on gene transcription in the yeast Saccharomyces cerevisiae. Previous 
studies showed that in the absence of heme, HAP1 is bound to Hsp70, Hsp40 and Hsp90 as 
well as other proteins in a high molecular weight complex and is repressed. Heme promotes 
the dissociation of the complex and activates HAP1, which in turn binds to DNA and 
stimulates transcription of target genes (Zhang et al. 1998; H. C. Lee et al. 2002; Lan et al. 
2004). In this case, HAP1 is similar to glucocorticoid receptor, as both were kept by the 
Hsp90 complex in a ligand-activation-competent conformation. 
We employed a heme-response element followed by GFP gene integrated into the 
yeast genome to examine the influence of S365-phosphorylation of Hsp90 on HAP1 
chaperoning. Surprisingly, in this case, neither non-phosphorylatable mutant S365A and 
S365N nor phosphomimetic mutant S365E displayed significant difference as compared to 
wild-type (Figure 2-13). 
Taken together, these data showed that the S365-phosphorylation status of 
human Hsp90 is not involved uniformly in all interactions of Hsp90 with client proteins. 
While this modification significantly influences the interaction or activity of some 
transcription factors and kinase include HSF-1, glucocorticoid receptor and MAPK Ste11, it 
seems not to participate in interaction with and chaperoning of the HAP1 transcription factor. 
 
 
 
FIGURE 2-13: PHOSPHORYLATION STATUS AT S365 OF HUMAN HSP90  HAS MINIMAL IMPACT 
ON HEME ACTIVATOR PR OTEIN (HAP) ACTIVATION 
The HAP response is expressed as mean   SEM from 4 independent clones. Experiments were 
performed in collaboration with R.Knieß.   
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2.2.3 PHOSPHO MUTANTS AT SERINE PHOSPHORYLATION SITE ALTERS 
INTERACTION OF HSP90 PROTEIN WITH COCHAPERONES IN VITRO 
To elucidate the mechanism how S365 phosphorylation contributes to mediation 
of Hsp90 function, I purified recombinant human wild-type and phospho-mutant Hsp90 
proteins from E.coli for in vitro assays. All S365 mutants behaved almost identical as wild-
type human Hsp90 protein in expression and purification from E.coli, indicating that the 
overall structures of the mutant proteins were minimally affected by the amino acid exchange 
itself. 
Limited proteolytic assay by Trypsin 
A partial digestion of purified Hsp90 proteins by Trypsin was also performed. 
The result showed that all mutants and wild-type have indistinguishable digestion pattern 
(Figure 2-14), confirming that these proteins have almost equal stability under the storage 
conditions. Interestingly, in the presence of AMPPNP which induces the close conformation of 
Hsp90, subtle variations could be observed for all the phospho-mutant proteins (S365A, 
S365E, S365N) as compared to the wild-type protein. In general, the S365 phospho-variant 
proteins seemed to be more protected from tryptic digestion in the presence of AMPPNP than 
all other proteins as the overall digestion was delayed (see Figure 2-14 in (C) and (D)). 
Especially in the case of S365A, the tryptic digestion pattern was even slightly alterred with 
the appearance of higher molecular-weight bands, indicating that in the structure of this 
phopho-variant, at least one tryptic site was protected in the presence of AMPPNP. However, 
the differences were relatively small and thus, should not disturb significantly our 
subsequent in-vitro experiments using these purified proteins. 
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FIGURE 2-14: LIMITED PROTEOLYSIS ASSAY OF PURIFIED HSP90 PROTEINS  
Purifed Hsp90 proteins (wild-type: WT, S365A: SA, S365E: SE and S365N: SN) were digested individually by 
Trypsin (E:S=1:100) at 37°C. At different time points ( 0, 1, 5, 10, 15, 20min), identical amount of each digestion 
reaction was taken for SDS-PAGE. In (A) and (B): without nucleotide, in (C) and (D): in the presence of AMPPNP. 
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In vitro binding to GA  
A similar pulldown experiment using biotinylated-GA was performed for purified 
proteins instead of cell lysates to examine whether the single S365 phosphorlyation status of 
Hsp90 mimicked by exchanging into glutamic acid would alter binding to GA. Besides, 
S365E – the phospho-mimetic variant, I also included the purified human Hsp90 and 
Hsp90 wild-type proteins as controls for non-phosphorylation status of Hsp90. In this 
experiment, the wild-type tagged Hsp90 protein (His6x-SUMO-Hsp90) was used, enabling 
me to distinguish and evaluate quantitatively (if necessary) the  versus  isoform on SDS 
polyacrylamide gels after Coomasie staining without the need of Western blotting since any 
antibody for Hsp90 might recognize the isoforms with different efficiency. 
 
FIGURE 2-15: GA-PULLDOWN OF EITHER HUMAN HSP90 ISOFORMS AND THE PHOSPHO-MIMETIC 
MUTANT OF HSP90  (S365E) 
SDS-PAGE of unbound and bound fractions from GA pulldown is shown. The Hsp90 isoform was purified without 
cleavage of N-terminal His6-SUMO tag to allow distinguishing between two isoforms by Coomasie staining. 
All three tested proteins exhibited a very similar binding behavior to GA: only a 
minority fraction was bound whereas the majority stayed unbound in flowthrough. Binding 
to GA was hardly influenced by the single S365 phosphorylation status of Hsp90 imitated by 
exchange of serine into an acidic amino acid. Notably, in the very similar experimental 
conditions (binding buffer, incubation time and temperature, amount of biotinylated-GA and 
streptavidin beads, etc), a bigger fraction of cellular Hsp90 (from comparable total amount in 
lysate input) was bound to GA as compared with purified Hsp90 (see section 2.1.1, page 40). 
This observation confirmed the findings reported by Kamal et al. that cellular Hsp90 
consisted of a high-affinity conformation which differs significantly from purified Hsp90 in 
binding to GA and other Hsp90 inhibitors (Kamal et al. 2003). 
In vitro glucocorticoid receptor (GR)-activation assay 
To dissect the underlying mechanism for the phenotype observed in yeast for 
glucocorticoid response, I reconstituted the minimal in vitro activation chaperone system for 
this client and assessed the impact of different S365 phospho mutants. A minimal activation 
chaperone system for glucocorticoid receptor comprises of Hsp40, Hsp70, HOP, p23 and 
Hsp90 (Dittmar et al. 1996; Dittmar & Pratt 1997; Dittmar et al. 1997). Earlier studies by 
Pratt and coworkers characterized not only these central proteins involved but also their 
general order in which they enter and exit the activation pathway (Y Morishima et al. 2000; 
Kanelakis et al. 2002) as depicted in Figure 1-2 , page 14. Most recent work by Kirschke et al. 
revealed even more interesting details referring to activity of each chaperone on GR during 
the process: Upon binding to the Hsp40-Hsp70 system, GR is partial unfolded, while 
interaction with Hsp90 then reverses this inactivation and promotes ligand binding. 
Together, the two chaperone system coordinate to ensure GR stability, function and 
regulation.  
Along with other members of the steroid hormone receptor (SHR) family, GR 
represents one of the most stringent Hsp90 clients (Taipale et al. 2012). Similar to other 
proteins of the family, GR consists of three major functional domains: an N-terminal 
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activation domain, a DNA-binding domain (DBD) and a ligand binding domain (LBD), linked 
by a short, flexible hinge-region (Kumar & Thompson 1999). The receptor activity is 
regulated through its C-terminal ligand binding domain (LBD). All LBDs have a similar mostly 
helical structure with the ligand binding pocket located in the core of the protein. In the 
absence of ligand, LBDs are assumed to be dynamic, while the ligand provides both structural 
stability for LBD and allosteric control of the LBD’s ability to interact with co-regulator 
proteins to modulate transcription (Bain et al. 2007). This important domain is also the 
interaction part of GR with Hsp90 (Howard et al. 1990). The in vivo function of GR strictly 
depends both on the interaction of the GR-LBD with the Hsp90 chaperone machinery and 
chaperone activity from the chaperone complex (Bresnick et al. 1989; Picard et al. 1990; 
Bohen 1995). Like most stringent Hsp90 clients, biochemical studies of GR have been 
hampered by the difficulty to obtain stable and functional apo protein for in vitro 
investigations. Since the wild-type GRLBD is a rather unstable and poor-soluble protein, I 
utilized a single solubility enhancing mutation (F602S) to obtain workable quantities of 
GRLBD while making least change to the wild-type protein (Bledsoe et al. 2002; Ricketson et 
al. 2007; Seitz et al. 2010; Lorenz et al. 2014). The GRLBD(F602S) were also purified in the 
apo state with an N-terminal MBP tag since it enhanced stability over long experimental time 
courses. This N-terminal MBP tag had already been verified to not interfere with in vitro 
experiments using the same chaperone system (Kirschke et al. 2014). MBP-GRLBD(F602S), 
referred to as GRLBD unless otherwise specified, was purified in the presence of ligand 
(dexamethasone) followed by extensive dialysis to remove the ligand. 
Ligand binding was monitored by microscale thermophoresis measuring the 
alterations in thermophoretic mobility behavior of fluorescein labeled dexamethasone (F-
dex) as it is bound to GRLBD. Taken into account that the ligand affinity of GRLBD was 
unaffected but rather the fractions of ligand-binding competent proteins were differentially 
affected by the minimal chaperone system, we fitted the data using the quadratic equation for 
tight-binding substrates (see section 3.2.3) to calculate this ligand-binding competent 
fraction with the constraint of a constant dissociation constant (Kd). We applied the Kd of 
150nM as reported by Kirschke et al, 2014 in which very similar experimental conditions 
were used. The ligand-binding competent fraction from here on will be referred to as “active 
fraction”. 
In our experiments, GRLBD was partially unfolded by the Hsp70-Hsp40 system, 
which was in agreement with the study by Kirschke et al, 2014. Also, addition of Hsp90 
together with the cochaperones HOP, p23 led not only to restoration of active GR fraction as 
in the absence of chaperones and adaptor proteins but also to further enrichment this active 
fraction. The highest ligand-binding competent fraction of GRLBD was obtained in the 
presence of the minimal chaperone system with Hsp90 S365E phosphomimetic variant ( 
Figure 2-16), indicating that this variant exhibited an enhanced chaperone 
activity for GRLBD as compared with all other Hsp90 tested in this experiment. Of note, the 
wild-type Hsp90 protein as expressed and purified from E.coli was absolutely in non-
phosphorylated form and therefore, behaved similar to S365A and S365N in this in-vitro 
experiment as expected. 
This result confirmed the positive effect of phosphorylation at S365 of human 
Hsp90 for GR response although with a lesser extent than observed in the in-vivo-system. 
The variations in modulation capacity of S365 phosphorylation in in-vivo- versus in-vitro- 
experiments could be explained by several possible reasons. First, in the yeast reporter 
system, we observed not only higher maximal response but also increased in activation rate 
of wild-type and S365E phospho-mimetic mutant than S365A and S365N 
nonphosphorylatable mutants (Figure 2-12). Therefore, additional time-course in-vitro-
experiments may provide more comparable effects between the S365 phospho-mutants with 
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results in in-vivo model. Secondly, in contrast with in-vivo settings, in-vitro reactions included 
only the minimal chaperone system of most important proteins involved in the chaperoning 
process of GR. Additional factors such as the Cyp40/Cpr6  which was shown to also be 
present in the Hsp90-GRLBD-HOP complex (Lorenz et al. 2014) might be responsible for 
another enhancement onto the final response that was observed in yeast. Since for most 
tested clients including not only glucocorticoid receptor but also heat shock factor and Ste11 
kinase, the S365E phosphomimetic variant provided better chaperone effect than S365A and 
S365N non-phosphorylatable variants, it is equally possible that the impact of 
phosphorylation is direct on client interaction(s) or indirect via cochaperone(s) that 
participate in the Hsp90-client complex, or the combination of both. The latter possibility also 
has been studied and is described in the next part. 
Normalized fraction of active GR 
 
GRLBD + + + + + + + + + 
Hsp40 + Hsp70  +  + + + + + + 
HOP + p23   + + + + + + + 
Hsp90     + + + + + 
       -SA -SE -SN 
 
 
FIGURE 2-16: PHOSPHOMIMETIC VARIANT (S365E:  -SE) OF HSP90  EXHIBITED ENHANCED 
CHAPERONE ACTIVITY I N IN VITRO MINIMAL GR -ACTIVATING SYSTEM 
as compared with human Hsp90 () , human Hsp90  wild-type () and non-phosphorylatable 
variant proteins (S365A: -SA and S365N: -SN).  The minimal GR-activting system includes Hsp70, 
Hsp40, HOP, p23 and different Hsp90 proteins. The activity of activated GR was measured as binding 
affinity to fluorescein dexamethasone using microscale thermophoresis. SEM were calculated for 2 -3 
repeats. A Student’s t-test was performed for the system with the wild -type Hsp90  and S365E 
protein.  
Another difference in the experimental setup for in-vivo vs in-vitro experiments 
was the output that I monitored. In the system consisted of purified chaperones and 
cochaperones that activate GR, binding to F-dex was measured as indicator for GR’s activity; 
whereas in the yeast model system, transcriptional activation activity of GR was recorded. It 
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is proven that Hsp90 does not involve only in restoring the binding capacity of GR for ligand 
but also in later events as the GR-Hsp90 complex is translocated into the nucleus. S365 
phosphorylation might also have an impact on these subsequent steps such as altering the 
transport of GR-Hsp90 complex into the nucleus or the release of ligand-bound GR from 
Hsp90 complex. These later steps from ligand binding to activation of target genes of GR 
response were not investigated in the in-vitro experiments. Further dissecting of these 
possibilities using in-vitro system would be quite challenging as well. 
Last but not least, different constructs of glucocorticoid receptor were utilized in 
the two systems: full-length wild-type rat glucocorticoid receptor in the yeast model and 
GRLBD(F602S) in biochemical experiments. The F602S mutant I employed in the purified-
protein system was shown to be less dependent on Hsp90 in vivo in a way that it responds to 
lower concentrations of dexamthasone than does wild-type GR as well as still retains partial 
response upon reduction of Hsp90 levels or in presence of geldanamycin (Bohen 1995; 
Ricketson et al. 2007). IP experiments also indicated that the F602S mutant binds with less 
affinity or more transient with Hsp90 (Ricketson et al. 2007). However, it should be 
emphasized that signal transduction by wild-type and F602S GR was similarly affected by a 
number of Hsp90 mutants, and, more importantly, the individual Hsp90 mutants followed the 
same order of severity within the spectrum of mutant (Bohen 1995). So in principle, Hsp90 
functions in a similar manner to chaperone both wild-type and F602S mutant and the F602S 
mutant is still valid as an effective tool for testing effects of Hsp90 mutants. Nevertheless, I 
could not completely rule out the possibility that dependency of the F602S mutant on Hsp90 
chaperone activity for ligand binding is lower than that of wild-type glucocorticoid receptor.  
Interaction with cochaperones 
I also looked at the effect of S365 phosphorylation on association with different 
cochaperones using the purified phospho-mutant and wild-type proteins. In these in vitro 
experiments, in contrast with in vivo models, I expected to observe distinguished impacts 
between S365E phosphomimetic variant and all three other Hsp90 proteins including wild-
type protein and non-phosphorylatable variants S365A and S365N, since wild-type Hsp90 
protein expressed and purified from E.coli was also not phosphorylated. 
HOP (Hsp70/Hsp90 organizing protein) 
The Hsp70/Hsp90 organizing protein HOP has the unique ability to interact with 
both Hsp70 and Hsp90. This simultaneous binding of HOP to the two chaperones is critical 
for coordination between these systems as it facilitates client transfer which is the first step 
and prerequisite for later folding process on the Hsp90 system. Since detected in many 
Hsp90-client complexes, HOP is referred to as a general cochaperone required for 
chaperoning most Hsp90 clients even though on its own this protein has no chaperoning 
activity. For that reason, it is comprehensible to hypothesize that the effects I observed in the 
yeast model system for different client proteins were mediated via such a general 
cochaperone like HOP. 
To study the interaction of HOP and human hsp90 wild-type or S365 phospho-
mutants, I employed size-exclusion chromatography (SEC) and purified proteins. HOP and 
Hsp90 protein(s) were incubated for 30min at 30°C with a 1:1 molar ratio to form the 
complex. Each protein alone was also prepared in the same buffer and incubated under 
identical conditions as controls. The protein alone or mixture(s) was then loaded onto a 
Superdex 200 analytical column and elution fractions were analyzed on SDS-PAGE. The 
difference in size of HOP (60kDa) and Hsp90 proteins (90kDa) allowed me to identify those 
proteins in the elution fractions without the need of further confirmation method such as 
Western blotting. 
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FIGURE 2-17: INTERACTIONS OF PURIFED HUMAN WILD -TYPE HSP90  AND S365 PHOSPHO 
MUTANT PROTEINS WITH HOP ARE HIGHLY SIMIL AR.  
SDS-PAGE of size-exclusion chromatography fractions (1 -12) from a Superdex 200 PC 3.2/30 
analytical column of HOP or human Hsp90  wild-type (WT) and S365 phospho-mutants (S365A: SA; 
S365E: SE: S35N: SN) as single protein alone and each Hsp90 protein forming complex with HOP as 
indicated.  
 
As expected, HOP eluted in later fractions than Hsp90 proteins when each of 
them was injected alone. However, when HOP was incubated with either wild-type Hsp90 or 
S365 mutant proteins, a complex was successfully formed as HOP protein was shifted to co-
elute with Hsp90 in higher molecular weight fractions (Figure 2-17). I observed no significant 
variation between complex formation of HOP and all Hsp90 proteins, indicating that S365 
phosphorylation has no effect on association of HOP and human Hsp90 under these 
conditions. Of note, in this interaction experiment with HOP and the in-vitro assay using the 
minimal GR-activating system, the similar experimental conditions which Hsp90 : HOP molar 
ratio is 1:1 was applied. No significant difference was observed in interaction of Hsp90 
proteins with HOP, indicating that the improved impact of S365E and cochaperones for GR 
activation was not likely to originate from indirect alterations in interaction of S365E and this 
cochaperone. It is intriguing, though, to see how HOP and those cochaperones that are 
already included in the minimal GR-activating system such as Hsp70 and p23 would interact 
with Hsp90 when they are used with lower physiological concentrations (in 
substoichiometric ratio as compared to Hsp90 proteins). It is possible that under those 
conditions, a binding preference to one variant could be revealed. 
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Aha1 (Activator of Hsp90 ATPase activity-1) 
Aha1 is the only Hsp90 cochaperone that can accelerate the weak ATPase activity 
of Hsp90. Nevertheless, the contribution of Aha1 to Hsp90 chaperone activity is still 
enigmatic. While for some clients such as ErbB2, v-src, Cdk4, c-Raf, etc, Aha1/Hsp90 
interaction is proven to be important (Panaretou et al. 2002; Lotz et al. 2003; Holmes et al. 
2008; Mollapour, Tsutsumi, et al. 2011), for some others such as HSF, GR and CFTR, the 
decreased Aha1 interaction with certain Hsp90 post-translational modified variants seems to 
have minimal or even beneficial effects (Mollapour, Tsutsumi, et al. 2011; Mollapour et al. 
2014). The various influences are obviously client-specific or cellular Aha1 concentration-
dependent, representing a complicated relationship of modulation between this cochaperone 
and Hsp90 protein.  
The involvement of Aha1 in chaperoning HSF1 and GR makes it a candidate for 
our in vitro investigation of the impact from S365 phosphorylation on Hsp90 chaperone 
based on the results from the yeast reporter system. Moreover, the majority of its interaction 
surface with Hsp90 is along the chaperone’s middle domain, where S365 phosphorylation 
site is located even though on the opposite side.  
I also performed similar SEC experiments to look at complex formation between 
purified human Hsp90 protein(s) and (yeast) Aha1, however, very little complex was 
observed under similar conditions as for HOP despite my several attempts by modifying the 
incubation duration and presence of nucleotide (data not shown). Hence, I labeled (yeast) 
Aha1 with Hilyte 488 C2 maleimide and used it in only substoichiometric amount with Hsp90 
to shift Aha1 as much as possible into the complex. The fluorescence labeling provided me 
with the necessary sensitivity to detect such small quantities of Aha1 in complex with Hsp90. 
Despite the low efficiency of complex formation between human Hsp90(s) and (yeast) Aha1, 
fluorescence detection coupled with SEC enabled me to assess differences between human 
Hsp90 wild-type and S365 phospho-mutants in binding with Aha1.  
Indeed, S365E phosphomimetic mutant displayed a diminished complex amount 
as compared with all other Hsp90 proteins including wild-type and nonphosphorylatable 
variant proteins (Figure 2-18). This observation is similar to another recently reported 
phosphorylation on human hsp90 (T36) which also attenuates Hsp90 interaction with Aha1 
and displayed enhanced chaperone activity for GR (Mollapour, Tsutsumi, et al. 2011) 
although these two phosphorylation sites seem to be unrelated. However, investigation of 
T36-phosphorylation only showed in GR activation assay elevated effect of the phospho-
mimetic variant (T36E) over wild-type and non-phosphorylatable variant (T36A) in yeast 
and human cells, suggesting that the protein is not phosphorylated at this position in vivo. 
Our data demonstrated a different scenario, as both wild-type and phospho-mimetic variant 
(S365E) exhibited similar in vivo activation levels and higher than that in case of two other 
non-phosphorylatable variant (S365A and S365N). The wild-type protein seems to be 
phosphorylated at S365 in yeast. Moreover, the modulation amplitude of S365 
phosphorylation was less than that of T36, suggesting an intermediate level of regulation 
provided by this S365 phosphorylation for Hsp90. 
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(A) 
 
(B) 
 
FIGURE 2-18: REDUCED INTERACTION OF PURIFED HUMAN HSP90  S365E (SE) 
PHOSPHOMIMETIC MUTANT WITH AHA1  
as compared with wild-type (WT) and nonphosphorylatable mutants S365A (SA) and S365N (SN). 
Aha1 protein was labeled with Hilyte 488 C2 maleimide and incubated with purified human Hsp90 protein(s) for 
15minutes at 30°C before loaded onto a Superdex 200 PC 3.2/30 analytical column. Both UV280 and fluorescence 
signals were recorded. 
(A) Overlay of fluorescence detection coupled with SEC for samples containing labeled Aha1 and different human 
Hsp90 protein(s): WT (blue), SA (pink), SE (green) and SN (brown). 
(B) Quantification of Aha1 in complex as percentage with total Aha1 by summation of fluorescence signal detected 
in time duration from 10-13.75min in SEC elution profile.  The values are expressed as average  SEM from 2 
independent repeats. 
 
Cdc37 (Cell division cycle 37 protein) 
Cdc37, one of the essential cochaperones of Hsp90, plays a specialized and crucial 
role in the maturation of many members from the protein kinase family, an important class of 
Hsp90 clients, such as EGFR, v-src, Lck, Raf-1, Cdk4, etc. Cdc37 acts as an adaptor to load 
these kinase clients onto the Hsp90 complex for further conformational activation. Even 
though the impact of S365 phosphorylation we observed in yeast model was not limited to 
the only kinase client Ste11 that we used, it is possible that these impacts can be mediated via 
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interactions of modified Hsp90 with Cdc37 as a few studies have shown that this 
cochaperone is not completely restricted to kinases as substrates (Rao et al. 2001; X. Wang et 
al. 2002). Therefore, I decided to investigate the interaction of human wild-type Hsp90 or 
phospho-variant proteins with human Cdc37 using purified proteins. Similar SEC was 
performed to assess complex formation between purified human Hsp90 protein(s) and 
human Cdc37 under similar conditions as for HOP. The results were also comparable to the 
case of HOP (data not shown). However, taken from the experience with HOP, I further 
investigated binding of Cdc37 and Hsp90(s) using isothermal titration calorimetry (ITC) since 
Cdc37 could be conveniently purified and concentrated to high concentration to be used in 
ITC. While this is not the case for Aha1, similar labeling as for Aha1 was not applicable for 
human Cdc37 due to the presence of 9 cysteines in total on this protein, which would 
definitely complicate the labeling outcome. The ITC result provided us with evidence that the 
phospho-mimetic variant S365E binds Cdc37 with an impaired affinity while both two non-
phosphorylatable variants (S365N and S365A) binds with similar affinity as compared with 
wild-type human Hsp90 in the simple context of purified proteins (Figure 2-19 and Table 
2-5).  
The decreased binding of Cdc37 is quite complicated to correlate with client 
activation effect. Partially it is due to the complexity and dynamic nature of Cdc37-and-
Hsp90-mediated protein kinase activation cycle as depicted in Figure 1-8 from work of 
Neckers and colleagues: several phosphorylation and dephosphorylation events needs to 
happen in a sequential order to drive the cycle unidirectionally (Xu et al. 2012). The impact of 
S365 phosphorylation on Hsp90 seems to relate with Y313 phosphorylation on Hsp90: 
they both weaken Hsp90-Cdc37 interactions. Nevertheless, it depends on the timing of 
phosphorylation/dephosphorylation in the cycle to decide whether their biological relevance 
is really similar. The couple of S365 phosphorylation with one or another phosphorylation 
site involved might help to integrate the role of S365 phosphorylation (if any) into the cycle. 
The presence of a kinase client might also be necessary. As S365 phosphorylation 
significantly affects Cdc37 binding to Hsp90 in a negatively way, it is potential that this 
phosphorylation event occurs to displace Cdc37 out of Cdc37-kinase client-Hsp90 complex 
and even prepares for association of another cochaperone that acts downstream in the 
complex, however, not Aha1. Looking from another angle, dephosphorylation of S365 
phosphorylation (probably by PP5) may free a sub-population of Hsp90 (that for e.g. engaged 
by other cochaperone and clients) so that Cdc37 can bind effectively for the kinase activation 
cycle to start. 
 WT SA SE SN 
Kd (µM) 0.83  0.14 1.21  0.25 6.08  2.02 0.59  0.1 
TABLE 2-5: DISSOCIATION CONSTANTS OF HUMAN HSP90  WILD-TYPE OR PHOSPHO-VARIANT 
PROTEINS TO CDC37 IN VITRO. 
The dissociation constants (Kd) were calculated from ITC data using Origin software and are expressed as average 
 SEM from 2 independent measurements. 
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WT      SA 
 
SE       SN 
 
FIGURE 2-19: HUMAN HSP90  S365E PHOSPHOMIMETIC MUTANT EXHIBITED AN IMPARED 
AFFINITY FOR CDC37  
as compared with wild-type (WT) and non-phosphorylatable mutants S365A (SA) and S365N (SN). 
Isothermal titration calorimetry (ITC) profile of human Cdc37 binding to human Hsp90 wild-type or variant 
proteins. Titrations of 300-400µM Cdc37 into 30-35µM Hsp90 protein(s) were measured on a Microcal ITC200 
microcalorimeter at room temperature. Both proteins were dialyzed into buffer containing 25mM Hepes, 50mM 
KCl, 5mM MgCl2 and 10% glycerol. The raw data (top panels) and their integrated data (bottom panels) of heat 
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changes are shown. Integrated data were fitted using a non-linear least square fit to one site model by Origin 
software (OriginLab).  
2.2.4 CONCLUSIONS 
Inspired from the results of previous part, we set out to characterize the 
phosphorylation at serine 365 in human Hsp90. This phosphorylation site is quite 
interesting as it is located in the middle domain of Hsp90, where a number of both 
cochaperone and clients already share binding surface. Although the position of S365 in 3D 
structure limits its phosphorylation when Hsp90 is in the closed form, it is still probable that 
the site can be phosphorylated at other steps in the conformational cycle of Hsp90 or at times 
when the kinase is directly recruited to Hsp90 as client or cofactors. This is in line with our 
predicament in MS detection for this specific phosphorylation site since it is highly likely that 
S365-phosphorylated Hsp90 form is not the dominant form of Hsp90 or easy to be “caught in 
the act”. This was also further supported by the fact that at the time we first detected this 
serine phosphorylation in human Hsp90, despite the fact that several of Hsp90 
phosphorylation sites are detected in proteomics studies, the site was not reported. Only 
much later, it was confirmed to be phosphorylated in human ES and iPS as well as Jurkat cells 
(T-cell leukemia cell line) by two independent studies (Phanstiel et al. 2012)(Phosphosite 
database). Surprisingly, the sequence surrounding matches well with CK2-recognition motif 
which suggests constitutive phosphorylation due to the constitutive activity as well as 
ubiquitous distribution of the kinase. However, since one of Hsp90 cochaperone is the 
phosphatase PP5 and together with the specific position of S365, it would still be regulatable 
and can cycle between phosphorylated and dephosphorylated states. 
 
The most recent publication highlighting the client binding surface of Hsp90 and 
Tau has provided also additional evidence for us that the serine 365 is indeed very close to 
and might as well directly participate in interaction with Tau and other client proteins. It is 
conceivable that phosphorylation at this position could have significant impact on client 
binding of Hsp90. Using a reporter system in which the activity of downstream GFP placed 
under response elements that is regulated by Hsp90 clients such as glucocorticoid receptor, 
heat shock factor, Ste11 and heme-activated protein, we were able to monitor the impact of 
human Hsp90 either wild-type or phospho-mutant proteins when they are expressed as the 
single source of Hsp90 chaperone in yeast cells. As an improvement, we added to the classical 
experimental design of Hsp90 reporter-systems the use of fluorescence-activated cell sorting 
(FACS) device for readout. In this way we could further select out the non-responding 
population of yeast cells (which are dead or cell cycle-arrested) that would otherwise affect 
our averaging across total population. The utilization of GFP as output signal and FACS also 
enabled us to circumvent the cell lysis step, which is quite tedious for yeast cells and might 
result in partial lysis, as well as the enzymatic reaction step that was required for -galactose 
or luciferase activity assay. Therefore, we could process more samples for one assay while 
monitoring in addition the overall growth and viability of yeast cells during the response to 
the treatment. Our data supported the hypothesis that S365 phosphorylation could influence 
Hsp90 in client interaction in a beneficial manner. All reporter systems, except heme 
activator protein (HAP), displayed a uniform general pattern of impact in which both the 
wild-type protein and phospho-mimetic variant (S365E) chaperoned Hsp90 client better and 
resulted in faster and/or higher expression level of the downstream GFP reporters than both 
non-phosphorylatable variant (S365A and S365N). On the one hand, the wildtpye Hsp90 
protein seems to be phosphorylated at S365 in yeast cells and S365 phosphorylation seems to 
promote the chaperone activity of Hsp90 for important clients such as GR, Hsf-1 and Ste11. 
On the other hand, our findings indicate that other specific client proteins like HAP may 
utilize other binding surfaces or is chaperoned by Hsp90 in another manner that does not 
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require S365 phosphorylation. Moreover, our in vivo experiments cannot exclude the 
involvement of altered cochaperone interaction caused by the variants. The final observation 
could be the summation of both impacts or of single one, depending on the specific case. This 
was further supported by our Hsp90-cochaperone interaction studies. 
In these in-vitro experiments, we expected that the wild-type Hsp90 protein 
exhibits a similar behavior as the two non-phosphorylatable mutant proteins (S365A and 
S365N) due to the lack of post-translational modification from E.coli expression and 
purification while the phospho-mimetic variant, S365E, should display a different behavior. 
By reconstituting the minimal GR-activating system using purified proteins, we confirmed the 
enhanced activating effect that S365E, the phospho-mimetic variant, exerts on ligand binding 
activity of GRLBD while the wild-type joins the other two non-phosphorylatable mutant 
proteins in having lower activating impact. The S365E variant is also the only protein that 
displays impaired affinity for Aha1 and Cdc37. While both cochaperones contribute certain 
significant roles in activation of specific clients, the impaired affinity to both of them might 
help drive the cycle in another direction(s) or provide preferences for other cochaperones. 
More experiments such as combination of S365 phosphorylation with other modifications on 
Hsp90 and/or cochaperone(s) in the presence of specific client proteins would be necessary 
to decipher the exact role of S365 phosphorylation in the chaperone cycle.  
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3 MATERIALS AND METHOD S 
3.1  MATERIALS 
3.1.1 CHEMICALS 
All chemicals were analytical grade and obtained from Roche, Sigma, Merck and Roth if not 
otherwise stated.  
3.1.2 MICROORGANISM STRAINS AND CELL LINES 
E. coli strains 
Name Genotype / Description Source 
E. coli TOP10F´ F´ g mcrA D(mrr-hsdRMS-mcrBC) 
f80lacZDM15 DlacX74 deoR recA1 
araD139 D(ara-leu)7697 galU 
galK rpsL (StrR) endA1 nupG 
Lab collection 
E. coli CJ236 FΔ(HindIII)::cat (Tra+ Pil+ Cmr)/ 
ung-1 relA1 dut-1 thi-1 spoT1 
mcrA 
Lab collection 
E. coli Rosetta (DE3)  F- ompT hsdSB(rB- mB-) gal dcm 
(DE3) pRARE (argU, argW, ileX, 
glyT, leuW, proL) (Cmr) 
 
Lab collection 
E. coli C2925 (dam-dcm-) ara-14 leuB6 fhuA31 lacY1 tsx78 
glnV44 galK2 galT22 mrcA dcm-6 
hisG4 rfbD1 R(zgb210::Tn10) Tetr 
endA1 rspL136(Strr) dam13:Tn9 
(Camr) xylA-5 mtl-1 thi-1 mcrB1 
hsdR2 
New England Biolabs 
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S. cerevisiae strains 
Name  Genotype / Description Source  
W303 On the background of W303 strain with 
mip1[]ade2 
Robert Knieß 
W303∆PN6CH2 
RP 
On the background of W303 with hsp82::nat 
hsc82::hygromycin and pRS416-pHsp82-hsp82 
Robert Knieß 
W303-TS4x On the background of W303 integrated with 
pTEF-T.Sapphire 4x from pRS304 vector 
Robert Knieß 
W303-TS4x-GRE On the background of W303-TS4x and 
integrated with (pMetLR-His-GRE-Sf4xGFP) 2x 
Robert Knieß 
W303-TS4x-
GRErGR 
On the background of W303-TS4x-GRE and 
integrated with pLysLR-Met-(pTEF-rGR) 2x 
Robert Knieß 
 W303-TS4x-HSE On the background of W303-TS4x and 
integrated with (pMetLR-His-HSE-Sf4xGFP) 2x 
Robert Knieß 
W303-TS4x-PRE On the background of W303-TS4x and 
integrated with (pMetLR-His-PRE-Sf4xGFP) 2x 
Robert Knieß 
W303-TS4x-
HapRE 
On the background of W303-TS4x and 
integrated with (pMetLR-His-HapRE-Sf4xGFP) 2x 
Robert Knieß 
3.1.3 PLASMIDS & OLIGONUCLEOTIDES 
Plasmids 
Name  Description Source  
pCA528 (= pSUMO)  
 
pET24 based with N-terminal His6- 
Smt3-Ulp1 site(SUMO)-tag, T7 
promotor, Kan R  
Dr. C. 
Andreasson 
pSUMO-hHsp90b His6-SUMO-hHsp90β wildtype Dr. C. Graf 
pSUMO-hHsp90b-
S365A/E/N 
His6-SUMO-hHsp90β S365A/E/N This work 
pRS415-pHsp82-
hHsp90b-pHsc82-
pRS415 based with 2x constructs of human 
Hsp90 wildtype genes, each under promoter of 
This work 
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hHsp90b 
(pRS415-2x hHsp90b) 
the yeast homologs 
pRS415- 2x- hHsp90b 
S365A/E/N 
Similar as above, but the corresponding 
phospho-mutant gene instead of wildtype 
This work 
   
Oligonucleotides  
Primer name N° Sequence Notes 
hHsp90b-NheI-F 359 ATGgctagcCCTGAGGAAGTGCACCAT PCR hHsp90 gene 
hHsp90b-SalI-Rrc 360 CAGTGTCGACGATCTAATCGACTTCTTC
CATGC 
PCR hHsp90 gene 
hHsp90b-S365A 
MluI(ap) 
361 CAACTCATCACAcgcGTCCATGATGAAC S365A mutagenesis 
hHsp90b-S365A 
MluI 
368 GTTCATCATGGACgcgTGTGATGAGTTG S365A mutagenesis 
hHsp90b-S365E 
BsmI(ap) 
362 GTATCAACTCATCgCAttcGTCCATGATG
AA 
S365E mutagenesis 
hHsp90b-S365E 
BsmI 
566 TTCATCATGGACgaaTGcGATGAGTTGAT
AC 
S365E mutagenesis 
Hsp90b 
gene_741+ 
378 CCCAAGATCGAAGATGTG Sequencing  
h90b-S365N-MfeI 431 TTCATCATGGACAatTGTGATGAGTTGA
TAC 
S365N mutagenesis 
h90b-S365N-MfeI 
ap 
432 GTATCAACTCATCACAatTGTCCATGATG
AA 
S365N mutagenesis 
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3.1.4 STANDARDS AND KITS 
QIAPrep Spin Miniprep Kit Qiagen  
QIAGEN Plasmid Midi Kit Qiagen 
QIAquick Gel extraction Kit Qiagen 
QIAGEN PCR purification kit Qiagen 
GeneRulerTM 1kb DNA ladder Fermentas 
Protein ladder (SM0431) Fermentas 
3.1.5 ANTIBODIES, LABELS AND PROTEINS 
Antibody against hHsp90 ADI-SPA-840-D (Enzo®Life Sciences) 
 CIN. 10011439 (Cayman, clone 
K41220A) 
 Self-made rabbit antibodies using 
purified Hsp90 proteins from E.coli 
 Self-made isoform-specific antibody 
using 4 pairs of synthetic peptides 
Hilyte488 C2 maleimide Anaspec, Inc. 
Polynucleotide kinase (and buffers) Fermentas 
Restriction enzymes (and buffers) Fermentas or  
 New England Biolabs 
T4 DNA ligase (and buffers) Fermentas 
T7 DNA polymerase (and buffers) Fermentas 
Ulp1 Protease Lab collection 
Aha1  Dr. M.Boysen und Dr. S.Daturpalli 
Cdc37  Dr. M.Boysen 
CK2 Dr. M.Boysen 
p23  Dr. C.Graf 
Ydj1  Dr. A. Szlachcic 
3.1.6 MEDIA  
Luria – Bertani (LB) medium 10g/l tryptone 
 5g/l yeast extract 
 5g/l NaCl 
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2X YT medium 16g/l tryptone 
 10g/l yeast extract 
 5g/l NaCl 
 (For plates, 15g/l agar is added.) 
Yeast Extract - Peptone – Dextrose (YPD) medium 10g yeast extract 
 20g peptone 
 2% glucose  
 (sterile separately and added later) 
Minimal Synthetic Defined (SD) medium 6,7g/l Yeast Nitrogen Base  
 2% Glucose 
 (Each component is prepared in 10X and filtered sterile) 
Synthetic Complete (SC) Dropout medium SD +  amino acids (except for 
the dropped out: Leucine / Histidine / Uracil) 
 (Amino acid is prepared in 100X and filtered sterile) 
5-FOA (5-Fluoroorotic acid) Dropout medium SC Drop-out + FOA 1% (w/v)  
 (filtered sterile afterwards) 
For plates, appropriate amount of 3% agar (autoclaved and cooled down to 50C) is added. 
DMEM-high glucose-GlutaMAXTM  
G418 BC Sulfate Biochrom AG, Berlin, Germany 
Fetal Calf Serum (FCS) Invitrogen, Karlsruhe, Germany 
Antibiotics stocks (1000X) 
Antibiotic Concentration Solvent 
Ampicillin 100 mg/mL distilled H2O then sterile filter 
Chloramphenicol 25 mg/mL absolute ethanol 
Kanamycin 25 mg/mL distilled H2O then sterile filter 
Tetracyclin 25 mg/mL absolute ethanol 
3.1.7 SOFTWARES & EQUIPMENTS 
Softwares 
Ape (A plasmid Editor) M. Wayne Davis 
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Bruker Daltonics DataAnalysis 4.0  Bruker Daltonics 
Biotools 3.0 Bruker Daltonics 
FACS-Diva vers.6.1.3  BD-Biosciences 
ImageJ Wayne Rasband 
MicroCalTM iTC200 System (control interface) GE Healthcare 
NTAnalysis  Nanotemper 
Odyssey LI-COR Imaging LI-COR Biosciences 
Office 2007  Microsoft 
OpenLAB CDS ChemStation Edition  Agilent technologies 
Origin  OriginLab (USA) 
Photoshop CS5  Adobe 
Prism  Graphpad 
UnicornTM  Control software GE Healthcare 
Equipments 
1260 Infinity Fluorescence Detector Agilent Technologies 
Äkta HPLC Explorer GE Healthcare 
ÄktaMicroTM chromatography system GE Healthcare 
Biofuge Pico Heraeus 
Centrifuge 5424R Eppendorf 
FACS Canto-II  BD-biosystems 
FLUOstarOmega BMG Labtech 
MaXis QTOF Bruker Daltonics 
MicroCalTM iTC200 System GE Healthcare 
Microfludizer EmulsiFlex-C5 Avestin 
MST Monolith NT.115 (Nano-BLUE/GREEN) NanoTemper Technologies 
nanoUPLC Aquity Waters 
Odyssey LI-COR Imaging LI-COR Biosciences 
Resource‐Q (6 mL)  GE Healthcare  
Superdex 75 Prep Grade (16/60)  GE Healthcare  
Superdex 200 Prep Grade (26/60)  GE Healthcare  
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Superdex 200 PC3.2 30 (analytical)  GE Healthcare  
Superloop 10, 50 or 150 mL GE Healthcare 
SDS gel chamber for minigels (Mini-Protean 4) Biorad 
Thermocycler Biometra 
Thermomixer  Eppendorf 
Universal 320 Hettich 
UV workbench & Image Printer IDA raytest, Mitsubishi P91 
UV/VIS spectrophotometer NanoDrop ND-1000 Thermo Scientific 
3.2 METHODS 
3.2.1 MOLECULAR BIOLOGY TECHNIQUES 
Cloning & Site-directed mutagenesis 
PCR for site-directed mutagenesis 
Cloning of Hsp90 single phospho-site variants was performed using wild-type 
Hsp90 gene on pCA528 as template. OptiTaq polymerase was used with the buffer 
containing MgCl2 and the reaction was performed as stated below. To introduce the specific 
mutation, a primer carrying the corresponding modified codon was used to amplify the entire 
plasmid. PCR products were analyzed by a 1% agarose gel electrophoresis supplemented 
with 0.001% ethidiumbromide solution. 
Standard PCR protocol: 
Template DNA  100ng 
dNTPs (10 mM)  1 μL 
OptiTaq polymerase (2.5 U/μL) 1 μL 
Each primer (10 pmol/μL)  1 μL 
10x buffer  5 μL 
Sterile H2O  up to V final = 50µl 
Standard PCR program: 
Step 1  melting 95 °C 2 min 
Repeat step 2-4 30x 
Step 2  melting 95 °C 1 min 
Step 3  annealing 52-55 °C 45second 
Step 4  elongation 68 °C 12 min 
Step 5  pausee 4 °C (on hold) 
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Amplified DNA was purified with the Qiagen PCR purification kit. DNA was stored 
at -20 °C in TE buffer. DNA was digested, dephosphorylated and ligated using the following 
protocols. 
Restriction digestion of DNA 
Restriction enzymes (type II endonucleases) which cut dsDNA site-specifically 
were used for screening of introduced mutations and cloning. 0.2 -1u corresponding enzyme 
(NEB or Fermentas) was incubated with target DNA (1-3 µg) and the recommended buffer in 
a total reaction volume of 20-50μl for at least 30 minutes to 2 hours at optimum temperature. 
The reactions were then analyzed by agarose gel electrophoresis and in the case of cloning, 
desired fragments were extracted using the QIAGEN Gel extraction Kit. 
DNA dephosphorylation 
After digestion with restriction enzymes, the vector DNA was treated with 
alkaline phosphatase to prevent its religation. To this end, 2μl of alkaline phosphatase (1 
U/μL) were added to the reaction mixture of a cut vector DNA and the mixture was incubated 
at 37 °C for 1hr. 
Ligation of DNA fragments 
DNA fragments were ligated as desire by formation of phosphodiester bonds 
between compatible ends using T4 DNA ligase. Fragments were mixed in a reaction of no 
more than 25μl together with T4 DNA ligase (Fermentas) and the recommended ligation 
buffer. The reactions were incubated either overnight at 4°C or 1.5hrs at 30°C. The optimal 
molar ratio of vector : insert DNA was 1:3 (sticky ends) and 1:1 (blunt ends). 
Sequencing of DNA 
All DNA constructs after preparation were sequenced to confirm their correct sequence. 
Purified plasmid DNAs were diluted to concentration of 50-100ng/µl and sent to GATC 
Biotech (Konstanz, Germany) for sequencing. 
Determination of DNA concentration by UV/VIS spectroscopy 
Concentrations of DNA solutions were determined by measuring the absorption 
at 260 nm using a NanoDrop®2000 spectrophotometer. The concentration was calculated 
according to the Beer-Lambert-Law: 
A = C. 260.d, 
with A being the absorption, C the concentration,  the molar extinction coefficient at the 
wavelength 260 nm for DNA and d the thickness of the light-path (10mm in this case). 
3.2.2 MICROBIOLOGY AND CELL CULTURE METHODS 
E.coli: transformation and expression 
Transformation into E.coli chemical competent cells using CaCl2-MgCl2 
Medium A (Standard Nutrient Agar No.1 3.7% w/v, Glucose 2% (w/v)) 
CaCl2-MgCl2 (CM) solution (CaCl2 100mM; MgCl2 100mM) 
The appropriate E. coli strain was inoculated from an overnight culture in 50 mL 
medium A from OD600 < 0.1 to OD600 ~ 0.3-0.4 (mid-log phase) (roughly in about 1.5hr). 
From here on, the bacterial cells were always treated at 4°C and cold solutions. The cells were 
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incubated with CM solutions and pelleted by gentle centrifugation in 10min. This step was 
repeated for 3 times and finally, the pellets were resuspended gently in CM solution, divided 
in 100μl-aliquots, snap-frozen by liquid nitrogen and stored at -80°C for later use (Sambrook, 
J. et al., 2001).  
1-3μl of plasmid DNA or the whole ligation reaction was mixed with a 100μl-
aliquot of E. coli competent cells on ice for 5 min, then heat shocked in 2 min at 42°C followed 
by 5min on ice. 1 mL LB medium were added to the mixture and it was incubated at 37°C for 
45min for recovery and expression of antibiotics resistance genes. Then it was spread onto 
LB-agar medium with corresponding antibiotics for selection. 
Expression of recombinant proteins in E.coli 
The vector pCA528-hHsp90 wild-type or its equivalent mutants was used to 
overexpress yeast Hsp82 protein (either wild type or mutant) in the E. coli BL21DE3 Rosetta 
strain. The culture was grown in 2 - 5l 2X YT medium supplemented with Ampicillin until 
OD600 ~1.0 at 37°C, followed by 30 minutes at 25°C for adaptation and then induced by IPTG 
0.5mM for expression overnight at 25°C. Cells were harvested by centrifugation at 4500rpm 
(Sorvall F7 rotor) in 20 minutes at 4°C and resuspended in 100 mL lysis buffer before being 
lysed by a microfluidizer. 
Yeast genetics techniques 
Transformation into S. cerevisiae competent cells using Lithium acetate 
The most commonly used yeast transformation protocol using lithium acetate is 
based on the fact that alkali cations such as Li+, Na+, K+... are efficient in inducing competence 
in yeast cells (Ito, H. et al., 1983). After yeast cells are incubated in buffered lithium acetate, 
transforming DNA is introduced with carrier DNA. Addition of polyethylene glycol (PEG) and 
a heat shock at 42°C in 10 minutes trigger DNA uptake. The yeast cells are then plated on 
selective media at 30°C for 2-3 days for selection of successly transformed cells. 
All solutions for preparing competent cells and transformation were sterile. 
10X TE buffer (Tris – HCl 0.1M, EDTA 10mM pH 7.5)  
10X LiAc pH 7.5 LiAC 1 M 
Salmon sperm DNA (10mg/ mL)  
PEG 4000 50% (w/v) 
PEG/LiAC solution (freshly prepared) (PEG 40% (w/v), 1X LiAc, 1X TE) 
The appropriate yeast strain was inoculated overnight at 30°C until OD600 
reaches 0.3-0.5 (~107 cells/mL) before being harvested by centrifugation at room 
temperature in 5 minutes at 4,000g. After being resuspended in sterile water, the cells were 
centrifuged again for 5 minutes at room temperature at 5,000-6,000g. Then the yeast cells 
were washed in 0.5V 1X LiAc/TE solution (V: volume of cell culture). A centrifugation at room 
temperature in 5 minutes at 4,000 g was followed. The wash step was repeated with 0.25V 1X 
LiAc/TE solution. The pellet was resuspended in 1/500V TE and use immediately or stored at 
-80°C. 
For each transformation, 10 μg carrier DNA with less than 5 μg transforming DNA 
were mixed in a sterile 1.5-mL microcentrifuge tube together with 50μl yeast competent cells. 
0.3 mL freshly prepared PEG/LiAc solution was added and the whole mixture was incubated 
at 30°C at least for 30 minutes. The mixture was subsequently heat shocked for 15 minutes at 
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42°C and centrifuged briefly at highest speed available. The cells were resuspended in 200μL 
1X LiAc/TE solution and plate on suitable selective media at 30°C in 2-3 days. 
Plasmid shuffling method using 5-Fluorootic acid (5-FOA) 
The method was applied as in Boeke, J. D. et al., 1987; Lundblad, V. and K. Struhl, 
2002. Plasmid shuffling is a method which is particularly useful for the analysis or 
mutagenesis of genes that are essential for cell growth and viability. The manipulation of such 
essential genes is complicated by the obvious fact that cells containing mutated versions of 
such genes cannot be propagated. Plasmid shuffling circumvents this problem by generating 
a yeast strain in which the sole copy of an essential gene is present on a URA3-marked 
plasmid (i.e., the chromosomal copy of the essential gene is deleted). Note that the functional 
URA3 gene encodes for an enzyme in the uracil metabolism pathway which convert 5-FOA 
into the toxic form (5-fluorouracil). This strain is transformed by a second plasmid (which 
carries a different marker) containing a mutated version of the essential yeast gene (carried 
on a plasmid with a different marker), whereupon the URA3 plasmid carrying the wild-type 
genes is eliminated (shuffled out) by replica plating the cells on 5-FOA. This procedure 
efficiently generates yeast cells that contain only the plasmid with the mutated copy of the 
essential gene. If the mutated gene is sufficiently functional to support cell growth, the 
colonies can be examined under a variety of conditions (e.g., low or high temperature). 
Alternatively, if the mutated gene is nonfunctional, colonies will not arise on the plates 
containing 5-FOA. 
Growth curve 
The yeast strains of interest were inoculated from a single colony on plate for 1-
2days at 30°C in synthetic medium (SC\Leucine). The cells were diluted to the starting OD600 
of 0.1 and measured every 2 hours. 
Reporter assay 
The yeast strains of interested were grown to early logharithmic phase in 
synthetic medium at 25°C and kept diluted (OD<0.4) for at least 8h. For slow growing 
mutants the duration could be extended to more than 12h. Depending on the reponse 
element, different inducing agents were applied. 
Response element Inducing agent Concentration / Volume 
of usage 
HapRE 
(Heme Activator protein 
response element) 
measure directly  
HSE 
(Heat shock element) 
Heat shock at 37°C/42°C  
GRE (Glucocorticoid 
receptor response 
element) 
Desoxycorticosterone (20mM) 1µl/mL  f.c. 20µM  
PRE (Pheromone 
response element) 
Alpha-factor (1mM) 3µl/mL  f.c. 3µM 
An aliquot of induced culture was transferred to a FACS-tube for measuring, 
which was sonified shortly for 5-10 seconds and signals were recorded for around 10000-
15000 events (presumably equals to number of single cells). For each induction time CST 
(Cytometer-Standard & Tracking) standard-beads were also recorded. The filters applied in 
FACS measurements were listed as following: 
 Excitation Emission 
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T-Sapphire 405 nm 510/50 
sfGFP 488 nm 530/30 
Propidium iodid 488 nm 670LP = 670-735 
FACS Data processing: All data was acquired with FACS-Diva version 6.1.3 
software. Compensation of spectral overlap was established with strains expressing either 
one of the respective proteins or none. Gating of T-Sapphire-positive events was used as vital-
parameter. The selection of single-cell-gate was performed via a FSC-W/SSC-W plot. The 
population mean of the GFP- and the T-Sapphire-channel were taken and subtracted for 
autofluorescence. Then the normalization cell-fluorescence to uncompensated values of the 
CST-beads in the respective channel was made (3 brightest beads were chosen). The GFP-
signal can be divided either by the absolute T-Sapphire-fluorescence (when different clones 
show similar expression and recombination events can be ruled out) or the relative values 
where time-point zero is set to a fluorescence of one. Since it is extremely time-consuming to 
build a GFP/T-Sapphire ratio based on individual cells (because of the CST-normalization), all 
the processing was done on the population mean. As long as there is no prominent sub-
population, this is a reasonable approach.  
Fitting of the data was done by a one-phase association with delay, to account for 
signaling tranfer from the reporters and synthesis of GFP after induction. 
Cell volume measurements 
For the microscopy, cells from 4 different from each of the S365-mutants were 
sorted on a microscope slide and stained with Solophenylflavin. Images of the maximal cell-
diameter were taken and the outer cell shape was selected manually in ImageJ. From this 
data, diameter and volume were estimated assuming an ellipsoid cell-shape. 
Cell culture 
Cell culture for HELA and HepG2 cells were cultured in DMEM-high glucose-
GlutaMAXTM (Gibco, Life Technologies) supplemented with 10% FCS. The cells were 
harvested in PBS-EDTA buffer and exchanged into Tris-based or HEPES-based Lysis buffer 
(Tris 25mM or HEPES 20mM pH 7.4-7.6, KCl 50mM, MgCl2 5mM, NP40 0.1%, supplemented 
with Phosphatase inhibitor (PhosSTOP, Roche) and/or cOmplete Protease inhibitors cocktail 
tablet (Roche).  The cells were then lysed by passing 15-20 times over syringe with two 
needle sizes (21G 1½”and 27G ¾”, BD-MicrolaneTM-3) on ice (15-20 times divided in 3 parts 
with intervals of 3min on ice in between). The lysate was then centrifuged at 13000rpm for 
15 minutes, 4°C and supernatant was collected into a new eppendorf tube. The total protein 
concentration was determined by a Bradford assay prior to immunoprecipitation or GA 
pulldown experiments.  
3.2.3 BIOCHEMICAL TECHNIQUES AND DATA ANALYSIS 
Electrophoresis (SDS-PolyAcrylamide Gel-Electrophoresis) 
The mobility of a protein in a meshwork under an electrical field is dependent on 
its shape, its charge and its mass or molecular weight (MW). After being boiled in buffer 
containing DTT (reducing disulfide bonds) and SDS (binding to all polypeptides and creates a 
constant charge/mass ratio between proteins), the mobility of proteins in a meshwork of 
acrylamide polymer under an electric field now only depends on their MW, thus, allowing 
separating proteins with different MW on a polyacryamide gel containing SDS (Walker, J. M., 
2002). 
In this work, SDS-PAGE gels of 10% acrylamide (separating gel) were mainly 
used. For 2 mini gels, the components were prepared as following: 
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 V (µl) 
 Stacking 
gel (4%) 
Separating 
gel (10%) 
H2O  3050 3000 
0.5 M Tris-HCl pH 
6.8 (stacking gel) , 
or  
 1250 0 
1.5M Tris-HCl pH 
8.8 (separating) 
0 1875 
10% (w/v) SDS 50 75 
30% Acrylamide: 
0.8% Bis-
acrylamide (w/v) 
 670 2500 
10% (w/v) APS  25  50 
TEMED  3  5 
(APS and TEMED were added just before casting the gel.) 
Different protein samples were mix with 5x Sample Loading buffer and boiled for 
5 minutes at 95°C, then briefly centrifuged (13,000rpm, 5 minutes) before being loaded to the 
rinsed wells of the gel. The whole system would start at 120V in Tris-glycine buffer until the 
samples enter separating gel, the voltage was then increased to 180V. The running was 
stopped when the bromophenol blue marker reached the end of the gel. For visualization of 
the protein bands, the gel was stained with Coomassie staining solution for at least 45 
minutes and subsequently destained in Destaining solution until the background was 
transparent enough and the bands were clearly visible. 
Coomassie staining solution (0.2% (w/v) Coomassive Brilliant R250, 5% (v/v) 
acetic acid, 50% (v/v) methanol) and filtered before use). 
Destaining solution (50% (v/v) methanol, 5% (v/v) acetic acid) 
Western blotting 
Proteins were first separated by SDS-PAGE and subsequently electrophoretically 
transferred on a PDVF membrane in a Semi-Dry blotting apparatus (Biorad) at a constant 
current of 75 mA per mini SDS-PAGE gel for 30 minutes. After the transfer, membranes were 
incubated in a PBST buffer supplemented with 5% milk powder with agitation at 4 °C 
overnight to block free binding sites. The primary antibody was diluted in PBS-T buffer 
supplemented with 5% non-fat milk powder (dilution depended on the individual antibody) 
and incubated for overnight at 4°C or 2 hrs at room temperature. The membrane was washed 
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5-7x for 5 min with PBS-T buffer and incubated for 45 minutes with a secondary antibody 
coupled with fluorescent dye (LI-COR antibodies, normally dilution 1:20000) followed by 3-5 
washing steps with PBS-T buffer, 5 min each. Detection was performed with Odysee LI-COR 
Imager. 
Protein purification 
His6x-SUMO tagged protein purification 
Proteins of interest (including human Hsp90 wild-type, S365A/E/N, 
humanHsp90, human Hsp70, HOP) were overexpressed from the corresponding vector as 
fusion proteins with His6-SUMO tag. The tag helps increase solubility of recombinant 
proteins and can be cleaved off by the specific protease (Ulp1) without remaining any amino 
acids (Malakhov, M. P. et al., 2004). 
Buffer HKM  (25 mM HEPES/KOH pH7.4, 100 mM KCl, 5mM 
MgCl2, 10% glycerol, 3 mM β-mercaptoethanol) 
Lysis buffer  (Buffer HKM with 1 mM PMSF, 10 μg/mL 
Aprotinin, 5 μg/mL Leupeptin, 10 μg/mL Pepstatin A) 
Washing Buffer  (Buffer HKM) 
Elution Buffer  (Buffer HKM + 250 mM imidazole) 
Buffer A  (Buffer HKM with 100 mM KCl) 
Buffer B  (Buffer HKM with 1M KCl) 
Storage buffer  (Buffer HKM with 50 mM KCl) 
The cell lysate was clarified by ultracentrifugation (40,000 rpm for 30 min at 4°C) 
and incubated with 3-5g Ni-IDA matrix (Protino) in 30min before being transferred to a 
disposable gravity column and washed with 5-10 Column volume (CV) Washing buffer. Bound 
proteins were eluted by 3-5 CV Elution buffer.  
The Elution fractions were pooled and dialysed overnight with Ulp1 to cleave 
His6x-SUMO tag and eliquibrated into low salt buffer before being loaded to a 6mL-
ResourceQ using an Äkta Explorer system. The proteins of interest were eluted by a gradient 
of 10CV from 0 to 100% buffer B. The eluted fractions were collected and analyzed on SDS-
PAGE before being pooled and concentrated to lower volume. Next, the proteins were 
subjected to Superdex 200 16/60 Prep grade column on the Äkta system to be further 
polished in storage buffer. The fractions containing purified proteins were concentrated and 
flash-frozen in liquid nitrogen to be stored at -80°C for further use. 
MBP-tagged protein purification 
For GRLBD, the LBD(F602S) fragment (521-777) was cloned into a pMAL-c2E 
backbone vector containing an extra recognition site for PreScission protease between MBP 
and gene fragment. MBP-GRLBD(F602S) was expressed in BL21 star (DE3) Typically, cells 
were grown at 37°C until OD reaches approximately 0.7-0.8 (~ 3hrs), and then the 
temperature was lowered to 18°C. Cells were kept growing at 18°C for 30 min (OD ~ 1.0-1.2) 
then dexamethasone (Dex) was added to a final concentration of 250 µM and cells were 
induced overnight with 0.5 mM IPTG. Next morning, harvested cells were lysed by 
microfluidizer (EmulsiFlex-C5, Avestin) in MBP-lysis/Amylose column Buffer. The lysate was 
clarified by centrifugation and the soluble fraction was bound to pre-equilibrated Amylose 
resin (NEB) at 4°C under gravity flow. The column was washed with 8-10CV Amylose Wash 
Buffer before elution (4-5CV). The eluted fraction was subjected to size-exclusion 
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chromatography (Superdex S75). The fractions containing the protein of interest were 
pooled, divided into 2 parts and dialysed overnight into Storage Buffer with or without Dex. 
Purification was finished by extensive dialysis into ligand free storage buffer twice, 2hrs each 
on the next morning. Proteins with ligand-bound were flash-frozen in liquid nitrogen and 
stored at -80°C. GRLBD protein without ligand cannot be stored frozen but has to be used 
within the next 3 days. 
Protein concentration determination by Bradford assay 
The Bradford assay is a colorimetric protein assay used to determine the protein 
concentration. The assay is based on the observation that the absorbance maximum of the 
dye Coomassie Brilliant Blue G-250 shifts from 465 nm (red form) to 595 nm (blue form) 
upon binding of a chromophore to particularly basic and aromatic amino acids in proteins 
(Bradford, 1976). To this end, the commercially available solution (Dye reagent concentrate, 
Biorad, Cat N° 500-0006) was first diluted 1:5 with water. 999 μL of the solution was mixed 
with 1µL of protein solution, incubated shortly at room temperature and the absorption at 
595 nm was measured. The standard curve was calculated on a BSA standard (measured for 
1-10µg/µl BSA solution). 
Limited proteolysis 
Purifed Hsp90 proteins (wildtype: WT, S365A: SA, S365E: SE and S365N: SN) 
were digested individually (6µg) by Trypsin (E:S = 1:100) at 37°C. At different time points (0, 
1, 5, 10, 15, 20min), 1/6 of the reaction volume was taken for SDS-PAGE. The reactions were 
stopped by adding Sample buffer 5x and boiled at 95°C for 3 minutes). 
Size-exclusive chromatography (SEC) 
The sample of interested were injected onto a Superdex 200 PC 3.2/20 analytical 
column using the ÄktaMicro system (GE Healthcare Life Sciences) at the flow of 0.1 µL/min. 
The buffer used in SEC experiments is storage buffer from protein purification (HKM with 
50mM KCl) without -mercaptoethanol and glycerol. The fractions were collected in the 
volume of 72µl manually or the outlet was directly connected to the 1260 Infinity 
Fluorescence Detector (Agilent Technologies). UV280 signal was monitored in Unicorn 
software (GE Healthcare Life Sciences) and fluorescent signal was recorded in the OpenLAB 
CDS ChemStation Edition software for LC and LC MS/MS systems (Agilent technologies). 
Protein labeling 
Proteins were dialyzed overnight at 4°C in Storage buffer from purification but 
without -mercaptoethanol to remove -mercaptoethanol. The cysteins in the proteins were 
then reduced by addition of 1 mM TCEP and incubated for 2hours at room temperature but 
on ice. The proteins were then labeled by 20-fold molar excess of Hilyte 488 C2 maleimide 
(dissolve in DMSO/DMF) while keeping the volume of DMSO less than 1% (by diluting the 
proteins by buffer to increase the volume if necessary). The labeling reactions were done at 
room temperature for 2 hours before the reaction mixture(s) were loaded on a self-packed 
Superdex G50 size exclusion column (pre-eliquibrated in HKM buffer) to separate free dye 
and labeled proteins. 10-12 fractions of approx. 100 µl were collected and checked for 
protein concentration by Bradford assay as well as fluorescence signal by spectro-
fluorimeter. The fractions with highest concentration of protein and high fluorescence signal 
were kept on ice in the 4°C room and used for further experiments in the next days (maximal 
1 week). The final concentration of labelled protein was determined by Bradford assay. 
Microscale Thermophoresis measurement  
All proteins were centrifuged using a table-top centrifugation at max speed for 
15min at 4°C before the experiment. A titration series of freshly purified GRLBD was 
prepared in MST buffer (Tris 20mM pH 8.3, 100mM KCl, 5mM MgCl2) supplemented with 
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freshly prepared ATP and DTT (final concentration of 2mM and 3mM, respetively), incubated 
at room temperature for 1hr alone or with components in the minimal GR-activating system. 
Then fluorescein-dexamethasone (F-dex) was added to the final concentration of 25 nM 
(stock solutions were dissolved in DMSO) and the whole mixture was incubated further at 
room temperature for 25-30 min before being measured by MST at laser power 20% or 40%. 
The MST instrument was Monolith NT.115 (NanoTemper Technologies).  Binding curves 
were obtained from the thermophoresis plus temperature-jump phase, with IR laser power of 
20 (which corresponds to a temperature gradient of 2°C from 25°C). Each experiment was 
repeated at least two times and the active fraction of GR was calculated using the quadratic 
equation with the constraint of a fixed Kd 150nM, ligand (L) 25 nM (Prism). To avoid day-to-
day differences orignated from the labile GRLBD itself, a MST measurement of GRLBD alone 
was always performed and the data was normalized using this measurement. I stopped using 
the current purified batch of GRLBD when the active fraction calculated from this control 
sample was under 20%. The minimal GR-activating system consists of 2µM Hsp40 (Ydj1), 
10µM Hsp70, 10µM Hsp90, 10µM HOP and 10µM p23. The fraction of active GR was 
calculated using Prism and the fitting used the modified quadratic equation as following: 
             
       
 
      
          
 
        
 
 
in which: 
y: thermophoretic motibility measured by fluorescence signal of F-dex unbound and 
bound by a given concentration of GR (x) at the IR-laser focus point (normalized to starting 
fluorescence) 
Fo: minimum value of y  to be determined by fitting 
Fm: maximum value of y  to be determined by fitting  
f: % active x (value must be between 0& 1)  to be determined by fitting 
x: concentration of GR (provided according to Bradford assay and dilution factor) 
L: F-dex concentration (=25 nM) 
K: dissociation constant (Kd = 150 nM) 
A Student’s t-test was performed for the MST measurements in the presence of 
the whole minimal GR-activating system to identify the significance of difference between the 
system containing Hsp90 wild-type and each of other variant proteins (one-tailed 
distribution, unequal variance or heteroscedastic). Each system sample included 2-4 repeats. 
A similar Student’s t-test was also performed for the system containing Hsp90 S365E 
variant protein and each of the other proteins. The significance values of each pair of samples 
are reported in Appendix Table S2. 
Isothermal Titration Calorimetry (ITC) 
Affinity of Hsp90(s) and Cdc37 was determined by ITC using a MicroCal ITC200 
microcalorimeter. All Hsp90 proteins were rapidly thawed and extensively dialysed at 4°C 
against 20 mM HEPES (pH7.4), 50 mM KCl, 5 mM MgCl2 and 10% glycerol. The final protein 
concentration in the cell is 30-45 µM. Cdc37 was loaded in the syringe at 300-500 μM in the 
same buffer as Hsp90(s). Run parameters were as follows: total number of injections: 
16×2.49 μl, injection duration of  4.98 s, injection spacing of 120-180 s, filter period of 5 s, cell 
temperature of 25°C, reference power of 11 μcal/s, initial delay of 60 s and stirring speed of 
2000 rev./min. Titration raw data were fitted to a one site model using Origin software 
(OriginLab). Final graphs show heats from each injection against the ratio of Cdc37 as ligand 
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and binding partner (Hsp90 protein) in the cell (top panel) and the binding 
isotherm/integrated heats (bottom panel). Dissociation constant were calculated as reverse 
of association constant calculated by the software. SEM was calculated for 2-3 repeats. 
In vitro phosphorylation with CK2 
1µg purified Hsp90 protein in 50 μl final reaction volume was incubated in 20 
mM Tris/HCl pH 7.8, 100 mM KCl, 5 mM MgCl2 in the presence of 0.2µg CK2 (purified protein 
from Dr. M. Boysen) and 1 mM ATP for 2 h at 37 °C. The samples were subjected to in-
solution digestion and subsequently analysed by LC MS/MS using UPLC system and the MaXis 
mass spectrometer as described in MS method part. Similar Mascot database searches were 
performed, in which Hsp90 and Hsp90 could be detected with sequence coverage 77% and 
83%, respectively. Phosphorylated peptides for the serines in the charge linker (S231/S263 
of Hsp90 or S226/S255 of Hsp90) were detected (with a few missed cleavages, too); but 
no other phosphorylated peptide(s) were identified. 
GA pulldown experiment (adapted protocol from M. Breinig) 
Usually 200 µg (could be upto 500 µg) of total cell lysate is used in GA pulldown 
experiments, generally in the volume of 200-500 µL. When using different samples in one GA 
pulldown experiment, the lysate samples were usually concentrated so that the starting 
volume is at least similar. 100 µL of the streptavidin magnetic beads (M-280, Invitrogen) was 
washed three times by 500 µL Lysis buffer before it was resuspended into 50µL Lysis buffer. 
20 µL of 1M Biotinylated-GA (InVivogen) (resuspended in DMSO) were added to the beads 
and incubated for 2hrs at 4°C with constant rotation. The GA-coupled beads were then 
washed three times by 500 µL Lysis buffer before they were incubated with lysates 
supplemented with Protease Inhibitors and PhosSTOP (Roche) overnight at 4°C with 
constant rotation. A magnetic field was applied to separate the beads with supernatant to 
collect the flowthrough fraction. The beads were washed three times, two times by 100 µL 
and one by 200 µL Lysis buffer supplemented with only PhosSTOP before finally resuspended 
in 50µL as Bound fraction. The Bound fraction was further subjected to in-solution digestion 
or loaded on SDS-PAGE for in-gel digestion. 
Immunoprecipitation experiment 
Indirect IP was applied after unsuccessful trials with direct IP (couple antibody to 
beads before incubating with lysate): the antibody was successfully coupled to beads but 
subsequent capture of Hsp90 from lysate by this complex is low. 
Hsp90 was isolated from lysate of 200 μg total protein by IP for overnight at 4 °C 
on a rotating wheel using 7 µg SPA840 -specific antibody. Then 50 μL of Dynabeads® 
protein A (LifeTechnologies) washed and resuspended in Binding buffer 
(Immunoprecipitation Kit, LifeTechnologies) was added and incubated for 4 hrs at 4°C. In 
these incubation times, Lysis or Binding buffer was used with supplement of Proteases 
Inhibitors and PhosSTOP. The Dynabeads® protein A in fact is protein A coupled to magnetic 
beads, which allows separation of beads and supernatant under magnetic field. The mixture 
was washed three times with 500 μL Wash buffer and eluted with 30-50µL of Elution buffer 
from Immunoprecipitation Kit Protein A (Life Technologies). (I made an attempt to make the 
Elution buffer according to their protocol: 50mM glycine pH 2.8, but it did not work as well as 
commercial buffer so from then on, I always used commercial buffers for IP). 
MS sample preparation  
Standard In-solution digestion 
The lysate or fraction of interest was lyophilized or Speed-Vac to dry up before 
resuspended in (usually) 50µL of 50mM Ammonium Bicarbonate pH 8.5 and 8M urea. DTT 
was added to the final concentration of 50mM and the sample was incubated in the dark for 
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20 min at room temperature. Fresh iodoacetamide (prepared and used within 1 week, better 
if only in 1 day) was supplemented to a final concentration of 10mM and incubated in the 
dark for 20 min at room temperature. The samples were diluted to less than 4M urea and 
incubated with 0.1 µg Lys-C protease overnight at 28°C. The digestion reaction was then 
diluted further to less than 2M Urea so that Trypsin could be applied. In some cases, if the 
volume is not limited by subsequent analysis, the urea concentration was diluted to less than 
1M. Normally Trypsin was supplied 2-3 times, 0.1-0.5 µg each with intervals 2-4 hrs before 
the samples were considered ready for MS analysis. Whenever the protein content could be 
measured (in case of total lysate digestion for MRM-MS), an enzyme amount of 
Enzyme:Substrate = 1:100 was used for each addition of enzyme. Similar protocol was 
applied for digestion by Asp-N or GluC except Lys-C digestion step. Trypsin, Lys-C, Asp-N and 
Glu-C were purchased from Promega or Roche. 
Filter-assisted sample preparation (FASP) 
A modified In-solution digestion (FASP) protocol was also tried for MRM-MS 
samples. In short, proteins are denatured in SDS, reduced & alkylated where after the 
proteins (now unfolded) are captured on a molecular weight cut-off filter (typically 30 kDa). 
On the filter, detergent is washed away using 6M Urea and followed by an on-filter digestion. 
 The generated peptides are small enough to pass through the filter and can be collected for 
analysis. For details, see (Wiśniewski et al. 2011). 
Mass Spectrometry analysis  
MS analysis by the MaXis mass spectrometer 
The digestion mixtures were injected into the UPLC system and analysed with the 
MaXis Q-TOF. In the UPLC system the sample is pushed onto a reversed phase trap column 
containing Poros 10 R1 or R2 at a flow rate of 400 µl/min and subsequently washed with 
0.1% formic acid for three minutes. Subsequently, the sample is eluted in a 120-min gradient 
from 90 % solvent A/10 % solvent B to 15% solvent A/85 % solvent B over an analytical 
reversed-phase column (Waters BEH C18) to separate the tryptic peptides before injected 
into the mass spectrometer. Hsp90 peptide spectra were acquired with a standard source 
(microflow), set to 4.5 kV capillary voltage, 0.8 bar nebuliser gas, 4 l/min dry gas at 190 °C 
and an end plate offset of -500 V. The spray was generated by the standard ESI-Sprayer 
supplied with the mass spectrometer. The MS/MS setting of the HyStar software was turned 
on during the experiment. Fragment spectra were recorded for the top five or ten MS signals. 
The resulting fragment spectra were processed with the Biotools 3.0 program (Bruker) and 
sent to the MASCOT search engine (Matrix Science) to identify proteins and peptides. Peptide 
lists were generated containing sequence, mass to charge ratio, charge and retention time of 
Hsp90 peptides. The search parameters used in Mascot search were: SwissProt database; 
taxonomy of Homo sapiens; enzyme Trypsin (or in a few cases, GluC(V8-E) or AspN) with 
maximum 4 missed cleavages; Fixed modifications include only oxidation for methionine;  
Variable modifications include Carbamidomethyl for cysteines, deamidation from asparagine 
to glutamine, phosphorylation for STY (serine, threonine and tyrosine); peptide tolerance 
1000ppm; peptide charge 1+, 2+ and 3+; MS/MS tolerance 0.05 Da and intrument ESI-QUAD-
TOF. Phosphorylation site assignments were further verified by manual inspection of MS/MS 
spectra.  
MS analysis by the Orbitrap mass spectrometer 
The MS experiments were performed in collaboration with Dr. Thomas Rupert 
(MS facility, ZMBH). Elution or bound fractions from IP or GA-pulldown experiments were 
loaded onto SDS-PAGE minigels and run for short distance (approx. 1cm) before stained by 
colloidal Coomassie and destained by water. The gel fragment of interest or whole lane was 
cut out and in-gel digestion by Trypsin was performed using the Digest Pro mass 
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spectrometry (MS) liquid-handling system (Intavis AG). Following digestion, tryptic peptides 
were extracted from the gel pieces with 50% acetonitrile-0.1% trifluoroacetic acid, 
concentrated, and analyzed by MS. Samples were analyzed by RP-HPLC (HPLC system 
HP1100; Hewlett-Packard,) equipped with a μRPC C2/C18 SC 2.1/10 column (Pharmacia): 
eluent A, 0.05% trifluoroacetic acid; eluent B, 70% acetonitrile, 0.045% trifluoroacetic acid; 
gradient 90min; flow rate, 50 μl/min. Analysis was performed on line with an ion trap mass 
spectrometer LTQ-Orbitrap (ThermoQuest) equipped with an electrospray ion source. Each 
scan was acquired over the range m/z = 300-1300 in 3 s. The peptides were identified by 
their molecular masses calculated from the m/z peaks of the single or multiple charged ions 
and were confirmed by mass-spectrometric sequencing analyses. MS data were searched 
similarly as in MS analysis by the MaXis mass spectrometer with only exception that the 
Carbamidomethylation was included as fixed modification and instrument ESI-TRAP. 
MRM-MS analysis 
MRM-MS analyses were performed in collaboration with S.Link or L. Behrens (MS 
facility, ZMBH, Heidelberg) using the Qtrap 5500 MS (ABSciex) coupled with nanoUPLC 
Aquity (Waters). This triple quadrupole mass spectrometer with full MS3 capabilities offers 
high quality, confidence and sensitivity for targeted quantification studies. The crude lysates 
samples either from in-solution/FASP digestion via Ziptip or in-gel digestion were applied 
onto the LC MS system.  
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4 ABBREVIATIONS 
5-FOA 5-fluoroorotic acid 
Ǻ Ǻngström 
ADP Adenosine diphosphate 
Aha1 Activator of Hsp90 ATPase 
AmpR Ampicilline resistance 
APS Ammonium persulfate 
ATP Adenosine triphosphate 
bp  Base pair 
BSA Bovine serum albumin 
Cdc37 Cell division cycle 37 
Cdk Cyclin-dependent kinase 
CHIP Carboxy terminus of Hsc70-interacting protein  
CmR Chloramphenicol resistance 
Cyp40 Cyclophillin 40 
Da Dalton (atomic mass unit) 
DMSO  Dimethylsulfoxid 
DNA  Deoxyribose nucleic acid 
dNTP Deoxynucleoside triphosphate 
DTT Dithiothreitol 
dTTP 2’-deoxythymidine 5’-triphosphate 
dUTP  2’-deoxyuridine 5’-triphosphate 
EDTA Ethylene diamine tetraacetic acid 
ES Embryonic stem cell 
ESI Electrospray ionization 
FCS Fetal calf serum 
FKBP52 FK506 (Fujimycin) binding protein 52 
GA Geldanamycin 
GHKL Gyrase B/Hsp90/Histidine Kinase/MutL ATPase superfamily 
GR Glucocorticoid receptor 
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GRLBD Glucocorticoid receptor ligand binding domain 
HEPES  4-(2-hydroxyethyl)piperazine-1-ethanesulfonic acid 
HOP Hsp70/Hsp90 organizing protein 
HPLC High performance liquid chromatography 
Hsc Heat shock cognate protein 
Hsp Heat shock protein 
HtpG High temperature protein in E. coli 
IMAC Immobilized metal affinity chromatography 
IP Immunoprecipitation 
iPS Induced pluripotent stem cell 
IPTG Isopropyl -D thiogalactoside 
ITC    Isothermal titration calorimetry 
LC Liquid chromatography 
LiAc Lithium acetate 
MCS Multi cloning site 
MRM Multiple reaction monitoring 
MS Mass Spectroscopy 
MS/MS  tandem mass spectrometry 
MST Microscale thermophoresis 
MW Molecular weight 
m/z mass-to-charge ratio 
OD Optical density 
QQQ triple quadrupole 
PAGE Polyacrylamide gel electrophoresis 
PDB Protein databank 
PEG Polyethylene glycol 
PMSF Phenylmethanesulfonyl fluoride 
PR Progesterone receptor 
RNase RNA-hydrolyzing enzyme 
SDS Sodium dodecyl sulfate 
SEM Standard error of the mean 
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SILAC Stable isotope labeling with amino acid in cell culture 
SHR Steroid hormone receptor 
SUMO Small ubiquitin-like modifier 
TAE Tris acetate ethylenediaminetetraacetate 
TEMED  N, N, N’, N’- tetramethylethylene diamine  
TFA Ttrifluoroacetic acid 
TPR Tetratricopeptide repeat 
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5 APPENDICES 
FIGURE S1: MRM-MS3 IN COMBINATION WITH LIBRARY INDENTIFICATION CONFIRMS S365 PHOSPHORYLATION OF HUMAN HSP90  IN HELA LYSATE.  
HELA lysate (total protein amount of 2mg) was digested by Trypsin using In-solution digestion protocol. 1/10 sample was subjected to MRM-MS3 and analyszed further by 
library identification. Library data were generated from synthetic phosphorylated peptides and digestion from purified proteins. 
(A) Library identification of y8++ fragment (transition 799.7/526.4). The MS3 fragmentation pattern of selected transition (y8++)  fits well to theoretical fragmentation pattern of the 
same transition from synthetic peptides with Fit value of 83.249. 
(B) Similar to (A) except for y6+ fragment (transition 799.7/825.6) and Fit value of 36.713. 
(A) 
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(B) 
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FIGURE S2: ACTIVATION RATE CONSTANT OF GLUCOCORTICOID RESPONSE IN YEAST STRAINS CONTAINING EITHER HUMAN HSP90  AS THE SOLE SOURCE OF 
HSP90 PROTEIN IN THE CELLS.  
GR response measured from GFP signals normalized for TEF signals were fitted to one-phase association with delay model. The data was expressed as mean  SEM from four independent 
clones. Experiments were performed in collaboration with R. Knieß. 
 
 
 
TABLE S1: LIST OF TRANSITIONS USED IN MRM-MS ANALYSIS (A) Tryptic digestion 
Heat shock protein 90 
MPEETQTQDQ PMEEEEVETF AFQAEIAQLM SLIINTFYSN KEIFLRELIS NSSDALDKIR YESLTDPSKL DSGKELHINL IPNKQDRTLT IVDTGIGMTK 
ADLINNLGTI AKSGTKAFME ALQAGADISM IGQFGVGFYS AYLVAEKVTV ITKHNDDEQY AWESSAGGSF TVRTDTGEPM GRGTKVILHL KEDQTEYLEE 
RRIKEIVKKH SQFIGYPITL FVEKERDKEV SDDEAEEKED KEEEKEKEEK ESEDKPEIED VGSDEEEEKK DGDKKKKKKI KEKYIDQEEL NKTKPIWTRN  
PDDITNEEYG EFYKSLTNDW EDHLAVKHFS VEGQLEFRAL LFVPRRAPFD LFENRKKKNN IKLYVRRVFI MDNCEELIPE YLNFIRGVVD SEDLPLNISR 
EMLQQSKILK VIRKNLVKKC LELFTELAED KENYKKFYEQ FSKNIKLGIH EDSQNRKKLS ELLRYYTSAS GDEMVSLKDY CTRMKENQKH IYYITGETKD 
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QVANSAFVER LRKHGLEVIY MIEPIDEYCV QQLKEFEGKT LVSVTKEGLE LPEDEEEKKK QEEKKTKFEN LCKIMKDILE KKVEKVVVSN RLVTSPCCIV 
TSTYGWTANM ERIMKAQALR DNSTMGYMAA KKHLEINPDH SIIETLRQKA EADKNDKSVK DLVILLYETA LLSSGFSLED PQTHANRIYR MIKLGLGIDE 
DDPTADDTSA AVTEEMPPLE GDDDTSRMEE VD 
Heat shock protein 90 
MPEEVHHGEE EVETFAFQAE IAQLMSLIIN TFYSNKEIFL RELISNASDA LDKIRYESLT DPSKLDSGKE LKIDIIPNPQ ERTLTLVDTG IGMTKADLIN 
NLGTIAKSGT KAFMEALQAG ADISMIGQFG VGFYSAYLVA EKVVVITKHN DDEQYAWESS AGGSFTVRAD HGEPIGRGTK VILHLKEDQT EYLEERRVKE 
VVKKHSQFIG YPITLYLEKE REKEISDDEA EEEKGEKEEE DKDDEEKPKI EDVGSDEEDD SGKDKKKKTK KIKEKYIDQE ELNKTKPIWT RNPDDITQEE 
YGEFYKSLTN DWEDHLAVKH FSVEGQLEFR ALLFIPRRAP FDLFENKKKK NNIKLYVRRV FIMDSCDELI PEYLNFIRGV VDSEDLPLNI SREMLQQSKI 
LKVIRKNIVK KCLELFSELA EDKENYKKFY EAFSKNLKLG IHEDSTNRRR LSELLRYHTS QSGDEMTSLS EYVSRMKETQ KSIYYITGES KEQVANSAFV 
ERVRKRGFEV VYMTEPIDEY CVQQLKEFDG KSLVSVTKEG LELPEDEEEK KKMEESKAKF ENLCKLMKEI LDKKVEKVTI SNRLVSSPCC IVTSTYGWTA 
NMERIMKAQA LRDNSTMGYM MAKKHLEINP DHPIVETLRQ KAEADKNDKA VKDLVVLLFE TALLSSGFSL EDPQTHSNRI YRMIKLGLGI DEDEVAAEEP  
NAAVPDEIPP LEGDEDASRM EEVD  
 
 
Transitions for tryptic peptides 
     
Include 
Precursor Mass 
(Da) 
Fragment Mass 
(Da) RT CE Fragment Type Sequence 
Mean 
Height % CV 
True 513.9227 831.46 18.7258 34 3+ / y8 YESLTDPSKLDSGK 21803 2.9448 
True 513.9227 688.85 18.7258 26 3+ / y13(2+) YESLTDPSKLDSGK 7103 3.4245 
True 513.9227 624.33 18.7258 26 3+ / y12(2+) YESLTDPSKLDSGK 30435 0.4365 
True 329.7285 559.38 15.3699 20 2+ / y5 VVVITK 6308475.5 1.8521 
True 329.7285 460.31 15.3699 18 2+ / y4 VVVITK 9713680 0.2168 
True 329.7285 361.24 15.3699 24 2+ / y3 VVVITK 3659741 2.7824 
True 345.2006 590.33 13.1884 20 2+ / y5 VTISNR 35933.5 6.7831 
True 345.2006 489.28 13.1884 18 2+ / y4 VTISNR 57043 12.0638 
True 345.2006 376.19 13.1884 24 2+ / y3 VTISNR 22418.5 5.5670 
True 374.2341 646.41 16.1158 21 2+ / y6 TLVSVTK 2055290 1.9277 
True 374.2341 533.33 16.1158 19 2+ / y5 TLVSVTK 9886684 0.2578 
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True 374.2341 434.26 16.1158 23 2+ / y4 TLVSVTK 4580995.5 1.7455 
True 858.4787 966.04 42.9190 43 3+ / y19(2+) TLTLVDTGIGMTKADLINNLGTIAK 176416 3.5978 
True 858.4787 943.56 42.9190 43 3+ / y9 TLTLVDTGIGMTKADLINNLGTIAK 85577 5.8253 
True 858.4787 915.51 42.9190 43 3+ / y18(2+) TLTLVDTGIGMTKADLINNLGTIAK 120837.5 0.2777 
True 715.3540 921.470994 32.1874 36.476 2+ / y9 TLT[Pho]LVDTGIGMTK 5268044 10.1317 
True 715.3540 822.40258 32.1874 34 2+ / y8 TLT[Pho]LVDTGIGMTK 4091614.75 11.7059 
True 715.3540 707.375637 32.1874 40 2+ / y7 TLT[Pho]LVDTGIGMTK 1590541.75 23.9234 
True 715.3540 615.879427 32.1874 38 
2+ / 
y12(2+)+Pho TLT[Pho]LVDTGIGMTK 715214.75 35.8565 
True 715.3540 606.327959 32.1874 38 2+ / y6 TLT[Pho]LVDTGIGMTK 1497661.25 11.6306 
True 715.3540 549.306495 32.1874 40 2+ / y5 TLT[Pho]LVDTGIGMTK 434329.5 17.0759 
True 683.3683 937.47 27.6036 35 2+ / y9 TLTLVDTGIGM[Oxi]TK 150881.5 5.4059 
True 683.3683 838.4 27.6036 31 2+ / y8 TLTLVDTGIGM[Oxi]TK 198867 4.7773 
True 683.3683 723.37 27.6036 37 2+ / y7 TLTLVDTGIGM[Oxi]TK 62356.5 0.9222 
True 675.3708 921.47 31.4907 35 2+ / y9 TLTLVDTGIGMTK 4504346 2.2590 
True 675.3708 822.4 31.4907 31 2+ / y8 TLTLVDTGIGMTK 4632110 3.2615 
True 675.3708 707.38 31.4907 39 2+ / y7 TLTLVDTGIGMTK 1586096.5 1.9081 
True 417.1995 746.4 12.4732 25 3+ / y7 TDTGEPMGRGTK 2344 3.7407 
True 417.1995 517.26 12.4732 21 3+ / y10(2+) TDTGEPMGRGTK 2581 1.4246 
True 417.1995 466.73 12.4732 21 3+ / y9(2+) TDTGEPMGRGTK 1195.5 41.1074 
True 367.2263 533.33 16.5515 19 2+ / y5 SLVSVTK 10223154 100.0000 
True 367.2263 434.26 16.5515 21 2+ / y4 SLVSVTK 5143038 1.0056 
True 367.2263 387.22 16.5515 25 2+ / b4 SLVSVTK 605407.5 1.9285 
True 583.6451 828.46 28.5267 29 3+ / b7 QDRTLTIVDTGIGMTK 587600.5 8.4563 
True 583.6451 822.4 28.5267 29 3+ / y8 QDRTLTIVDTGIGMTK 745569 5.1680 
True 583.6451 715.37 28.5267 31 3+ / b6 QDRTLTIVDTGIGMTK 688280 5.9958 
True 964.3852 997.164077 23.2475 49 2+ / f997 NPDDITQEEY[Pho]GEFYK 165210.25 27.9054 
True 964.3852 886.338262 23.2475 49 2+ / y6 NPDDITQEEY[Pho]GEFYK 737665.5 12.6858 
True 643.2592 997.138547 23.2475 32 3+ / f997 NPDDITQEEY[Pho]GEFYK 329447.5 10.2253 
True 643.2592 886.338262 23.2475 32 3+ / y6 NPDDITQEEY[Pho]GEFYK 1686874 12.3542 
True 643.2592 457.244547 23.2475 36.163 3+ / y3 NPDDITQEEY[Pho]GEFYK 1355100.25 8.3708 
True 616.6038 935.41 26.8226 31 3+ / y7 NPDDITQEEYGEFYK 33910.5 0.7899 
True 616.6038 806.37 26.8226 31 3+ / y6 NPDDITQEEYGEFYK 104451.5 3.5305 
True 616.6038 643.31 26.8226 31 3+ / y5 NPDDITQEEYGEFYK 121936.5 3.2282 
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True 957.3774 900.356 22.8620 45 2+ / y14(2+) NPDDITNEEY[Pho]GEFYK 2304214.25 5.0651 
True 957.3774 886.338262 22.8620 51 2+ / y6 NPDDITNEEY[Pho]GEFYK 933715.25 15.4447 
True 957.3774 851.8296 22.8620 43 2+ / y13(2+) NPDDITNEEY[Pho]GEFYK 189351.25 34.1573 
True 957.3774 794.3161 22.8620 45 2+ / y12(2+) NPDDITNEEY[Pho]GEFYK 56589.25 7.3709 
True 917.8863 935.41 26.3149 47 2+ / y7 NPDDITN[Dea]EEYGEFYK 36016 1.2682 
True 611.9319 935.41 26.3208 31 3+ / y7 NPDDITNEEYGEFYK 18936.5 4.9328 
True 611.9319 806.37 26.3208 31 3+ / y6 NPDDITNEEYGEFYK 80786 0.4985 
True 611.9319 643.31 26.3208 31 3+ / y5 NPDDITNEEYGEFYK 89493 1.2846 
True 654.8433 978.49 17.6672 38 2+ / b8 IRYESLTDPSK 1288370.5 5.2720 
True 436.8979 649.33 17.6672 24 3+ / b5 IRYESLTDPSK 595054 0.5003 
True 436.8979 547.27 17.6672 24 3+ / y5 IRYESLTDPSK 718747.5 1.6229 
True 594.9880 827.5 25.5201 34 3+ / y7 HLEINPDHPIVETLR 6223604.5 3.7299 
True 594.9880 819.4 25.5201 34 3+ / b7 HLEINPDHPIVETLR 2619105 4.6253 
True 594.9880 617.36 25.5201 36 3+ / y5 HLEINPDHPIVETLR 2924624.5 4.9990 
True 446.2159 744.36 21.3400 23 2+ / y6 FYEAFSK 2680896 2.4080 
True 446.2159 581.29 21.3400 23 2+ / y5 FYEAFSK 5531887 1.8987 
True 446.2159 452.25 21.3400 27 2+ / y4 FYEAFSK 1358879 1.6506 
True 432.2181 734.39 13.5527 22 2+ / y6 EMLQQSK 4618.5 11.8655 
True 432.2181 603.35 13.5527 24 2+ / y5 EMLQQSK 72227 7.1056 
True 432.2181 490.26 13.5527 20 2+ / y4 EMLQQSK 57715 4.0725 
True 646.3224 936.43 19.4537 31 2+ / y9 ELISNSSDALDK 4311637.5 0.6905 
True 646.3224 849.39 19.4537 31 2+ / y8 ELISNSSDALDK 1547126.5 3.4373 
True 646.3224 735.35 19.4537 31 2+ / y7 ELISNSSDALDK 1553285 4.1623 
True 638.3249 920.43 22.2790 31 2+ / y9 ELISNASDALDK 5285075 4.6984 
True 638.3249 833.4 22.2790 31 2+ / y8 ELISNASDALDK 1999516.5 3.7138 
True 638.3249 719.36 22.2790 31 2+ / y7 ELISNASDALDK 1996254.5 0.4264 
True 650.6774 936.43 38.9703 33 3+ / y9 EIFLRELISNSSDALDK 738577 1.2140 
True 650.6774 901.51 38.9703 37 3+ / b7 EIFLRELISNSSDALDK 402117 3.2572 
True 650.6774 854.45 38.9703 35 3+ / y15(2+) EIFLRELISNSSDALDK 853093 0.4943 
True 618.3043 992.52 18.2559 30 2+ / y9 DQVANSAFVER 2233215 1.5644 
True 618.3043 893.45 18.2559 30 2+ / y8 DQVANSAFVER 3739184 0.9177 
True 618.3043 822.41 18.2559 34 2+ / y7 DQVANSAFVER 2210815 1.8834 
True 624.7564 932.4 22.5315 30 2+ / y8 DNSTMGYMMAK 392562.5 0.4174 
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True 624.7564 831.36 22.5315 30 2+ / y7 DNSTMGYMMAK 759131 0.1904 
True 624.7564 700.32 22.5315 30 2+ / y6 DNSTMGYMMAK 970791.5 1.9975 
True 439.5372 768.41 15.4235 26 3+ / y7 DNSTMGYMAAKK 189052 0.3325 
True 439.5372 544.27 15.4235 22 3+ / y10(2+) DNSTMGYMAAKK 93771.5 4.4137 
True 439.5372 450.23 15.4235 22 3+ / y8(2+) DNSTMGYMAAKK 165596 3.6186 
True 317.8262 510.19 12.6694 16 3+ / b5 ADHGEPIGR 5598 8.1599 
True 317.8262 442.28 12.6694 16 3+ / y4 ADHGEPIGR 2748 27.6358 
True 317.8262 345.22 12.6694 22 3+ / y3 ADHGEPIGR 6022.5 0.2949 
 
 (B)GluC digestion 
Heat shock protein 90  
MPEETQTQDQ PMEEEEVETF AFQAEIAQLM SLIINTFYSN KEIFLRELIS NSSDALDKIR YESLTDPSKL DSGKELHINL IPNKQDRTLT IVDTGIGMTK 
ADLINNLGTI AKSGTKAFME ALQAGADISM IGQFGVGFYS AYLVAEKVTV ITKHNDDEQY AWESSAGGSF TVRTDTGEPM GRGTKVILHL KEDQTEYLEE 
RRIKEIVKKH SQFIGYPITL FVEKERDKEV SDDEAEEKED KEEEKEKEEK ESEDKPEIED VGSDEEEEKK DGDKKKKKKI KEKYIDQEEL NKTKPIWTRN  
PDDITNEEYG EFYKSLTNDW EDHLAVKHFS VEGQLEFRAL LFVPRRAPFD LFENRKKKNN IKLYVRRVFI MDNCEELIPE YLNFIRGVVD SEDLPLNISR 
EMLQQSKILK VIRKNLVKKC LELFTELAED KENYKKFYEQFSKNIKLGIHE/DSQNRKKLSE/LLRYYTSASGDE/MVSLKDYCTRMKENQKH IYYITGETKD 
QVANSAFVER LRKHGLEVIY MIEPIDEYCV QQLKEFEGKT LVSVTKEGLE LPEDEEEKKK QEEKKTKFEN LCKIMKDILE KKVEKVVVSN RLVTSPCCIV 
TSTYGWTANM ERIMKAQALR DNSTMGYMAA KKHLEINPDH SIIETLRQKA EADKNDKSVK DLVILLYETA LLSSGFSLED PQTHANRIYR MIKLGLGIDE 
DDPTADDTSA AVTEEMPPLE GDDDTSRMEE VD  
Heat shock protein 90 
MPEEVHHGEE EVETFAFQAE/IAQLMSLIIN TFYSNKEIFL RELISNASDA LDKIRYE/SLT DPSKLDSGKE/LKIDIIPNPQ ERTLTLVDTG IGMTKADLIN 
NLGTIAKSGT KAFMEALQAG ADISMIGQFG VGFYSAYLVA EKVVVITKHN DDEQYAWESS AGGSFTVRAD HGEPIGRGTK VILHLKEDQT EYLEERRVKE 
VVKKHSQFIG YPITLYLEKE REKEISDDEA EEEKGEKEEE DKDDEEKPKI EDVGSDEEDD SGKDKKKKTK KIKEKYIDQE ELNKTKPIWT RNPDDITQEE 
YGEFYKSLTN DWEDHLAVKH FSVEGQLEFR ALLFIPRRAP FDLFENKKKK NNIKLYVRRV FIMDSCDELI PEYLNFIRGVVDSE/DLPLNI SREMLQQSKI 
LKVIRKNIVK KCLELFSELA EDKENYKKFY EAFSKNLKLG IHEDSTNRRR LSELLRYHTS QSGDEMTSLS EYVSRMKETQ KSIYYITGE/SKEQVANSAFV 
ERVRKRGFEV VYMTEPIDEY CVQQLKEFDG KSLVSVTKEG LELPEDEEEK KKMEESKAKF ENLCKLMKEI LDKKVEKVTI SNRLVSSPCC IVTSTYGWTA 
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NMERIMKAQA LRDNSTMGYM MAKKHLEINP DHPIVETLRQ KAEADKNDKA VKDLVVLLFE TALLSSGFSL EDPQTHSNRI YRMIKLGLGI DEDEVAAEEP  
NAAVPDEIPP LEGDEDASRM EEVD  
 
 Transitions for GluC Peptides 
     
Include 
Precursor Mass 
(Da) 
Fragment Mass 
(Da) RT CE Fragment Type Sequence 
Mean 
Height % CV 
True 817.0955 963.54 43.899 36 3+ / b8 YLNFIRGVVDSEDLPLNISRE 27479.25 115.9396 
True 817.0955 941.54 43.899 36 3+ / y8 YLNFIRGVVDSEDLPLNISRE 30141.25 115.6112 
True 817.0955 828.46 43.899 36 3+ / y7 YLNFIRGVVDSEDLPLNISRE 371090.75 115.8763 
True 706.3644 963.54 37.767 30 2+ / b8 YLNFIRGVVDSE 215487 99.6151 
True 706.3644 874.46 37.767 36 2+ / y8 YLNFIRGVVDSE 159430.75 102.3599 
True 706.3644 761.38 37.767 33 2+ / y7 YLNFIRGVVDSE 154505.5 103.6115 
True 611.3071 846.44 39.419 23 2+ / b7 VIYMIEPIDE 288676.5 79.8791 
True 611.3071 749.39 39.419 23 2+ / b6 VIYMIEPIDE 983494.5 46.9956 
True 611.3071 620.35 39.419 23 2+ / b5 VIYMIEPIDE 1001428.5 34.8969 
True 521.2479 823.4 32.283 19 2+ / b7 VETFAFQAE 70445 18.7745 
True 521.2479 695.34 32.283 19 2+ / b6 VETFAFQAE 127813.5 10.8793 
True 521.2479 548.27 32.283 22 2+ / b5 VETFAFQAE 258742.75 61.7897 
True 549.6138 884.45 21.319 25 3+ / b7 TQKSIYYITGESKE 111846.75 74.7358 
True 549.6138 721.39 21.319 28 3+ / b6 TQKSIYYITGESKE 107368.75 88.0663 
True 549.6138 650.3 21.319 25 3+ / y6 TQKSIYYITGESKE 440144.75 85.7008 
True 651.8324 997.54 25.928 28 2+ / b8 TQKSIYYITGE 1014512 48.5091 
True 651.8324 884.45 25.928 31 2+ / b7 TQKSIYYITGE 821513.5 77.5079 
True 651.8324 721.39 25.928 28 2+ / b6 TQKSIYYITGE 503816 66.4555 
True 423.2455 631.35 19.156 15 2+ / y5 TLRQKAE 2069.25 79.1982 
True 423.2455 627.39 19.156 15 2+ / b5 TLRQKAE 11595.5 85.1565 
True 654.8251 915.45 20.935 25 2+ / b9 TKDQVANSAFVE 434696 93.0728 
True 654.8251 844.42 20.935 25 2+ / b8 TKDQVANSAFVE 72645.6667 73.0753 
True 654.8251 757.38 20.935 25 2+ / b7 TKDQVANSAFVE 133695.833 39.6642 
True 407.1924 666.32 29.229 17 2+ / b6 TFAFQAE 812022.75 54.9420 
True 407.1924 595.29 29.229 17 2+ / b5 TFAFQAE 1255641.75 15.0244 
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True 407.1924 467.23 29.229 23 2+ / b4 TFAFQAE 1211806.5 48.4376 
True 459.5682 588.79 17.660 18 3+ / y11(2+) SLTDPSKLDSGKE 5283779 30.2108 
True 459.5682 538.27 17.660 18 3+ / y10(2+) SLTDPSKLDSGKE 1502967.5 14.4638 
True 459.5682 480.75 17.660 18 3+ / y9(2+) SLTDPSKLDSGKE 4647355 63.2741 
True 654.8251 915.45 20.941 25 2+ / b9 SKEQVANSAFVE 522450.667 69.1306 
True 654.8251 844.42 20.941 25 2+ / b8 SKEQVANSAFVE 84779.1667 58.5654 
True 654.8251 757.38 20.941 25 2+ / b7 SKEQVANSAFVE 142761 35.3815 
True 482.7403 718.35 23.172 17 2+ / b7 QVANSAFVE 257171 19.6262 
True 482.7403 571.28 23.172 17 2+ / b6 QVANSAFVE 169617.667 87.4326 
True 482.7403 500.25 23.172 17 2+ / b5 QVANSAFVE 36362.75 90.5380 
True 471.9331 696.4 20.171 19 3+ / y6 QFSKNIKLGIHE 178042.5 116.9632 
True 471.9331 569.83 20.171 19 3+ / y10(2+) QFSKNIKLGIHE 327221.75 116.3572 
True 471.9331 568.31 20.171 19 3+ / y5 QFSKNIKLGIHE 618638 116.6141 
True 554.2666 765.38 22.422 23 3+ / y12(2+) MVSLKDYC[CAM]TRMKE 302720.25 115.1212 
True 554.2666 715.84 22.422 23 3+ / y11(2+) MVSLKDYC[CAM]TRMKE 908051.25 114.3221 
True 554.2666 615.78 22.422 23 3+ / y9(2+) MVSLKDYC[CAM]TRMKE 455643.75 116.0373 
True 687.8304 968.52 21.433 26 2+ / b8 LLRYYTSASGDE 1482509 97.8541 
True 687.8304 897.48 21.433 26 2+ / b7 LLRYYTSASGDE 561357.75 100.5018 
True 687.8304 810.45 21.433 26 2+ / b6 LLRYYTSASGDE 715873.25 97.4900 
True 469.2283 683.4 15.421 30 3+ / b5 LLRYHTSQSGDE 771822 43.4210 
True 469.2283 629.81 15.421 21 3+ / b11(2+) LLRYHTSQSGDE 3876018.75 31.4634 
True 469.2283 500.27 15.421 24 3+ / b8(2+) LLRYHTSQSGDE 880328.25 37.8155 
True 575.3001 805.9 26.829 24 3+ / y14(2+) LISNSSDALDKIRYE 808574.25 65.7922 
True 575.3001 749.36 26.829 24 3+ / y13(2+) LISNSSDALDKIRYE 5899390 23.1308 
True 575.3001 705.85 26.829 24 3+ / y12(2+) LISNSSDALDKIRYE 839311.25 77.6107 
True 569.9685 797.91 29.367 23 3+ / y14(2+) LISNASDALDKIRYE 662215.5 69.9015 
True 569.9685 741.37 29.367 23 3+ / y13(2+) LISNASDALDKIRYE 5050484 36.0333 
True 569.9685 640.83 29.367 23 3+ / y11(2+) LISNASDALDKIRYE 845495.75 97.4065 
True 462.7190 777.38 15.186 16 2+ / b6 KYIDQEE 834969.75 93.6643 
True 462.7190 648.34 15.186 16 2+ / b5 KYIDQEE 725980.5 105.8815 
True 462.7190 520.28 15.186 16 2+ / b4 KYIDQEE 942143.25 99.4379 
True 519.2667 890.47 21.565 19 2+ / b8 INPDHSIIE 1228520.5 40.5843 
True 519.2667 810.4 21.565 19 2+ / y7 INPDHSIIE 4687219 68.5244 
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True 519.2667 777.39 21.565 19 2+ / b7 INPDHSIIE 2665757.25 79.3017 
True 517.2692 806.4 20.471 19 2+ / y7 INPDHPIVE 6750996 25.0723 
True 517.2692 787.41 20.471 19 2+ / b7 INPDHPIVE 692420.25 35.6244 
True 517.2692 594.32 20.471 19 2+ / y5 INPDHPIVE 623809.25 95.8938 
True 715.6627 916.9007 51.900 18 3+ / y14(2+) IAQLMSLIINT[Pho]FY[Pho]SNKE 14310.5 116.2016 
True 715.6627 720.260012 51.900 44 3+ / y5 IAQLMSLIINT[Pho]FY[Pho]SNKE 4950 106.4803 
True 689.0073 984.4421 52.011 40 3+ / y8+Pho IAQLMSLIINT[Pho]FYSNKE 4115.5 86.9558 
True 689.0073 870.511737 52.011 36 3+ / y7+Pho IAQLMSLIINT[Pho]FYSNKE 13940.5 75.3087 
True 689.0073 867.328426 52.004 26 3+ / y6 IAQLMSLIINTFY[Pho]SNKE 2049.5 71.7975 
True 689.0073 787.362096 52.011 40 3+ / y6 IAQLMSLIINT[Pho]FYSNKE 9252.5 69.5834 
True 689.0073 769.3515 52.004 29 3+ / y6+Pho IAQLMSLIINTFY[Pho]SNKE 467.5 68.5175 
True 689.0073 640.293682 52.011 46 3+ / y5 IAQLMSLIINT[Pho]FYSNKE 9729.5 74.6461 
True 689.0073 477.230353 52.011 38 3+ / y4 IAQLMSLIINT[Pho]FYSNKE 24433.25 91.6941 
True 662.6799 870.51 42.096 28 3+ / b8 IAQLMSLIIN[Dea]TFYSNKE 794.5 34.0871 
True 662.6799 787.36 42.096 28 3+ / y6 IAQLMSLIIN[Dea]TFYSNKE 706 15.6245 
True 662.3518 640.293682 42.099 28 3+ / y5 IAQLMSLIINTFYSNKE 2294.5 27.3351 
True 662.3518 477.230353 42.099 28 3+ / y4 IAQLMSLIINTFYSNKE 3530 50.2386 
True 354.5448 563.3 16.018 13 3+ / y5 GKTLVSVTKE 1882578.33 87.1138 
True 354.5448 400.26 16.018 13 3+ / b4 GKTLVSVTKE 1367965.25 116.1309 
True 354.5448 377.2 16.018 13 3+ / y3 GKTLVSVTKE 1663156 115.8978 
True 651.8036 992.47 29.152 31 2+ / y8 FYKSLTNDWE 94216.25 83.7327 
True 651.8036 969.47 29.152 31 2+ / b8 FYKSLTNDWE 295229.25 84.8041 
True 651.8036 740.4 29.152 28 2+ / b6 FYKSLTNDWE 46955 78.2324 
True 437.2380 648.34 23.339 17 3+ / b6 FDGKSLVSVTKE 1212988.5 76.4954 
True 437.2380 581.83 23.339 17 3+ / b11(2+) FDGKSLVSVTKE 1336366.25 61.0311 
True 437.2380 563.3 23.339 17 3+ / y5 FDGKSLVSVTKE 3224568 72.6292 
True 528.7878 828.46 28.490 25 2+ / y7 DLPLNISRE 2902130.75 71.9018 
True 528.7878 731.4 28.490 34 2+ / y6 DLPLNISRE 1720832.75 66.3069 
True 528.7878 618.32 28.490 34 2+ / y5 DLPLNISRE 3346665.75 56.1028 
True 452.9259 643.37 22.374 24 3+ / y11(2+) AFSKNLKLGIHE 276559.75 102.9635 
True 452.9259 569.83 22.374 24 3+ / y10(2+) AFSKNLKLGIHE 1047146.75 99.5015 
True 452.9259 568.31 22.374 24 3+ / y5 AFSKNLKLGIHE 551597 107.5382 
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TABLE S2: SIGNIFICANCE VALUES CALCULATED FROM STUDENT’S T-TEST FOR MST MEASUREMENTS USING THE MINI MAL GR-ACTIVATING SYSTEM 
CONTAINING DIFFERENT HSP90 PROTEINS 
0.01 < p-value <= 0.05: strong presumption against the null-hypothesis (“no difference between two groups in comparison); 0.05 < p-value: low or no presumption against the null 
hypothesis. 
 p-value 
t-test vs 
Hsp90 S365E 
t-test vs Hsp90 
WT 
Hsp90 0.0394 0.3064 
Hsp90 
WT 0.0357 
 
SA 0.0274 0.1425 
SE 
 
0.0357 
SN 0.0207 0.0511 
 
 110 
 
6 REFERENCES 
Abbas-Terki, T. et al., 2002. The Hsp90 co-chaperones Cdc37 and Sti1 interact physically and 
genetically. Biological chemistry, 383(9), pp.1335–42. 
Abbas-Terki, T., Donzé, O. & Picard, D., 2000. The molecular chaperone Cdc37 is required for 
Ste11 function and pheromone-induced cell cycle arrest. FEBS letters, 467(1), pp.111–6. 
Adinolfi, E. et al., 2003. Tyrosine phosphorylation of HSP90 within the P2X7 receptor complex 
negatively regulates P2X7 receptors. The Journal of biological chemistry, 278(39), 
pp.37344–37351. 
Ali, M.M.U. et al., 2006. Crystal structure of an Hsp90-nucleotide-p23/Sba1 closed chaperone 
complex. Nature, 440(7087), pp.1013–7. 
Bain, D.L. et al., 2007. Nuclear receptor structure: implications for function. Annual review of 
physiology, 69, pp.201–20. 
Bali, P. et al., 2005. Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone 
function of heat shock protein 90: a novel basis for antileukemia activity of histone 
deacetylase inhibitors. The Journal of biological chemistry, 280(29), pp.26729–34. 
Barabutis, N. et al., 2013. LPS induces pp60c-src-mediated tyrosine phosphorylation of Hsp90 
in lung vascular endothelial cells and mouse lung. American journal of physiology. Lung 
cellular and molecular physiology, 304(12), pp.L883–93. 
Barati, M.T. et al., 2006. A Proteomic Screen Identified Stress-induced Chaperone as Targets 
of Akt Phosphorylation in mesangial cells. J Proteome Res, 5(7), pp.1636–1646. 
Barent, R.L. et al., 1998. Analysis of FKBP51/FKBP52 chimeras and mutants for Hsp90 
binding and association with progesterone receptor complexes. Molecular 
endocrinology, 12(3), pp.342–54. 
Basso, A.D. et al., 2002. Akt forms an intracellular complex with heat shock protein 90 
(Hsp90) and Cdc37 and is destabilized by inhibitors of Hsp90 function. The Journal of 
biological chemistry, 277(42), pp.39858–66. 
Bennetzen, M. V et al., 2010. Site-specific phosphorylation dynamics of the nuclear proteome 
during the DNA damage response. Molecular & cellular proteomics : MCP, 9(6), pp.1314–
23. 
Biamonte, M. a et al., 2006. Orally active purine-based inhibitors of the heat shock protein 90. 
Journal of medicinal chemistry, 49(2), pp.817–28. 
Bledsoe, R.K. et al., 2002. Crystal structure of the glucocorticoid receptor ligand binding 
domain reveals a novel mode of receptor dimerization and coactivator recognition. Cell, 
110(1), pp.93–105. 
Bohen, S.P., 1995. Hsp90 mutants disrupt glucocorticoid receptor ligand binding and 
destabilize aporeceptor complexes. The Journal of biological chemistry, 270(49), 
pp.29433–8. 
 111 
 
Booher, R.N., Deshaies, R.J. & Kirschner, M.W., 1993. Properties of Saccharomyces cerevisiae 
wee1 and its differential regulation of p34CDC28 in response to G1 and G2 cyclins. The 
EMBO journal, 12(9), pp.3417–26. 
Bose, S. et al., 1996. Chaperone Function of Hsp9O-Associated Proteins. Science, 
274(December), pp.1715–1717. 
Breinig, M. et al., 2009. Targeting heat shock protein 90 with non-quinone inhibitors: a novel 
chemotherapeutic approach in human hepatocellular carcinoma. Hepatology (Baltimore, 
Md.), 50(1), pp.102–12. 
Bresnick, E.H. et al., 1989. Evidence that the 90-kDa heat shock protein is necessary for the 
steroid binding conformation of the L cell glucocorticoid receptor. The Journal of 
biological chemistry, 264(9), pp.4992–7. 
Brinker, A. et al., 2002. Ligand Discrimination by TPR Domains : Relevance and selectivity of 
EEVD-Recognition in Hsp70.HOP.Hsp90 complexes. JBC, 277, pp.19265–19275. 
Chadli, A. et al., 2000. Dimerization and N-terminal domain proximity underlie the function of 
the molecular chaperone heat shock protein 90. Proceedings of the National Academy of 
Sciences of the United States of America, 97(23), pp.12524–9. 
Chang, H.C., Nathan, D.F. & Lindquist, S., 1997. In vivo analysis of the Hsp90 cochaperone Sti1 
(p60). Molecular and cellular biology, 17(1), pp.318–25. 
Chen, S. & Smith, D.F., 1998. Hop as an Adaptor in the Heat Shock Protein 70 (Hsp70) and 
Hsp90 Chaperone Machinery. Journal of Biological Chemistry, 273(52), pp.35194–35200. 
Chiosis, G. & Neckers, L., 2006. Tumor selectivity of Hsp90 inhibitors: the explanation remains 
elusive. ACS chemical biology, 1(5), pp.279–84. 
Cunningham, C.N., Krukenberg, K. a & Agard, D. a, 2008. Intra- and intermonomer interactions 
are required to synergistically facilitate ATP hydrolysis in Hsp90. The Journal of 
biological chemistry, 283(30), pp.21170–8. 
Czar, M.J. et al., 1997. Geldanamycin, a heat shock protein 90-binding benzoquinone 
ansamycin, inhibits steroid-dependent translocation of the glucocorticoid receptor from 
the cytoplasm to the nucleus. Biochemistry, 36(25), pp.7776–85. 
Davenport, E.L. et al., 2007. Heat shock protein inhibition is associated with activation of the 
unfolded protein response pathway in myeloma plasma cells. Blood, 110(7), pp.2641–9. 
Davies, T.H., Ning, Y.-M. & Sánchez, E.R., 2002. A new first step in activation of steroid 
receptors: hormone-induced switching of FKBP51 and FKBP52 immunophilins. The 
Journal of biological chemistry, 277(7), pp.4597–600. 
Degiorgis, J.A. et al., 2005. Phosphoproteomic Analysis of Synaptosomes from Human 
Cerebral Cortex research articles. Journal of proteome research, 4, pp.306–315. 
Dephoure, N. et al., 2008. A quantitative atlas of mitotic phosphorylation. Proceedings of the 
National Academy of Sciences of the United States of America, 105(31), pp.10762–7. 
 112 
 
Dezwaan, D.C. & Freeman, B.C., 2008. HSP90 The Rosetta stone for cellular protein dynamics? 
Cell Cycle, 7(8), pp.1006–1012. 
Dittmar, K.D. et al., 1997. Folding of the Glucocorticoid Receptor by the Heat Shock Protein 
(hsp) 90-based Chaperone Machinery : The role of p23 is to stabilize receptor · hsp90 
heterocomplexes formby hsp90 · p60 · hsp70. JBC, 272, pp.21213–220. 
Dittmar, K.D. et al., 1996. Reconstitution of the Steroid Receptor hsp90 Heterocomplex 
Assembly System of Rabbit Reticulocyte Lysate. Journal of Biological Chemistry, 271(22), 
pp.12833–12839. 
Dittmar, K.D. & Pratt, W.B., 1997. Folding of the Glucocorticoid Receptor by the Reconstituted 
hsp90-based Chaperone Machinery: The initial hsp90-p60-hsp70-dependent step is 
sufficient for creating the steroid binding conformation. JBC, 272(20), pp.13047–13054. 
Dote, H. et al., 2006. Inhibition of hsp90 compromises the DNA damage response to radiation. 
Cancer research, 66(18), pp.9211–9220. 
Dougherty, J. et al., 1987. Identification of the 90Kda substrate of rat liver type II casein 
kinase with the heat shock protein which binds steroid receptors. BBA, 927, pp.74–80. 
Duval, M. et al., 2007. Src-mediated phosphorylation of Hsp90 in response to vascular 
endothelial growth factor (VEGF) is required for VEGF receptor-2 signaling to 
endothelial NO synthase. Molecular biology of the cell, 18(11), pp.4659–4668. 
Echeverría, P.C. et al., 2009. Nuclear import of the glucocorticoid receptor-hsp90 complex 
through the nuclear pore complex is mediated by its interaction with Nup62 and 
importin beta. Molecular and cellular biology, 29(17), pp.4788–97. 
Ecroyd, H., Jones, R.C. & Aitken, R.J., 2003. Tyrosine phosphorylation of HSP-90 during 
mammalian sperm capacitation. Biology of reproduction, 69(6), pp.1801–1807. 
Eiseman, J.L. et al., 2005. Pharmacokinetics and pharmacodynamics of 17-demethoxy 17-[[(2-
dimethylamino)ethyl]amino]geldanamycin (17DMAG, NSC 707545) in C.B-17 SCID mice 
bearing MDA-MB-231 human breast cancer xenografts. Cancer chemotherapy and 
pharmacology, 55(1), pp.21–32. 
Esser, C., Scheffner, M. & Höhfeld, J., 2005. The chaperone-associated ubiquitin ligase CHIP is 
able to target p53 for proteasomal degradation. The Journal of biological chemistry, 
280(29), pp.27443–8. 
Felts, S.J. & Toft, D.O., 2003. P23, a Simple Protein With Complex Activities. Cell stress & 
chaperones, 8(2), pp.108–13. 
Finka, A. & Goloubinoff, P., 2013. Proteomic data from human cell cultures refine mechanisms 
of chaperone-mediated protein homeostasis. Cell stress & chaperones, 18(5), pp.591–
605. 
Flom, G. et al., 2007. Definition of the minimal fragments of Sti1 required for dimerization, 
interaction with Hsp70 and Hsp90 and in vivo functions. The Biochemical journal, 
404(1), pp.159–67. 
 113 
 
Fontana, J., 2002. Domain Mapping Studies Reveal That the M Domain of hsp90 Serves as a 
Molecular Scaffold to Regulate Akt-Dependent Phosphorylation of Endothelial Nitric 
Oxide Synthase and NO Release. Circulation Research, 90(8), pp.866–873. 
Forafonov, F. et al., 2008. p23/Sba1p protects against Hsp90 inhibitors independently of its 
intrinsic chaperone activity. Molecular and cellular biology, 28(10), pp.3446–56. 
Franco, M.C. et al., 2013. Nitration of Hsp90 induces cell death. Proceedings of the National 
Academy of Sciences of the United States of America, 110(12), pp.E1102–11. 
Freeman, B.C. et al., 2000. The p23 molecular chaperones act at a late step in intracellular 
receptor action to differentially affect ligand efficacies. Genes & Development, 14, 
pp.422–434. 
Freeman, B.C., Toft, D.O. & Morimoto, R.I., 1996. Molecular chaperone machines: chaperone 
activities of the cyclophilin Cyp-40 and the steroid aporeceptor-associated protein p23. 
Science (New York, N.Y.), 274(5293), pp.1718–20. 
Frydman, J., 2001. Folding of newly translated proteins in vivo: the role of molecular 
chaperones. Annual review of biochemistry, 70, pp.603–47. 
Gaiser, A.M., Kretzschmar, A. & Richter, K., 2010a. Cdc37-Hsp90 complexes are responsive to 
nucleotide-induced conformational changes and binding of further cofactors. The 
Journal of biological chemistry, 285(52), pp.40921–32. 
Gaiser, A.M., Kretzschmar, A. & Richter, K., 2010b. Cdc37-Hsp90 complexes are responsive to 
nucleotide-induced conformational changes and binding of further cofactors. The 
Journal of biological chemistry, 285(52), pp.40921–32. 
Galigniana, M.D. et al., 2002. Binding of hsp90-associated immunophilins to cytoplasmic 
dynein: direct binding and in vivo evidence that the peptidylprolyl isomerase domain is 
a dynein interaction domain. Biochemistry, 41(46), pp.13602–10. 
Galigniana, M.D. et al., 2001. Evidence that the peptidylprolyl isomerase domain of the hsp90-
binding immunophilin FKBP52 is involved in both dynein interaction and glucocorticoid 
receptor movement to the nucleus. The Journal of biological chemistry, 276(18), 
pp.14884–9. 
Galigniana, M.D., 1998. Heat Shock Protein 90-Dependent (Geldanamycin-Inhibited) 
Movement of the Glucocorticoid Receptor through the Cytoplasm to the Nucleus 
Requires Intact Cytoskeleton. Molecular Endocrinology, 12(12), pp.1903–1913. 
Galigniana, M.D. et al., 2004. Retrograde transport of the glucocorticoid receptor in neurites 
requires dynamic assembly of complexes with the protein chaperone hsp90 and is 
linked to the CHIP component of the machinery for proteasomal degradation. Brain 
research. Molecular brain research, 123(1-2), pp.27–36. 
Galigniana, M.D., Erlejman, A.G. & Piwien-pilipuk, G., 2010. Role of molecular chaperones and 
TPR-domain proteins in the cytoplasmic transport of steroid receptors and their 
passage through the nuclear pore. Nucleus, 1(August), pp.299–308. 
Gao, Y. et al., 2013. Distinct roles of molecular chaperones HSP90α and HSP90β in the 
biogenesis of KCNQ4 channels. PloS one, 8(2), p.e57282. 
 114 
 
García-Cardeña, G. et al., 1998. Dynamic activation of endothelial nitric oxide synthase by 
Hsp90. Nature, 392(6678), pp.821–4. 
Gerber, M.R. et al., 1995. Cdc37 is required for the association of Cdc28 with G1 and mitotic 
cyclins. PNAS, 92(May), pp.4651–4655. 
Gnad, F. et al., 2010. Evolutionary constraints of phosphorylation in eukaryotes, prokaryotes, 
and mitochondria. Molecular & cellular proteomics : MCP, 9(12), pp.2642–53. 
Gooljarsingh, L.T. et al., 2006. A biochemical rationale for the anticancer effects of Hsp90 
inhibitors: slow, tight binding inhibition by geldanamycin and its analogues. Proceedings 
of the National Academy of Sciences of the United States of America, 103(20), pp.7625–30. 
Graf, C. et al., 2009. Spatially and kinetically resolved changes in the conformational dynamics 
of the Hsp90 chaperone machine. The EMBO journal, 28(5), pp.602–13. 
Grammatikakis, N. et al., 1999. p50(cdc37) acting in concert with Hsp90 is required for Raf-1 
function. Molecular and cellular biology, 19(3), pp.1661–72. 
Grbovic, O.M. et al., 2006. V600E B-Raf requires the Hsp90 chaperone for stability and is 
degraded in response to Hsp90 inhibitors. Proceedings of the National Academy of 
Sciences of the United States of America, 103(1), pp.57–62. 
Hainzl, O. et al., 2009. The charged linker region is an important regulator of Hsp90 function. 
The Journal of biological chemistry, 284(34), pp.22559–67. 
Han, G. et al., 2008. Large-scale phosphoproteome analysis of human liver tissue by 
enrichment and fractionation of phosphopeptides with strong anion exchange 
chromatography. Proteomics, 8(7), pp.1346–61. 
Harrell, J.M. et al., 2004. Evidence for glucocorticoid receptor transport on microtubules by 
dynein. The Journal of biological chemistry, 279(52), pp.54647–54. 
Harst, A., Lin, H. & Obermann, W.M.J., 2005. Aha1 competes with Hop, p50 and p23 for 
binding to the molecular chaperone Hsp90 and contributes to kinase and hormone 
receptor activation. The Biochemical journal, 387(Pt 3), pp.789–96. 
Hartmann, F. et al., 1997. Effects of the tyrosine-kinase inhibitor geldanamycin on ligand-
induced Her-2/neu activation, receptor expression and proliferation of Her-2-positive 
malignant cell lines. International journal of cancer., 70(2), pp.221–9. 
Harvey, S.L. & Kellogg, D.R., 2003. Conservation of mechanisms controlling entry into mitosis: 
budding yeast wee1 delays entry into mitosis and is required for cell size control. 
Current biology : CB, 13(4), pp.264–75. 
Hawle, P. et al., 2006a. The middle domain of Hsp90 acts as a discriminator between different 
types of client proteins. Molecular and cellular biology, 26(22), pp.8385–95. 
Hawle, P. et al., 2006b. The middle domain of Hsp90 acts as a discriminator between different 
types of client proteins. Molecular and cellular biology, 26(22), pp.8385–95. 
He, H. et al., 2006. Identification of potent water soluble purine-scaffold inhibitors of the heat 
shock protein 90. Journal of medicinal chemistry, 49(1), pp.381–90. 
 115 
 
Hernández, M.P., Sullivan, W.P. & Toft, D.O., 2002. The assembly and intermolecular 
properties of the hsp70-Hop-hsp90 molecular chaperone complex. The Journal of 
biological chemistry, 277(41), pp.38294–304. 
Herskowitz, J.H. et al., 2011. Phosphoproteomic analysis reveals site-specific changes in GFAP 
and NDRG2 phosphorylation in fronttemporal lobar degeneration. Journal of Proteome 
Research, 9(12), pp.6368–6379. 
Hessling, M., Richter, K. & Buchner, J., 2009. Dissection of the ATP-induced conformational 
cycle of the molecular chaperone Hsp90. , 16(3), pp.287–293. 
Höhfeld, J., Cyr, D.M. & Patterson, C., 2001. From the cradle to the grave: molecular 
chaperones that may choose between folding and degradation. EMBO reports, 2(10), 
pp.885–90. 
Holmes, J.L. et al., 2008. Silencing of HSP90 cochaperone AHA1 expression decreases client 
protein activation and increases cellular sensitivity to the HSP90 inhibitor 17-
allylamino-17-demethoxygeldanamycin. Cancer research, 68(4), pp.1188–97. 
Holt, S.E. et al., 1999. Functional requirement of p23 and Hsp90 in telomerase complexes. 
Genes & development, 13(7), pp.817–26. 
Howard, J. et al., 1990. Mapping the HSPSO Binding Region of the Glucocorticoid Receptor. 
JBC, 265, pp.11928–35. 
Hsieh, Y.-Y., Hung, P.-H. & Leu, J.-Y., 2013. Hsp90 regulates nongenetic cariation in response to 
environmental stress. Molecular cell, 50, pp.82–92. 
Hsu, P.P. et al., 2011. The mTOR-regulated Phosphoproteome reveals a mechanism of 
mTORC1-mediated inhibition of growth factor signaling. Science, 332(6035), pp.1317–
1322. 
Hu, J., Toft, D.O. & Seeger, C., 1997. Hepadnavirus assembly and reverse transcription require 
a multi-component chaperone complex which is incorporated into nucleocapsids. The 
EMBO journal, 16(1), pp.59–68. 
Iannotti, M., Rabideau, A. & Dougherty, J., 1988. Characterization of purified Avian 90kDa heat 
shock protein. Archives, 264(1), pp.54–60. 
Iliuk, A.B. et al., 2010. In-depth analyses of kinase-dependent tyrosine phosphoproteomes 
based on metal ion-functionalized soluble nanopolymers. Molecular & cellular 
proteomics : MCP, 9(10), pp.2162–72. 
Jakob, U. et al., 1995. Transient Interaction of Hsp90 with early unfolding Intermediates of 
Citrate Synthase. JBC, 270(March 31), pp.7288–94. 
Johnson, J.L. et al., 1994. Characterization of a novel 23-kilodalton protein of unactive 
progesterone receptor complexes. Molecular and cellular biology, 14(3), pp.1956–63. 
Johnson, J.L. & Brown, C., 2009. Plasticity of the Hsp90 chaperone machine in divergent 
eukaryotic organisms. Cell stress & chaperones, 14(1), pp.83–94. 
 116 
 
Johnson, J.L., Halas, A. & Flom, G., 2007. Nucleotide-dependent interaction of Saccharomyces 
cerevisiae Hsp90 with the cochaperone proteins Sti1, Cpr6, and Sba1. Molecular and 
cellular biology, 27(2), pp.768–76. 
Johnson, J.L. & Toft, D.O., 1995. Binding of p23 and hsp90 during assembly with the 
progesterone receptor. Molecular endocrinology (Baltimore, Md.), 9(6), pp.670–8. 
Kamal, A. et al., 2003. A high-affinity conformation of Hsp90 confers tumour selectivity on 
Hsp90 inhibitors. Nature, 425(6956), pp.407–10. 
Kanelakis, K.C., Shewach, D.S. & Pratt, W.B., 2002. Nucleotide binding states of hsp70 and 
hsp90 during sequential steps in the process of glucocorticoid receptor.hsp90 
heterocomplex assembly. The Journal of biological chemistry, 277(37), pp.33698–703. 
Karagöz, G.E. et al., 2014. Hsp90-tau complex reveals molecular basis for specificity in 
chaperone action. Cell, 156(5), pp.963–74. 
Katschinski, D.M. et al., 2002. Heat induction of the unphosphorylated form of hypoxia-
inducible factor-1alpha is dependent on heat shock protein-90 activity. The Journal of 
biological chemistry, 277(11), pp.9262–7. 
Kekatpure, V.D., Dannenberg, A.J. & Subbaramaiah, K., 2009. HDAC6 modulates Hsp90 
chaperone activity and regulates activation of aryl hydrocarbon receptor signaling. The 
Journal of biological chemistry, 284(12), pp.7436–45. 
Kelley, P.M. & Schlesinger, M.J., 1982. Antibodies to two major chicken heat shock proteins 
cross-react with similar proteins in widely divergent widely divergent species. 
Molecular and Cellular Biology, 2(3), pp.267–274. 
Kettenbach, A.N. et al., 2013. Quantitative Phosphoproteomics identifies Subtrates and 
Functional Modules of Aurora and Polo-like kinase activities in mitotic cells. Science 
Signal, 4(179). 
Kimura, Y. et al., 1997. Cdc37 is a molecular chaperone with specific functions in signal 
transduction. Genes & Development, 11(14), pp.1775–1785. 
Kirschke, E. et al., 2014. Glucocorticoid Receptor Function Regulated by Coordinated Action of 
the Hsp90 and Hsp70 Chaperone Cycles. Cell, 157(7), pp.1685–1697. 
Kjærulff, S. et al., 2005. Constitutive Activation of the Fission Yeast Pheromone-Responsive 
Pathway Induces Ectopic Meiosis and Reveals Ste11 as a Mitogen-Activated Protein 
Kinase Target Constitutive Activation of the Fission Yeast Pheromone-Responsive 
Pathway Induces Ectopic Meio. 
Kosano, H., 1998. The Assembly of Progesterone Receptor-hsp90 Complexes Using Purified 
Proteins. Journal of Biological Chemistry, 273(49), pp.32973–32979. 
Koulov, A. V et al., 2010. Biological and Structural Basis for Aha1 Regulation of Hsp90 ATPase 
Activity in Maintaining Proteostasis in the Human Disease Cystic Fibrosis. Molecular 
biology of the Cell, 21, pp.871–884. 
Kovacs, J.J. et al., 2005. HDAC6 regulates Hsp90 acetylation and chaperone-dependent 
activation of glucocorticoid receptor. Molecular cell, 18(5), pp.601–7. 
 117 
 
Kumar, R. & Thompson, E.B., 1999. The structure of the nuclear hormone receptors. Steroids, 
64(5), pp.310–9. 
Kuo, C.-C. et al., 2007. Involvement of heat shock protein (Hsp)90 beta but not Hsp90 alpha in 
antiapoptotic effect of CpG-B oligodeoxynucleotide. Journal of immunology (Baltimore, 
Md. : 1950), 178(10), pp.6100–8. 
Kurokawa, M. et al., 2008. Inhibition of apoptosome formation by suppression of Hsp90beta 
phosphorylation in tyrosine kinase-induced leukemias. Molecular and cellular biology, 
28(17), pp.5494–5506. 
Lan, C. et al., 2004. A novel mode of chaperone action: heme activation of Hap1 by enhanced 
association of Hsp90 with the repressed Hsp70-Hap1 complex. The Journal of biological 
chemistry, 279(26), pp.27607–12. 
Lee, C. et al., 2012. Dynamics of the regulation of Hsp90 by the cochaperone Sti1. The EMBO 
Journal, 31(6), pp.1518–1528. 
Lee, H.C., Hon, T. & Zhang, L., 2002. The molecular chaperone Hsp90 mediates heme 
activation of the yeast transcriptional activator Hap1. The Journal of biological chemistry, 
277(9), pp.7430–7. 
Lee, P. et al., 2004. Sti1 and Cdc37 Can Stabilize Hsp90 in Chaperone Complexes with a 
Protein Kinase. Molecular Biology of the Cell, 15(April), pp.1785–1792. 
Lee, P. et al., 2002. The Cdc37 protein kinase-binding domain is sufficient for protein kinase 
activity and cell viability. The Journal of cell biology, 159(6), pp.1051–9. 
Lees-Miller, S.P. & Anderson, C.W., 1989. The Human Double-stranded DNA-activated Protein 
Kinase phosphorylates the 90KDa Hsp (hsp90a) at two N-terminal Threonine residues. 
Journal of Biological Chemistry, 264(29), pp.17275–17280. 
Lees-Miller, S.P. & Anderson, C.W., 1989. Two human 90-kDa heat shock proteins are 
phosphorylated in vivo at conserved serines that are phosphorylated in vitro by casein 
kinase II. The Journal of biological chemistry, 264(5), pp.2431–7. 
Li, J. et al., 2013. Integration of the accelerator Aha1 in the Hsp90 co-chaperone cycle. Nature 
structural & molecular biology, 20(3), pp.326–31. 
Li, J., Richter, K. & Buchner, J., 2011. Mixed Hsp90-cochaperone complexes are important for 
the progression of the reaction cycle. Nature structural & molecular biology, 18(1), 
pp.61–66. 
Lindquist, S., Jarosz, D.F. & Taipale, M., 2010. HSP90 at the hub of protein homeostasis: 
emerging mechanistic insights. Nature reviews. Molecular cell biology, 11(7), pp.515–
528. 
Llauger-Bufi, L. et al., 2003. Synthesis of novel fluorescent probes for the molecular 
chaperone Hsp90. Bioorganic & Medicinal Chemistry Letters, 13(22), pp.3975–3978. 
Loo, M. a et al., 1998. Perturbation of Hsp90 interaction with nascent CFTR prevents its 
maturation and accelerates its degradation by the proteasome. The EMBO journal, 
17(23), pp.6879–87. 
 118 
 
Lorenz, O.R. et al., 2014. Modulation of the hsp90 chaperone cycle by a stringent client 
protein. Molecular cell, 53(6), pp.941–53. 
Lotz, G.P. et al., 2003. Aha1 binds to the middle domain of Hsp90, contributes to client protein 
activation, and stimulates the ATPase activity of the molecular chaperone. The Journal of 
biological chemistry, 278(19), pp.17228–35. 
Louvion, J.F., Abbas-Terki, T. & Picard, D., 1998. Hsp90 is required for pheromone signaling in 
yeast. Molecular biology of the cell, 9(11), pp.3071–83. 
Lu, Z. et al., 2010. Celastrol, a novel HSP90 inhibitor, depletes Bcr-Abl and induces apoptosis 
in imatinib-resistant chronic myelogenous leukemia cells harboring T315I mutation. 
Cancer letters, 290(2), pp.182–91. 
MacLean, M. & Picard, D., 2003. Cdc37 goes beyond Hsp90 and kinases. Cell stress & 
chaperones, 8(2), pp.114–9. 
Mann, M. & Jensen, O.N., 2003. Proteomic analysis of post-translational modifications. Nature 
biotechnology, 21(3), pp.255–61. 
Martínez-Ruiz, A. et al., 2005. S-nitrosylation of Hsp90 promotes the inhibition of its ATPase 
and endothelial nitric oxide synthase regulatory activities. Proceedings of the National 
Academy of Sciences of the United States of America, 102(24), pp.8525–30. 
Mayer, M.P. & Bukau, B., 1999. Molecular chaperones: the busy life of Hsp90. Current biology : 
CB, 9(9), pp.R322–5. 
McCollum, A.K. et al., 2009. Cisplastin abrogates the GA-induced heat shock response. 
Molecular cancer therapeutics, 7(10), pp.3256–3264. 
McGowan, C.H. & Russell, P., 1993. Human Wee1 kinase inhibits cell division by 
phosphorylating p34cdc2 exclusively on Tyr15. The EMBO journal, 12(1), pp.75–85. 
McLaughlin, S.H. et al., 2006. The co-chaperone p23 arrests the Hsp90 ATPase cycle to trap 
client proteins. Journal of molecular biology, 356(3), pp.746–58. 
McLaughlin, S.H., Smith, H.W. & Jackson, S.E., 2002. Stimulation of the weak ATPase activity of 
human hsp90 by a client protein. Journal of molecular biology, 315(4), pp.787–98. 
McLean, P.J. et al., 2004. Geldanamycin induces Hsp70 n and prevents alpha-synuclein 
aggregaton and toxicity in vitro. Biochemical and biophysical research communications, 
321, pp.665–669. 
Meyer, P. et al., 2003. Structural and functional analysis of the middle segment of hsp90: 
implications for ATP hydrolysis and client protein and cochaperone interactions. 
Molecular cell, 11(3), pp.647–58. 
Meyer, P. et al., 2004. Structural basis for recruitment of the ATPase activator Aha1 to the 
Hsp90 chaperone machinery. The EMBO journal, 23(6), pp.1402–10. 
Mickler, M. et al., 2009. The large conformational changes of Hsp90 are only weakly coupled 
to ATP hydrolysis. Nature structural & molecular biology, 16(3), pp.281–6. 
 119 
 
Milicevic, Z. et al., 2008. Molecular characterization of hsp90 isoforms in colorectal cancer 
cells and its association with tumour progression. International journal of oncology, 
32(6), pp.1169–78. 
Millson, S.H. et al., 2007. Expressed as the sole Hsp90 of yeast, the alpha and beta isoforms of 
human Hsp90 differ with regard to their capacities for activation of certain client 
proteins, whereas only Hsp90beta generates sensitivity to the Hsp90 inhibitor radicicol. 
The FEBS journal, 274(17), pp.4453–63. 
Mimnaugh, E.G. et al., 1995. Possible Role for Serine / Threonine Phosphorylation in the 
Regulation of the Heteroprotein Complex between the hsp90 Stress Protein and the 
pp60 v- src Tyrosine Kinase *. Journal of Biological Chemistry, 270(48), pp.28654–
28659. 
Minami, Y. et al., 1994. The carboxy-terminal region of mammalian HSP90 is required for its 
dimerization and function in vivo. Molecular and cellular biology, 14(2), pp.1459–64. 
Miyata, Y., 2009. CK2: the kinase controlling the Hsp90 chaperone machinery. Cellular and 
molecular life sciences : CMLS, 66(11-12), pp.1840–1849. 
Miyata, Y. & Yahara, I., 1992. The 90-kDa heat shock protein, HSP90, binds and protects 
casein kinase II from self-aggregation and enhances its kinase activity. The Journal of 
biological chemistry, 267(10), pp.7042–7. 
Mohammed, S. et al., 2008. Multiplexed proteomics mapping of yeast RNA polymerase II and 
III allows near-complete sequence coverage and reveals several novel phosphorylation 
sites. Analytical chemistry, 80(10), pp.3584–92. 
Molina, H. et al., 2007. Global proteomic profiling of phosphopeptides using electron transfer 
dissociation tandem mass spectrometry. Proceedings of the National Academy of Sciences 
of the United States of America, 104(7), pp.2199–204. 
Mollapour, M. et al., 2014. Asymmetric Hsp90 N domain SUMOylation recruits Aha1 and ATP-
competitive inhibitors. Molecular cell, 53(2), pp.317–29. 
Mollapour, M., Tsutsumi, S., Kim, Y.S., et al., 2011. Casein kinase 2 phosphorylation of Hsp90 
threonine 22 modulates chaperone function and drug sensitivity. Oncotarget, 2(5), 
pp.407–417. 
Mollapour, M., Tsutsumi, S., Truman, A.W., et al., 2011. Manuscript: Threonine 22 
phosphorylation attenuates Hsp90 interaction with co-chaperone Aha1 and regulates 
chaperone activity. Molecular cell, 41(6), pp.672–681. 
Mollapour, M., Tsutsumi, S., et al., 2010. Swe1/Wee1-dependent tyrosine Phosphorylation of 
Hsp90 regulates chaperone function, 
Mollapour, M., Tsutsumi, S., et al., 2010. Swe1Wee1-dependent tyrosine phosphorylation of 
Hsp90 regulates distinct facets of chaperone function. Molecular cell, 37(3), pp.333–343. 
Mollapour, M., Tsutsumi, et al., 2011. Threonine 22 phosphorylation attenuates Hsp90 
interaction with cochaperones and affects its chaperone activity. Molecular cell, 41(6), 
pp.672–681. 
 120 
 
Morano, K. a & Thiele, D.J., 1999. The Sch9 protein kinase regulates Hsp90 chaperone 
complex signal transduction activity in vivo. The EMBO journal, 18(21), pp.5953–62. 
Morishima, Y. et al., 2008. CHIP deletion reveals functional redundancy of E3 ligases in 
promoting degradation of both signaling proteins and expanded glutamine proteins. 
Human molecular genetics, 17(24), pp.3942–52. 
Morishima, Y. et al., 2000. Stepwise assembly of a glucocorticoid receptor.hsp90 
heterocomplex resolves two sequential ATP-dependent events involving first hsp70 and 
then hsp90 in opening of the steroid binding pocket. The Journal of biological chemistry, 
275(24), pp.18054–60. 
Morishima, Y. et al., 2000. The Hsp Organizer Protein Hop Enhances the Rate of but Is Not 
Essential for Glucocorticoid Receptor Folding by the System The Hsp Organizer Protein 
Hop Enhances the Rate of but Is Not Essential for Glucocorticoid Receptor F. Journal of 
Biological Chemistry, 275, pp.6894–6900. 
Mort-Bontemps-Soret, M., Facca, C. & Faye, G., 2002. Physical interaction of Cdc28 with Cdc37 
in Saccharomyces cerevisiae. Molecular genetics and genomics : MGG, 267(4), pp.447–58. 
Müller, L. et al., 2004. Hsp90 regulates the activity of wild type p53 under physiological and 
elevated temperatures. The Journal of biological chemistry, 279(47), pp.48846–54. 
Muller, P. et al., 2012. C-terminal phosphorylation of Hsp70 and Hsp90 regulates alternate 
binding to co-chaperones CHIP and HOP to determine cellular protein 
folding/degradation balances. Oncogene, 32(25), pp.3101–10. 
Müller, P., Ceskova, P. & Vojtesek, B., 2005. Hsp90 is essential for restoring cellular functions 
of temperature-sensitive p53 mutant protein but not for stabilization and activation of 
wild-type p53: implications for cancer therapy. The Journal of biological chemistry, 
280(8), pp.6682–91. 
Murata, S. et al., 2001. CHIP is a chaperone-dependent E3 ligase that ubiquitylates unfolded 
protein. EMBO reports, 2(12), pp.1133–8. 
Murphy, P.J.M. et al., 2005. Regulation of the dynamics of hsp90 action on the glucocorticoid 
receptor by acetylation/deacetylation of the chaperone. The Journal of biological 
chemistry, 280(40), pp.33792–9. 
Nair, S.C. et al., 1996. A pathway of multichap interactions comon to diverse regulatory 
proteins: estrogen receptor, Fes tyrosine kinase, heat shock transcription factor Hsf1 
and the aryl hydrocarbon receptor. Cell stress & chaperones, 1, pp.237–250. 
Nathan, D.F. & Lindquist, S., 1995. Mutational analysis of Hsp90 function: interactions with a 
steroid receptor and a protein kinase. Molecular and cellular biology, 15(7), pp.3917–25. 
Nathan, D.F., Vos, M.H. & Lindquist, S., 1999. Identification of Ssf1, Cns1 and Hch1 as 
suppressors of a Sc Hsp90 loss-of-function mutation. PNAS, 96(February), pp.1409–
1414. 
Nathan, D.F., Vos, M.H. & Lindquist, S., 1997. In vivo functions of the Saccharomyces cerevisiae 
Hsp90 chaperone. Proceedings of the National Academy of Sciences of the United States of 
America, 94(24), pp.12949–56. 
 121 
 
Nguyen, D.M. et al., 2001. Enhancement of paclitaxel-mediated cytotoxicity in lung cancer 
cells by 17-allylamino geldanamycin: in vitro and in vivo analysis. The Annals of thoracic 
surgery, 72(2), pp.371–8; discussion 378–9. 
Nimmanapalli, R. et al., 2003. Histone Deacetylase Inhibitor LAQ824 Both Lowers Expression 
and Promotes Proteasomal Degradation of Bcr-Abl and Induces Apoptosis of Imatinib 
Mesylate-sensitive or -refractory Chronic Myelogenous Leukemia-Blast Crisis Cells 
Histone Deacetylase Inhibitor L. 
Nimmanapalli, R., O’Bryan, E. & Bhalla, K., 2001. Geldanamycin and its analogue 17-
allylamino-17-demethoxygeldanamycin lowers Bcr-Abl levels and induces apoptosis 
and differentiation of Bcr-Abl-positive human leukemic blasts. Cancer research, 61(5), 
pp.1799–804. 
Obermann, W.M. et al., 1998. In vivo function of Hsp90 is dependent on ATP binding and ATP 
hydrolysis. The Journal of cell biology, 143(4), pp.901–10. 
Ogiso, H. et al., 2004. Phosphorylation analysis of 90 kDa heat shock protein within the 
cytosolic arylhydrocarbon receptor complex. Biochemistry, 43(49), pp.15510–15519. 
Old, W.M. et al., 2009. Functional proteomics identifies targets of Phosphorylation by B-Raf 
signaling in Melanoma. Molecular Cell, 34(1), pp.115–131. 
Olsen, J. V et al., 2010. Quantitative phosphoproteomics reveals widespread full 
phosphorylation site occupancy during mitosis. Science signaling, 3(104), p.ra3. 
Panaretou, B. et al., 2002. Activation of the ATPase activity of hsp90 by the stress-regulated 
cochaperone aha1. Molecular cell, 10(6), pp.1307–18. 
Panaretou, B. et al., 1998a. ATP binding and hydrolysis are essential to the function of the 
Hsp90 molecular chaperone in vivo. The EMBO journal, 17(16), pp.4829–36. 
Panaretou, B. et al., 1998b. ATP binding and hydrolysis are essential to the function of the 
Hsp90 molecular chaperone in vivo. The EMBO journal, 17(16), pp.4829–36. 
Panse, V.G. et al., 2004. A proteome-wide approach identifies sumoylated substrate proteins 
in yeast. The Journal of biological chemistry, 279(40), pp.41346–51. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/15292183 [Accessed April 14, 2014]. 
Park, J. et al., 2008. Class-II HDACs play pivotal roles in hsp90-mediated proteasome degrad 
of VEGF receptors. Biochemical and biophysical research communications, 368, pp.318–
322. 
Pearl, L.H. & Prodromou, C., 2006. Structure and mechanism of the Hsp90 molecular 
chaperone machinery. Annual review of biochemistry, 75, pp.271–94. 
Phanstiel, D.H. et al., 2012. Proteomic and phosphoproteomic comparison of human ES and 
iPS cells. Nature Methods, 8(10), pp.821–827. 
Picard, D., 2002. Heat-shock protein 90 , a chaperone for folding and regulation. Cellular and 
Molecular Life Sciences, 59, pp.1640–1648. 
 122 
 
Picard, D. et al., 1990. Reduced levels of hsp90 compromise steroid receptor action in vivo. 
Nature, 348, pp.166–168. 
Piwien Pilipuk, G. et al., 2007. Evidence for NL1-independent nuclear translocation of the 
mineralocorticoid receptor. Biochemistry, 46(5), pp.1389–97. 
Polier, S. et al., 2013. ATP-competitive inhibitors block protein kinase recruitment to the 
Hsp90-Cdc37 system. Nature chemical biology, 9(5), pp.307–12. 
Pountney, D.L. et al., 2008. NSF, Unc-18-1, dynamin-1 and HSP90 are inclusion body 
components in neuronal intranuclear inclusion disease identified by anti-SUMO-1-
immunocapture. Acta neuropathologica, 116(6), pp.603–14. 
Prince, T. & Matts, R.L., 2005. Exposure of protein kinase motifs that trigger binding of Hsp90 
and Cdc37. Biochemical and biophysical research communications, 338(3), pp.1447–54. 
Available at: http://www.ncbi.nlm.nih.gov/pubmed/16269130 [Accessed January 23, 
2014]. 
Prodromou, C. et al., 1997. Identification and structural characterization of the ATP/ADP-
binding site in the Hsp90 molecular chaperone. Cell, 90(1), pp.65–75. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/9230303. 
Prodromou, C. et al., 1999. Regulation of Hsp90 ATPase activity by tetratricopeptide repeat 
(TPR)-domain co-chaperones. The EMBO journal, 18(3), pp.754–62. 
Quanz, M. et al., 2012. Heat shock protein 90 alpha (Hsp90α) is phosphorylated in response 
to DNA damage and accumulates in repair foci. The Journal of biological chemistry, 
287(12), pp.8803–15. 
Queitsch, C., Sangster, T. a & Lindquist, S., 2002. Hsp90 as a capacitor of phenotypic variation. 
Nature, 417(6889), pp.618–24. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/12050657. 
Rao, J. et al., 2001. Functional interaction of human Cdc37 with the androgen receptor but not 
with the glucocorticoid receptor. The Journal of biological chemistry, 276(8), pp.5814–
20. 
Rao, R. et al., 2008. HDAC6 inhibition enhances 17-AAG--mediated abrogation of hsp90 
chaperone function in human leukemia cells. Blood, 112(5), pp.1886–93. 
Ratzke, C. et al., 2010. Dynamics of heat shock protein 90 C-terminal dimerization is an 
important part of its conformational cycle. Proceedings of the National Academy of 
Sciences of the United States of America, 107(37), pp.16101–6. 
Reed, S.I., 1980. The selection of S.cerevisiae mutants defective in the start event of cell 
division. Genetics, 95, pp.561–577. 
Retzlaff, M. et al., 2010. Asymmetric activation of the hsp90 dimer by its cochaperone Aha1. 
Molecular cell, 37(3), pp.344–54. 
Retzlaff, M. et al., 2009. Hsp90 is regulated by a switch point in the C-terminal domain. EMBO 
reports, 10(10), pp.1147–53. 
 123 
 
Richter, K. et al., 2001. Coordinated ATP hydrolysis by the Hsp90 dimer. The Journal of 
biological chemistry, 276(36), pp.33689–96. 
Richter, K. et al., 2006. Intrinsic inhibition of the Hsp90 ATPase activity. The Journal of 
biological chemistry, 281(16), pp.11301–11. 
Richter, K. et al., 2003. Sti1 Is a Non-competitive Inhibitor of the Hsp90 ATPase : BINDING 
PREVENTS THE N-TERMINAL DIMERIZATION REACTION DURING THE ATPASE CYCLE. 
JBC, 278, pp.10328–10333. 
Richter, K., Reinstein, J. & Buchner, J., 2002. N-terminal residues regulate the catalytic 
efficiency of the Hsp90 ATPase cycle. The Journal of biological chemistry, 277(47), 
pp.44905–10. Available at: http://www.ncbi.nlm.nih.gov/pubmed/12235160 [Accessed 
February 4, 2014]. 
Richter, K., Walter, S. & Buchner, J., 2004. The Co-chaperone Sba1 connects the ATPase 
reaction of Hsp90 to the progression of the chaperone cycle. Journal of molecular 
biology, 342(5), pp.1403–13. 
Ricketson, D. et al., 2007. A conformational switch in the ligand binding domain regulates the 
dependence of the glucocorticoid receptor on Hsp90. Journal of molecular biology, 
368(3), pp.729–741. 
Roe, S.M. et al., 2004. The Mechanism of Hsp90 Regulation by the Protein Kinase-Specific 
Cochaperone p50 cdc37. Cell, 116, pp.87–98. 
Rutherford, S.L. & Lindquist, S., 1998. Hsp90 as a capacitor for morphological evolution. 
Nature, 396(6709), pp.336–42. 
Sato, S., Fujita, N. & Tsuruo, T., 2000. Modulation of Akt kinase activity by binding to Hsp90. 
Proceedings of the National Academy of Sciences of the United States of America, 97(20), 
pp.10832–7. 
Scheufler, C. et al., 2000. Structure of TPR Domain – Peptide Complexes : Critical Elements in 
the Assembly of the Hsp70 – Hsp90 Multichaperone Machine. , 101, pp.199–210. 
Schulte, T.W. et al., 1996. Destabilization of Raf-1 by geldanamycin leads to disruption of the 
Raf-1-MEK-mitogen-activated protein kinase signalling pathway . Destabilization of Raf-
1 by Geldanamycin Leads to Disruption of the Raf-1 – MEK – Mitogen-Activated Protein 
Kinase Signalli. Molecular and cellular biology, 16, pp.5389–5845. 
Scroggins, B.T. et al., 2007. An acetylation site in the middle domain of Hsp90 regulates 
chaperone function. Molecular cell, 25(1), pp.151–9. 
Sefton, B.M., Beemon, K. & Hunter, T., 1978. Comparison of the expression of the src gene of 
Rous sarcoma virus in vitro and in vivo. Journal of Virology, 28(3), pp.957–971. 
Seitz, T. et al., 2010. Enhancing the stability and solubility of the glucocorticoid receptor 
ligand-binding domain by high-throughput library screening. Journal of molecular 
biology, 403(4), pp.562–77. 
 124 
 
Sepehrnia, B. et al., 1996. Heat Shock Protein 84 forms a Complex with Mutant p53 Protein 
predominantly within a cytoplasmic compartment of the cell. Journal of Biological 
Chemistry, 271(25), pp.15084–15090. 
Shao, J. et al., 2003. Functional dissection of cdc37: characterization of domain structure and 
amino acid residues critical for protein kinase binding. Biochemistry, 42(43), pp.12577–
88. 
Shao, J. et al., 2001. Hsp90 regulates p50(cdc37) function during the biogenesis of the 
activeconformation of the heme-regulated eIF2 alpha kinase. The Journal of biological 
chemistry, 276(1), pp.206–14. 
Shiromizu, T. et al., 2013. Identification of Missing Proteins in the neXtProt Database and 
Unregistered Phosphopeptides in the PhosphoSitePlus Database As Part of the 
Chromosome-Centric Human Proteome Project. Journal of proteome research, 12, 
pp.2414–2421. 
Siligardi, G. et al., 2002. Regulation of Hsp90 ATPase activity by the co-chaperone 
Cdc37p/p50cdc37. The Journal of biological chemistry, 277(23), pp.20151–9. 
Silva, A. et al., 2013. Involvement of yeast HSP90 isoforms in response to stress and cell death 
induced by acetic acid. PloS one, 8(8), p.e71294. 
Smith, D.F., 1993. Dynamics of heat shock protein 90-progesterone receptor binding and the 
disactivation loop model for steroid receptor complexes. Molecular endocrinology 
(Baltimore, Md.), 7(11), pp.1418–29. 
Smith, D.F. et al., 1993. Identification of a 60-Kilodalton Stress-Related Protein , p60 , which 
Interacts with hsp90 and hsp70. Molecular and cellular biology, 13, pp.869–876. 
Smith, D.F. et al., 1995. Progesterone receptor structure and function altered by 
geldanamycin, an hsp90-binding agent. Molecular and cellular biology, 15(12), pp.6804–
12. 
Solier, S. et al., 2012. Heat shock protein 90 (HSP90 ), a substrate and chaperone of DNA-PK 
necessary for the apoptotic response. Proceedings of the National Academy of Sciences, 
109(32), pp.12866–12872. 
Solit, D.B. et al., 2002. Advances in Brief 17-Allylamino-17-demethoxygeldanamycin Induces 
the Degradation of Androgen Receptor and HER-2 / neu and Inhibits the Growth of 
Prostate Cancer Xenografts 1. , 8(May), pp.986–993. 
Song, Y. & Masison, D.C., 2006. Independent regulation of Hsp70 and Hsp90 chaperones by 
HOP. JBC, 280(40), pp.34178–34185. 
Soroka, J. et al., 2012. Conformational Switching of the Molecular Chaperone Hsp90 via 
Regulated Phosphorylation. Molecular Cell, 45, pp.517–528. 
Soroka, J. et al., 2013. Phospho-regulation of the Hsp90 chaperone machinery. Molecular Cell. 
Southworth, D.R. & Agard, D. a, 2008. Species-dependent ensembles of conserved 
conformational states define the Hsp90 chaperone ATPase cycle. Molecular cell, 32(5), 
pp.631–40. 
 125 
 
Stankiewicz, M. et al., 2010. CHIP participates in protein triage decisions by preferentially 
ubiquitinating Hsp70-bound substrates. The FEBS journal, 277(16), pp.3353–67. 
Stepanova, L. et al., 1996. Mammalian p50Cdc37 is a protein kinase-targeting subunit of 
Hsp90 that binds and stabilizes Cdk4. Genes & Development, 10(12), pp.1491–1502. 
Street, T.O., Lavery, L. a & Agard, D. a, 2011. Substrate binding drives large-scale 
conformational changes in the Hsp90 molecular chaperone. Molecular cell, 42(1), pp.96–
105. 
Subbarao Sreedhar, A. et al., 2004. Hsp90 isoforms: functions, expression and clinical 
importance. FEBS Letters, 562(1-3), pp.11–15. 
Sullivan, W. et al., 1997. Nucleotides and Two Functional States of Nucleotides and Two 
Functional States of hsp90. Protein Chemistry and Structure. 
Sun, L. et al., 2012. Characterization of the interaction of Aha1 with components of the Hsp90 
chaperone machine and client proteins. Biochimica et biophysica acta, 1823(6), 
pp.1092–101. 
Taipale, M. et al., 2012. Quantitative Analysis of Hsp90-client interactions reveals principles 
of substrate recognition. Cell, 150, pp.987–1001. 
Terasawa, K. et al., 2006. Cdc37 Interacts with the Glycine-Rich Loop of Hsp90 Client Kinases. 
Molecular and cellular biology, 26(9), pp.3378–3389. 
Tsutsumi, S. et al., 2009. Hsp90 charged-linker truncation reverses the functional 
consequences of weakened hydrophobic contacts in the N domain. Nature structural & 
molecular biology, 16(11), pp.1141–7. 
Uehara, Y. et al., 1986. Phenotypic change from transformed to normal induced by 
benzoquinonoid ansamycins accompanies inactivation of p60src in rat kidney cells 
infected with Rous sarcoma virus. Molecular and cellular biology, 6, pp.2198–2206. 
Unwin, R.D. et al., 2005. Multiple reaction monitoring to identify sites of protein 
phosphorylation with high sensitivity. Molecular & cellular proteomics : MCP, 4(8), 
pp.1134–44. 
Vaughan, C.K. et al., 2009. A common conformationally coupled ATPase mechanism for yeast 
and human cytoplasmic HSP90s. The FEBS journal, 276(1), pp.199–209. 
Vaughan, C.K. et al., 2006. Structure of an Hsp90-Cdc37-Cdk4 complex. Molecular cell, 23(5), 
pp.697–707. 
Wandinger, S.K. et al., 2006. The phosphatase Ppt1 is a dedicated regulator of the molecular 
chaperone Hsp90. The EMBO journal, 25(2), pp.367–76. 
Wandinger, S.K., Richter, K. & Buchner, J., 2008. The Hsp90 chaperone machinery. The Journal 
of biological chemistry, 283(27), pp.18473–7. 
Wang, H. et al., 2002. C/EBPalpha triggers proteasome-dependent degradation of cdk4 during 
growth arrest. The EMBO journal, 21(5), pp.930–41. 
 126 
 
Wang, X. et al., 2009. The regulatory mechanism of Hsp90alpha secretion and its function in 
tumor malignancy. PNAS, 106(50), pp.21288–21293. 
Wang, X. et al., 2012. Thr90 phosphorylation of Hsp90α by protein kinase A regulates its 
chaperone machinery. Biochemical Journal, 441(1), pp.387–397. 
Wang, X., Grammatikakis, N. & Hu, J., 2002. Role of p50/CDC37 in hepadnavirus assembly and 
replication. The Journal of biological chemistry, 277(27), pp.24361–7. 
Weaver, A.J. et al., 2000. Crystal structure and activity of human p23, a heat shock protein 90 
co-chaperone. The Journal of biological chemistry, 275(30), pp.23045–52. 
Weber, C., Schreiber, T.B. & Daub, H., 2012. Dual phosphoproteomics and chemical 
proteomics analysis of erlotinib and gefitinib interference in acute myeloid leukemia 
cells. Journal of proteomics, 75(4), pp.1343–56. 
Wegele, H. et al., 2003. Dissection of the contribution of individual domains to the ATPase 
mechanism of Hsp90. The Journal of biological chemistry, 278(41), pp.39303–10. 
Wegele, H. et al., 2006. Substrate transfer from the chaperone Hsp70 to Hsp90. Journal of 
molecular biology, 356(3), pp.802–11. 
Wegele, H., Müller, L. & Buchner, J., 2004. Hsp70 and Hsp90--a relay team for protein folding. 
Reviews of physiology, biochemistry and pharmacology, 151(January), pp.1–44. 
Weikl, T. et al., 2000. C-terminal regions of Hsp90 are important for trapping the nucleotide 
during the ATPase cycle. Journal of molecular biology, 303(4), pp.583–92. 
Weikl, T., Abelmann, K. & Buchner, J., 1999. An unstructured C-terminal region of the Hsp90 
co-chaperone p23 is important for its chaperone function. Journal of molecular biology, 
293(3), pp.685–91. 
Welch, W.J. et al., 1983. Biochemical characterization of the mammalian stress proteins and 
identification of two stress proteins as glucose- and Ca2+-ionophore-regulated proteins. 
JBC, 258(11), pp.7102–11. 
Whitesell, L. et al., 1992. Benzoquinonoid ansamycins possess selective tumoricidal activity 
unrelated to src kinase inhibition. Cancer research, 52(7), pp.1721–8. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/1551101. 
Whitesell, L. et al., 1994. Inhibition of heat shock protein HSP90-pp60v-src heteroprotein 
complex formation by benzoquinone ansamycins: essential role for stress proteins in 
oncogenic transformation. Proceedings of the National Academy of Sciences of the United 
States of America, 91(18), pp.8324–8. 
Whitesell, L. et al., 1998. The physical association of multiple molecular chaperone proteins 
with mutant p53 is altered by geldanamycin, an hsp90-binding agent. Molecular and 
cellular biology, 18(3), pp.1517–24. 
Wiśniewski, J.R., Ostasiewicz, P. & Mann, M., 2011. High recovery FASP applied to the 
proteomic analysis of microdissected formalin fixed paraffin embedded cancer tissues 
retrieves known colon cancer markers. Journal of proteome research, 10(7), pp.3040–9. 
 127 
 
Woo, S.H. et al., 2009. A truncated form of p23 down-regulates telomerase activity via 
disruption of Hsp90 function. The Journal of biological chemistry, 284(45), pp.30871–
30880. 
Xia, Q. et al., 2009. Phosphoproteomic analysis of human brain by calcium phosphate 
precipitation and MS. J of Proteome Research, 7(7), pp.2845–2851. 
Xu, W. et al., 2002. Chaperone-dependent E3 ubiquitin ligase CHIP mediates a degradative 
pathway for c-ErbB2/Neu. Proceedings of the National Academy of Sciences of the United 
States of America, 99(20), pp.12847–52. 
Xu, W. et al., 2012. Dynamic tyrosine phosphoryation modulates cycling of the Hsp90-
p50Cdc37-Aha1 chaperone machinery. Molecular cell, 47(3), pp.434–443. 
Xu, W. & Neckers, L., 2007. Targeting the molecular chaperone heat shock protein 90 
provides a multifaceted effect on diverse cell signaling pathways of cancer cells. Clinical 
cancer research : an official journal of the American Association for Cancer Research, 
13(6), pp.1625–9. 
Xu, Y. & Lindquist, S., 1993. Heat-shock protein hsp90 governs the activity of pp60v-src 
kinase. Proceedings of the National Academy of Sciences, 90(15), pp.7074–7078. 
Yang, Y. et al., 2008. Role of acetylation and extracellular location of heat shock protein 
90alpha in tumor cell invasion. Cancer research, 68(12), pp.4833–42. 
Youker, R.T. et al., 2004. Distinct Roles for the Hsp40 and Hsp90 Molecular Chaperones 
during Cystic Fibrosis Transmembrane Conductance Regulator Degradation in Yeast. , 
15(November), pp.4787–4797. 
Young, J.C., 2001. Hsp90: a specialized but essential protein-folding tool. The Journal of Cell 
Biology, 154(2), pp.267–274. 
Young, J.C. et al., 2004. Pathways of chaperone-mediated protein folding in the cytosol. Nature 
reviews. Molecular cell biology, 5(10), pp.781–91. 
Young, J.C. & Hartl, F.U., 2000. Polypeptide release by Hsp90 involves ATP hydrolysis and is 
enhanced by the co-chaperone p23. The EMBO journal, 19(21), pp.5930–40. 
Yu, X. et al., 2002. Modulation of p53, ErbB1, B2 and Raf-1 expression in Lung Cancer Cells by 
Depsipeptide FR901228. Journal of the National Cancer Institute, 94(7), pp.504–513. 
Zarzov, P., Boucherie, H. & Mann, C., 1997. A yeast heat shock transcription factor (Hsf1) 
mutant is defective in both Hsc82/Hsp82 synthesis and spindle pole body duplication. 
Journal of cell science, 110 ( Pt 1, pp.1879–91. 
Zhang, L., Hach, A. & Wang, C., 1998. Molecular mechanism governing heme signaling in yeast: 
a higher-order complex mediates heme regulation of the transcriptional activator HAP1. 
Molecular and cellular biology, 18(7), pp.3819–28. 
Zhao, X. et al., 2011. Phosphoproteome analysis of functional mitochondria isolated from 
resting human muscle reveals extensive phosphorylation of inner membrane protein 
complexes and enzymes. Molecular & cellular proteomics : MCP, 10(1), p.M110.000299. 
 128 
 
Zhao, Y.G. et al., 2001. Hsp90 phosphorylation is linked to its chaperoning function. Assembly 
of the reovirus cell attachment protein. The Journal of biological chemistry, 276(35), 
pp.32822–32827. 
Zhou, H. et al., 2013. Toward a comprehensive characterization of a human cancer cell 
phosphoproteome. Journal of proteome research, 12(1), pp.260–71. 
Zhou, Q. et al., 2008. Inhibition of histone deacetylases promotes ubiquitin-dependent 
proteasomal degradation of DNA methyltransferase 1 in human breast cancer cells. 
Molecular cancer research : MCR, 6(5), pp.873–83. 
Zhou, W., Ryan, J.J. & Zhou, H., 2004. Global analyses of sumoylated proteins in 
Saccharomyces cerevisiae. Induction of protein sumoylation by cellular stresses. The 
Journal of biological chemistry, 279(31), pp.32262–8. 
Zhou, Z. et al., 1993. Saccharomyces cerevisiae requires the sequential function of three 
protein kinases . Pheromone-Induced Signal Transduction in Saccharomyces cerevisiae 
Requires the Sequential Function of Three Protein Kinases. , 13(4). 
 
 
